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Abstract 
 
A seizure emergency occurs when an individual experiences a seizure that lasts for 
more than five minutes (status epilepticus) or multiple distinct seizures with incomplete 
recovery between them (acute repetitive seizures).  A patient experiencing a seizure 
emergency must be treated as quickly as possible to avoid lasting neurological damage and 
other life-threatening complications.  Benzodiazepines are the primary rescue medications 
used to treat seizure emergencies, the most commonly used being intravenous lorazepam 
or rectal diazepam.  Despite the effectiveness of these drugs, the delivery routes are not 
ideal for first-line, outpatient treatments.  A skilled caregiver must be present to administer 
drugs intravenously, and the social stigma associated with rectal administration results in 
low compliance.  Intranasal delivery is an attractive alternative because it requires little 
training, is easily performed by non-medical personnel, carries a low risk of injury to the 
patient, and can provide a rapid therapeutic effect.  However, formulating a benzodiazepine 
nasal spray is challenging because these drugs have very low aqueous solubilities.   
 
One strategy to circumvent solubility issues relies on in situ production of drug 
from co-administration of soluble reactants.  Herein, we describe how a prodrug/enzyme 
reaction or an acid/base reaction can be used to deliver a benzodiazepine in an aqueous 
vehicle with a volume and pH appropriate for intranasal administration.  When the soluble 
components of these two-part reactive formulations are mixed at the time of administration, 
a metastable supersaturated solution of the benzodiazepine is produced.  The 
supersaturated state of the benzodiazepine provides a large chemical activity gradient for 
rapid absorption across the nasal mucosa and into systemic circulation.  In vitro 
vi 
characterization of the reaction kinetics and supersaturation behaviors for diazepam 
prodrug/enzyme reactions, midazolam prodrug/enzyme reactions, and midazolam 
acid/base reactions demonstrated that these two-part formulations generate predictable 
levels of supersaturated drug.  An in vivo pharmacokinetic study in rats showed that rapid 
absorption and high bioavailability of diazepam results from intranasal administration of a 
diazepam prodrug/enzyme formulation.  Furthermore, a dual chamber nasal spray device 
capable of mixing and atomizing the components of a two-part formulation was designed, 
prototyped, and tested.  These two-part reactive formulations, coupled with the specialized 
nasal spray device, exemplify a new intranasal drug delivery strategy that may be 
applicable to a variety of other drugs with poor stability or low solubility. 
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Chapter 1: Introduction 
  
2 
 
1.1 Background 
 
1.1.1 Seizure emergencies 
 
Seizure activity is defined as abnormally excessive or synchronous neuronal 
activity in the brain.1  The symptoms of a seizure can vary from subtle loss of awareness 
as occurs with absence seizures to complete loss of consciousness coupled with 
convulsions as occurs with tonic-clonic seizures.  The duration of seizure activity can also 
vary.  Some are brief, isolated events while others can be prolonged episodes lasting several 
minutes or more.  Seizures that last longer than 5 minutes (status epilepticus) or present in 
clusters with only temporary or partial recovery between events (acute repetitive seizures) 
are serious medical emergencies that require immediate treatment.2  As little as 15 minutes 
of continuous seizure activity can damage neurons and cause focal neurological deficits, 
cognitive impairment, or epileptogenesis.2,3  There are also life threatening complications 
associated with prolonged seizure activity such as hypoxia, metabolic acidosis, 
hyperthermia, aspiration, or pulmonary edema.  Mortality increases with seizure duration.     
 
It is estimated that 126,000 - 195,000 cases of status epilepticus occur per year in 
the United States, with costs associated from hospital visits on the order of $4 billion/year.4-
6  Of those cases, 22,200 - 42,000 cases result in death.6  The risk of injury or death is 
mitigated by prompt medical treatment.7  However, treatment of seizure emergencies can 
be significantly delayed if the patient must wait for medical personnel or transportation to 
the emergency room.  A study performed at one emergency room found the average delay 
to treatment was 85 minutes.2,8  Epileptic patients who experience an aura before the onset 
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of a seizure, receive a warning from a seizure prediction device, or are conscious between 
clustered events may be able to self-administer a rescue therapy to prevent an oncoming 
episode.9  Furthermore, a rescue therapy could be carried by the patient or included in first 
aid kits in places like airplanes to be administered by bystanders during a seizure 
emergency.  Therefore, there is a need for outpatient treatments that can be administered 
immediately at the onset of a seizure by non-medical personnel.   
 
1.1.2 Benzodiazepines as rescue therapy  
 
Benzodiazepines are the primary rescue medications used to treat seizure 
emergencies such as status epilepticus.  This class of drugs includes lorazepam, diazepam 
(DZP), and midazolam (MDZ).  An intravenous (IV) injection of lorazepam or diazepam, 
or an intramuscular injection of MDZ are the recommended first-line treatment options.10  
However, a medical professional must be present to perform IV administration because 
there is risk of infiltration, hematoma, air embolism, phlebitis, infection, extravascular drug 
delivery, or intraarterial injection if done incorrectly.  Intramuscular drug delivery can also 
be problematic, especially for non-medical personnel.  The technique requires training and 
comes with similar risks of improper injection or injury.  It can be particularly difficult to 
carry out on obese or emaciated individuals, in the presence of multiple layers of clothing, 
or in public places.  Other benzodiazepine-based treatment modalities have been developed 
for outpatient use, each exhibiting advantages and disadvantages.  The only outpatient first-
line treatment approved in the US is Diastat®, rectally administered DZP.  This product 
demonstrated that outpatient management of seizure emergencies by nonmedical personnel 
is possible, safe, and highly effective.11  However, there is social stigma associated with 
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rectal administration and patients often object to this route despite its proven benefits.12  A 
product for buccal administration of MDZ is available in Europe under the trade name 
Buccolam®.  Buccal administration carries the risk of aspiration and inconsistent 
absorption due to ictal salivation.13  Intranasal (IN) delivery of benzodiazepines is an 
attractive alternative because it leads to rapid onset of therapeutic effect, requires little 
training, is easily performed, and carries a low risk of injury.14     
 
1.1.3 Intranasal delivery 
 
Benzodiazepines are small, lipophilic drugs.  Systemic delivery of these types of 
drugs by IN administration offers several important advantages that make the IN route 
attractive over other routes of administration, especially for outpatient treatments requiring 
a rapid onset of therapeutic effect.  Four of these advantages are well known and commonly 
cited.14,15  1) Peak plasma concentrations can be quickly attained due to the large surface 
area, high vascularization, and thin epithelium of the nasal mucosa; 2) First pass 
metabolism can be avoided, thus improving the bioavailability of some drugs; 3) The nasal 
cavity is easily accessed during a medical emergency, posing a lower risk of injury to the 
patient compared to parenteral routes of administration; 4) Operation of nasal spray devices 
does not require special skills, dosing is generally intuitive and easily performed.  An 
additional key advantage is less obvious and is the subject of this dissertation:  the nasal 
cavity, as such, offers a convenient location where drug can be produced in situ from the 
administration of two-part reactive formulations.  
 
The nasal cavity is a dynamic environment that enables rapid drug absorption, but 
also limits the amount of time available for drug absorption.  The bulk of the liquid 
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introduced into the nasal cavity by a nasal spray pump initially deposits in the less 
permeable atrium region of the nasal cavity, just past the nasal valve.16,17  The surface area 
of epithelium exposed to drug expands from the area of initial deposition as the formulation 
mixes with nasal secretions and gets carried across the highly permeable respiratory 
mucosa at a rate of 5–6 mm/min by mucociliary clearance.18,19  The total surface area of 
the nasal cavity has been reported to be 150–250 cm2 with mucosal thicknesses varying 
from 0.3–5 mm.20-24  The respiratory mucosa, containing the turbinates, provides most of 
the surface area.  In this region the 40–100 µm thick epithelium is the rate limiting barrier 
to absorption, with porous subepithelial tissue and a dense network of fenestrated 
capillaries acting as an effective sink for rapid drug absorption.25   
 
The capillary beds allow drug to enter directly into the systemic circulation, thereby 
bypassing gastric and hepatic first pass metabolism.  For some drugs, such as butorphanol, 
avoiding first pass metabolism by IN delivery can result in a substantial increase in 
bioavailabilty.26   However, the transit time for lateral transport of drugs across the surface 
of the mucosa by mucociliary clearance is generally 15–20 minutes.19  Slower absorption 
and lower bioavailability may result for any portion of the dose that gets cleared to the 
digestive tract.    
 
In emergency situations, IN administration can be faster than IV administration. A 
retrospective study performed by Inokuchi et al. compared the efficacy of IV versus IN 
delivery of a DZP parenteral formulation for the treatment of status epilepticus.27  These 
authors found that IN DZP was administered nine times faster than IV DZP (1 min IN vs 
9.5 min IV), and the difference in time to seizure termination after dosing was not 
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statistically significant between the two routes (3 min IN vs 0.5 min IV, p=0.43).  Although 
nasal pain and hemorrhaging from IN administration of commercial parenteral 
formulations containing organic solvents were mentioned in the medical records, they 
concluded that IN administration of DZP is safe, effective, and can be implemented outside 
of hospital settings.  Off-label IN administration of parenteral benzodiazepine formulations 
(usually MDZ) to treat seizure emergencies is fairly common; however, there is currently 
no nasal spray benzodiazepine product on the market (reasons discussed below).  A 
benzodiazepine rescue medication specifically formulated and approved for IN 
administration would permit outpatient treatment, with potential to reduce emergency 
department visits and improve the quality of life for patients who experience seizure 
emergencies. 
 
1.1.4 Solubility of benzodiazepines 
 
The poor aqueous solubility of benzodiazepines presents a challenge in formulating 
them as nasal sprays.  The thermodynamic aqueous solubilities of MDZ and DZP are 55 ± 
4 µM  (0.018 ± 0.001 mg/mL) and 130 ± 11 μM (0.037 ± 0.003 mg/mL) respectively, at 
pH 7.4 and 32 °C.28  In comparison, the therapeutic dose of IN DZP or IN MDZ is 0.1-0.3 
mg/kg.29-31  The volume of liquid that can be reliably deposited in the human nasal cavity 
without causing loss by runoff of excess solution through the nasal vestibule or drainage 
into the nasopharynx is less than 200 µL.22,24  Most commercial nasal spray products 
deliver 50-140 µL dose volumes, but the optimum volume for an adult is 100 µL per half-
cavity.32,33  Therefore, drugs must be sufficiently potent and concentrated to be candidates 
for the IN route.   
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There are several low volume IN formulations of DZP and MDZ currently being 
developed which utilize co-solvents or other additives to improve solubility.29,34  One such 
IN formulation of MDZ contains propylene glycol and uses a low pH of 4 to achieve 
adequate solubility.35  The use of organic solvents or a formulation pH below normal nasal 
pH can be highly irritating to nasal mucosa.  Transient epistaxis, nasal discomfort, nasal 
congestion, and rhinitis have been reported as common adverse events with these 
formulations.30,36,37  Furthermore, the time to maximum plasma concentration (tmax) for 
these formulations can be delayed.  For IN DZP formulations containing solubilizers have 
been reported with tmax in the range of 0.75-1 hr.
12,37  MDZ is more rapidly absorbed (tmax 
= 10-30 min) following IN administration and has a relatively rapid onset of effect, but its 
bioavailability is intermediate and variable, with fraction absorbed F = 60-70% ± 20-
25%.12  Limited and variable absorption exposes patients to the risk of inconsistent 
response. 
 
1.1.5 Two-part, reactive formulation strategy 
 
Water is the preferred solvent for nasal spray formulations.  Organic co-solvents or 
other solubilizing additives reduce the driving force for permeation of drug across 
membranes38,39 and can irritate or injure sensitive nasal tissues.34,40  One strategy to 
formulate lipophilic drugs in aqueous solutions employs a water-soluble prodrug and 
typically relies on endogenous enzymes for in vivo biotransformation to active drug.41  Our 
group has been developing an extension to this strategy that involves either the co-
administration of a prodrug with its converting enzyme or co-administration of other 
reactive precursors to produce a supersaturated solution of active drug at the site of 
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administration (Figure 1 and Figure 3).  The precursors are designed to be highly water 
soluble, so they can be formulated to therapeutically relevant concentrations for IN delivery 
at physiological pH without the use of organic co-solvents.  In addition to overcoming 
solubility issues, the supersaturated state of benzodiazepine produced by these two-part 
reactive formulations provides an increased driving force for enhanced permeation of the 
drug across nasal mucosa.  A series of in vitro experiments demonstrated enhanced 
permeation of drug across cell membranes using aqueous prodrug/enzyme 
formulations.28,42,43  Therefore, an earlier tmax and more complete absorption is expected, 
resulting in a rapid onset of therapeutic effect and the ability to abort a seizure emergency 
quickly.   
 
 
 
Figure 1.  Hydrolysis of amino acid derivatized benzodiazepine prodrugs.  Enzymatic 
hydrolysis of the amino acid moiety (AA) from the soluble prodrug produces an open ring 
intermediate that spontaneously cyclized to form the insoluble active drug.  Core structure 
of benzodiazepines shown with R denoting substitution locations that give rise to specific 
benzodiazepines, such as DZP or MDZ. 
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Figure 2.  Soluble salt precursor combined with a base to form active benzodiazepine.  
Salts of open ring forms of benzodiazepines are soluble but produce low pH solutions.  
Combining the acidic salt with a base liberates the open ring intermediate, which 
spontaneously cyclizes to form the active benzodiazepine and a solution pH appropriate 
for IN delivery.  The symbol X- is a counter anion such as a chloride.   
 
Although this work is focused on the IN delivery of benzodiazepines to treat seizure 
emergencies, the two-part reactive formulation approach to enhance drug permeation and 
overcome drug solubility issues may be applicable to a variety of therapeutics.  Drugs that 
were previously considered unsuitable for IN delivery due to poor solubility may be 
reevaluated for IN delivery as co-administered soluble precursors.  Examples of conditions 
that may benefit from this two-part reactive formulation approach for rapid IN drug 
delivery are numerous and include panic disorders, pain, migraines, erectile dysfunction, 
allergic reactions, nausea, cardiac events, or motion sickness.     
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1.2 Chapter descriptions 
 
 
1.2.1 Chapter 2. Conversion of a soluble diazepam prodrug to supersaturated diazepam 
for rapid intranasal delivery: kinetics and stability 
 
 
System examined: This chapter discusses the supersaturation behavior of DZP 
generated from a prodrug/enzyme reaction.  Avizafone (AVF), a water-soluble lysyl-
prodrug of DZP, was converted to DZP using a fungal enzyme, Aspergillus oryzae protease 
(AOP).  Enzymatic hydrolysis of the lysine moiety from avizafone releases an open ring 
intermediate species (ORI) that spontaneously cyclizes to form DZP.   
 
Initial hypothesis: We hypothesized that the rate, extent, and time course of DZP 
supersaturation from AVF hydrolysis would be dependent on reaction conditions (pH, 
buffer agent, tonicity, enzyme concentration, etc.), and optimizing these parameters would 
allow the identification of a formulation that balances the DZP production rate with the 
absorption rate across membranes without leading to precipitation of DZP.  
 
Methods: The reaction conditions were varied, and solution concentrations for the 
AVF, ORI, and DZP were monitored using a second derivative spectroscopic method.  The 
time points and concentrations at which DZP began to phase separate under each condition 
were determined by light scattering.  And the precipitates were analyzed for crystallinity.     
 
Conclusions: Phase separation of DZP in prodrug/enzyme formulations that 
produce DZP concentrations in excess of the upper limit of supersaturation would not be 
detrimental to IN delivery of DZP by virtue of the precipitate being amorphous rather than 
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crystalline.  The presence of the amorphous precipitate leads to a constant, predictable, and 
maximal level of supersaturation.  Pharmaceutical formulations of DZP prodrug/enzyme 
combinations should utilize buffering agents, pH, and enzyme concentrations that achieve 
the highest rate of DZP production and absorption without causing nasal tissue irritation.  
In the case of AVF/AOP, a formulation pH at the upper bound of the physiological pH 
range of the nasal cavity provided the fastest reaction rate.  The rate of DZP production 
increased with AOP concentration until a maximum was reached, then counterintuitively 
slowed with increasingly higher enzyme concentrations.  
 
 
 
 
1.2.2 Chapter 3. Intranasal co-administration of a diazepam prodrug with a converting 
enzyme results in rapid absorption of diazepam in rats 
 
 
System examined: This chapter discusses an in vivo pharmacokinetic study 
performed in rats to test IN delivery of DZP using a prodrug/enzyme formulation.  The 
prodrug, AVF, was co-administered with the converting enzyme, human aminopeptidase 
B (APB).   
 
Initial hypothesis: We hypothesized that intranasal administration of a 
prodrug/enzyme formulation would result in rapid and complete absorption of DZP into 
systemic circulation, with correspondingly rapid distribution into the brain.     
 
Methods: A rat model was used to test the hypothesis. The plasma and brain 
pharmacokinetics of IN AVF/APB were compared with IN AVF and IV DZP.  In addition 
to standard noncompartmental pharmacokinetic analyses, we augmented an established 
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physiologically based pharmacokinetic (PKPB) model to incorporate mechanistic 
components, including enzyme reaction kinetics, absorption of both ORI and DZP across 
the nasal mucosa, supersaturation of DZP, and liquid-liquid phase separation of DZP.   
 
Conclusions: The results indicated that IN co-administration of AVF with APB is 
a viable method to rapidly deliver DZP into systemic circulation and subsequently to the 
brain. 
 
 
 
1.2.3 Chapter 4. Substrate stabilizes human aminopeptidase B during lyophilization 
 
 
System examined: For the DZP prodrug/enzyme formulation, both AVF and APB 
would need to have adequate stability to be used in a pharmaceutical product.  Their 
solution and solid state stabilities were investigated.  
 
Initial hypothesis: We hypothesized that the prodrug substrate, AVF, would 
stabilize the enzyme, APB, in the solid state by docking in the active site (i.e. substrate 
binding pocket) and preventing the collapse of the active site during lyophilization.     
   
Methods: Solutions of AVF, APB, and other excipients were combined at low 
temperatures to prevent substrate turnover.  The solutions were then snap frozen, 
lyophilized, and stored.  When the lyophilizates were reconstituted in warm buffer, DZP 
production initiated.  The DZP concentration-time profiles were used to infer the 
concentration of active APB remaining in each sample after lyophilization and storage.   
 
13 
Conclusions: Co-lyophilization of the enzyme, APB, with a low concentration of 
its substrate, AVF, imparted initial stability on par with a high concentration of the 
commonly used lyoprotectant, trehalose.  The combination of substrate and trehalose 
provided a greater stabilizing effect than either additive alone.  The use of a substrate as 
stabilizer for lyophilizing enzymes may be applicable to a variety of substrate/enzyme 
pairs. 
 
 
 
 
1.2.4 Chapter 5. Reactive formulations for intranasal delivery of midazolam 
 
 
System examined: In this chapter, MDZ prodrug/enzyme reactions and MDZ 
acid/base reactions were investigated.  Both two-part reactive formulation approaches 
produce an open ring intermediate species (ORI) that spontaneously cyclizes to form MDZ.    
 
Initial hypothesis: We hypothesized that production of ORI using an acid/base 
reaction would result in faster reaction rates and thus more rapid delivery of MDZ than 
could be achieved by cleavage of an amino acid moiety from a prodrug using an enzyme.   
   
Methods: UV spectroscopy was used to determine the upper limit of supersaturation 
for MDZ and measure the time course of MDZ prodrug/enzyme reactions and MDZ 
acid/base reactions.  Drug transport studies were performed with selected formulations 
using canine kidney epithelial cell monolayers as a model for nasal epithelium.     
 
Conclusions: The ORI cyclization step was found to be slow and rate limiting.  
Thus, rapid liberation of ORI from both prodrug/enzyme reactions and acid/base reactions 
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resulted in accumulation of ORI in solution.  The permeability of ORI and MDZ were pH 
dependent, with the fastest rates of permeation for both observed at the highest pH tested, 
pH 7.4.  The MDZ prodrug/enzyme reaction was not amenable to formulation at 
therapeutic concentrations near this pH because the pH dependent solubility of the prodrug 
was not favorable.  Conversely, the MDZ acid/base reaction could be formulated to very 
high concentrations and the amount of base component adjusted such that a specific pH 
could be easily obtained.  
 
 
 
 
1.2.5 Chapter 6. Nasal spray device for administration of two-part drug formulations 
 
 
System examined: The reactive components of a two-part reactive formulation 
must be either inactivated or kept separate from each other during storage.  At the time of 
administration, mixing the components or otherwise activating them creates a metastable 
solution that can be sprayed into the nasal cavity to deliver drug.  In this chapter, a 
specialized nasal spray device capable of mixing components of a drug formulation and 
atomizing the mixture as part of the actuation process is presented.   
 
Initial hypothesis: Rapid reconstitution of a lyophilizate and subsequent 
atomization of the mixture can be automated in a dual chamber nasal spray device, thereby 
enabling convenient storage and administration of two-part reactive formulations for 
intranasal delivery of benzodiazepines. 
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Methods: A pneumatically driven, dual chamber nasal spray device that utilizes 
single dose drug cartridges was designed, prototyped, and tested.  Testing included 
measurements of spray cone angle as a function of stagnation pressure, dye formulation 
deposition experiments using silicone nasal cavity molds, measurements of enzyme 
degradation upon spraying using a DZP prodrug/enzyme formulation, and visualization of 
the pH profiles of spray patterns produced by an MDZ acid/base formulation. 
 
Conclusions: The performance of the nasal spray device was dependent on the 
formulation properties.  In most cases, lyophilizates could be rapidly reconstituted and 
atomized without an issue, thus demonstrating the potential to use a device such as the one 
described here to administer two-part drug formulations.  However, the slow dissolution of 
formulations with collapsed lyophilizates or lyophilizates that contained a lot of mass (e.g. 
>25 mg AVF) tended to clog the atomizer tip.  The device parameters (pressure, atomizer 
tip orifice size, etc.) would need to be optimized for specific formulations.  Furthermore, 
instantaneous dissolution of lyophilizates and content uniformity between individual spray 
droplets does not appear to be critical since mixing and continued dissolution can occur on 
the surface of the nasal mucosa.   
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Chapter 2: Conversion of a soluble diazepam prodrug to supersaturated 
diazepam for rapid intranasal delivery: kinetics and stability 
 
 
 
 
 
The contents of this chapter were published in: 
Rautiola D, Cloyd JC, Siegel RA. Conversion of a soluble diazepam prodrug to 
supersaturated diazepam for rapid intranasal delivery: Kinetics and stability. Journal 
of Controlled Release. 2018 Nov 10; 289:1-9. 
 
 
 
 
  
17 
2.1 Summary 
 
The low aqueous solubility of diazepam (DZP) presents a challenge in formulating 
nasal sprays without the use of organic solvents.  One approach to overcome this challenge 
involves co-administration of a soluble prodrug, avizafone (AVF), with a converting 
enzyme to produce supersaturated DZP at the site of administration.  In addition to 
overcoming solubility issues, the supersaturated state of DZP provides an increased driving 
force for enhanced permeation across nasal mucosa.  However, supersaturated solutions 
are metastable, and there is a limit to the degree of supersaturation (S) that can be reached 
without causing spontaneous phase separation of the solute.  The aim of this article was to 
determine how formulation parameters affect the rate of DZP supersaturation, maximum 
degree of supersaturation, and phase separation kinetics.  A model enzyme, Aspergillus 
oryzae protease (AOP) was used to convert AVF to DZP, via an open ring intermediate 
(ORI).  A second derivative UV spectroscopic method was developed to simultaneously 
monitor DZP solution concentration and the time course of DZP phase separation.  Fitting 
a kinetic model, with prior knowledge of the enzyme kinetic parameters, the rate constant 
for conversion of ORI to DZP was found to be 0.470 ± 0.012 min-1.  Kinetics and 
supersaturated solution stability were studied as a function of formulation parameters, 
including temperature, pH, buffering agent, AVF concentration, and enzyme 
concentration.  The maximum aqueous solution concentration for DZP at 32 oC was 
determined to be 1.22 ± 0.03 mM DZP (S = 9.38) and was insensitive to changes in 
formulation parameters, excepting temperature.  Supersaturated solutions of DZP could be 
maintained at the maximum concentration for more than 24 hr, even in the presence of 
phase separated DZP.  Polarized light microscopy, PXRD, and DSC analysis indicated that 
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the phase separated DZP was amorphous upon formation and remained so for more than 
24 hr.  Our findings suggest that co-administration of AVF with a suitable human 
converting enzyme will provide a viable mechanism for IN delivery of DZP and result in 
very rapid and complete absorption to quickly terminate seizure emergencies. 
 
 
2.2 Introduction 
 
Patients with epilepsy who experience acute repetitive seizures or sustained seizure 
activity (status epilepticus) require immediate medical attention.  Left untreated, these 
seizure emergencies can result in death or debilitating neurological deficits, and it is 
estimated that costs associated with hospital visits due to status epilepticus are on the order 
of $4 billion/year.4,5  Thus, there is substantial interest in developing formulations of 
diazepam (DZP) for rapid outpatient treatment of seizure emergencies.  Currently the only 
approved outpatient treatment is a rectal diazepam gel (Diastat®), which relies on a drug 
delivery route that is inconvenient and acceptable to very few.  Among possible alternative 
routes of administration, intranasal (IN) drug delivery is noninvasive and offers the 
potential for rapid drug absorption.29,34,44  However, the low aqueous solubility of DZP 
presents a challenge in formulating nasal sprays. The nasal cavity accommodates up to 200 
µL of liquid, so IN formulation concentrations must be high.24,33,45  The aqueous 
thermodynamic equilibrium solubility of DZP ([DZP]aq,sat) is 130 ± 11 μM (0.037 ± 0.003 
mg/mL) at pH 7.4 and 32 °C.28  In comparison, the therapeutic dose of IN DZP is 0.1-0.3 
mg/kg with a maximum of 20 mg/dose.29,30,36  Extensive literature, reviewed in ref 34, exists 
in which the solubility of DZP is improved by adding organic cosolvents and surfactants.  
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While these formulations enable liquid sprays, the additives are irritating and potentially 
toxic. 
 
A prodrug approach can be utilized to overcome the poor aqueous solubility of 
DZP.  Avizafone (AVF) is a soluble prodrug of DZP reported by Hassall et al. in 1977 and 
subsequently developed by the French military to terminate seizures caused by battlefield 
nerve agents.46,47  The dihydrochloride salt of AVF is so hydrophilic that the solid material 
will deliquesce when exposed to the atmosphere.  Structurally, AVF is a Lys-Gly dipeptide 
derivative of a 2-methylamino-5-chlorobenzophenone, which is susceptible to enzymatic 
hydrolysis of lysine (Lys) at the peptide bond (Figure 3).  Cleavage of the N-terminal Lys 
by an endopeptidase produces an open ring intermediate (ORI) form of DZP, which 
undergoes intramolecular condensation to close the diazepine ring 48.   
 
 
 
Figure 3.  Hydrolysis of AVF to form DZP.  Transformation of the hydrophilic prodrug 
AVF to hydrophobic active drug DZP progresses through an open ring intermediate, ORI. 
 
 
AVF has a large polar surface area, so it is expected to have low membrane 
permeability and IN bioavailability.19  Indeed, we showed previously that the apparent 
permeability coefficient (Papp) of AVF across wild type Madin-Darby canine kidney 
epithelial cell (MDCKII-wt) monolayers is negligible compared to Papp = 2.2 × 10
-5  cm/s 
for DZP.28  Therefore, we have been investigating the feasibility of co-administering AVF 
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with a converting enzyme to produce DZP in situ.28,42,49  Following rapid mixing at the 
point of administration, the prodrug/enzyme systems can quickly generate supersaturated 
solutions of DZP when the initial molar concentration of AVF ([AVF]0) exceeds the 
equilibrium solubility of DZP, with degree of supersaturation S = [DZP]aq/[DZP]aq,sat.  
Since the flux of a drug that passively diffuses across mucosal membranes is proportional 
to its thermodynamic activity gradient, the supersaturated solution of DZP on the apical 
side of the nasal mucosa is expected to be more rapidly absorbed compared to DZP whose 
solubility is increased by incorporating a cosolvent, surfactant, or other solubilizing 
additive.38,39   
 
Supersaturated solutions are metastable and will ultimately form crystalline 
precipitates.50,51   When supersaturated concentrations are sufficiently high, the solute can 
phase separate to form a concentrated amorphous phase that precedes crystallization, as 
illustrated in Figure 4.  This process is known as ‘oiling out’ or liquid-liquid phase 
separation (LLPS).52,53  The amorphous precipitate is in quasi-equilibrium with the 
relatively dilute, but still supersaturated solution.  If absorption of drug, either directly from 
the solution or from the coexisting amorphous precipitate, is faster than crystallization, 
then crystallization will be averted.   
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Figure 4.  Supersaturation of DZP produced enzymatically from AVF drives 
absorption and precipitation.  Dotted arrows indicate the slow crystallization process.  
Dashed arrow indicates potential absorption directly from the amorphous precipitate.  
 
The aim of the work presented in this article was to determine how formulation 
parameters affect the rate of DZP supersaturation, maximum degree of supersaturation, and 
precipitation kinetics.  Kinetic studies of conversion of aqueous AVF to supersaturated 
DZP and subsequent phase separation of DZP were performed in vitro.  Effects of 
temperature, pH, buffering agent, AVF concentration, and enzyme concentration on these 
processes were determined using second derivative UV spectroscopy to measure DZP 
solution concentrations and zero order UV spectroscopy to monitor for phase separation.  
When the DZP concentration exceeded a critical concentration (Cind), phase separation 
commenced and caused light scatting.  This scattering was detected in the zero order 
spectra as a sharp increase in the extinction (Ext) of incident light at the induction time 
(tind).  Analysis of the precipitated phase by polarized light microscopy, differential 
scanning calorimetry (DSC), and powder x-ray diffraction (PXRD) indicated that the phase 
separated DZP was initially amorphous and kinetically stable against crystallization for 
several days.  The amorphous precipitate was also shown to undergo rapid dissolution.  
Therefore, the precipitate can serve as a high activity reservoir, available to supply the 
concentration gradient driving DZP absorption through the nasal mucosa.  Direct transfer 
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of DZP from the amorphous precipitate into the mucosal membrane is also a possibility 
(Figure 4). 
 
2.3 Methods 
 
2.3.1 Materials 
 
Diazepam USP (DZP, cat# 803899) was purchased from Fagron, Inc.  Aspergillus 
oryzae protease (AOP, 1470 U/mL, cat# P6110), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES, cat# H4034), and 2-(N-morpholino)ethanesulfonic 
acid (MES, cat# M3671) were purchased from Sigma-Aldrich Corporation.  (AOP was 
selected to probe the potential utility of an enzyme/prodrug combination in vitro; it is not 
a suitable enzyme for a commercial drug product owing to its fungal origin and ill-defined 
composition.)  Phosphate buffered saline (PBS, 20 mM phosphate and 100 mM NaCl) was 
prepared from sodium phosphate dibasic and sodium phosphate monobasic purchased from 
Fisher Scientific.  S-avizafone dihydrochloride (AVF, 99% ee) was synthesized from 5-
chloro-2-methylaminobenzophenone according to the procedure described previously.42    
 
2.3.2 UV spectroscopy 
 
UV measurements to simultaneously determine [AVF], [ORI], [DZP]aq, and tind 
(see below) were performed in a quartz cuvette (path length 1 cm) in an Agilent 
Technologies, Inc. Cary 100 Bio UV/Vis Double Beam Spectrophotometer equipped with 
a temperature controller.  Prior to data collection, working solutions of the AVF and AOP 
reactants were prepared in buffer and equilibrated to the desired experimental temperature.  
Reaction progress was monitored by collecting scans over time in the vicinity of 338 nm 
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at a scan rate of 600 nm/min using the Cary WinUV version 3.10(246) Scan Application.  
At low concentrations where all species were in solution, the scans revealed isosbestic 
points at 301 and 338 nm, with maximum absorption sensitivity at 315 nm.  Phase 
separation of DZP at high concentrations was detected by the appearance of a broadband 
scattering contribution to the spectrum which eliminated the isosbestic points.  As shown 
in the Appendices A1 Section 2, the concentration of DZP in solution at time t ([DZP]aq,t) 
could be monitored by taking the second derivative of extinction, tExt , at = 338 nm, and 
using the formula 
( )
( ) ( )
2 2 2 2
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2 2 2 2
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where   is molar absorptivity and  is the optical path length.  At 32 °C, where most of 
our measurements were made, this expression reduced to 
2
2 t
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d Ext
[DZP] (0.183 M nm ) 0.0495[AVF]
d
= −

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where 0[AVF]  was the initial molar concentration of AVF.  
 
2.3.3 Polarized light microscopy  
 
AVF (2.00 mM) was hydrolyzed by 8.0 U/mL AOP in pH 7.4 PBS at 32 oC to form 
DZP precipitates.  Aliquots of the reaction mixture were removed at regular time points to 
view under a Nikon P-1 microscope equipped with a Nikon 40x/0.65 NA - WD 0.65 Pol 
objective, Nikon Digital Sight DS-Fi1 camera, and temperature-controlled stage.  Images 
were captured using NIS-Elements F 3.0 software. 
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2.3.4 Powder x-ray diffraction (PXRD)  
 
AVF (7.9 mg) was dissolved in 100 μL of 20 mM phosphate buffer pH 7.4 
containing 4.0 U/mL AOP, and the solution was immediately transferred to a PXRD 
sample holder.  The reaction was allowed to proceed for 1 hr at room temperature, during 
which DZP precipitate settled to the bottom of the holder.  A Kimwipe was used to wick 
away the supernatant containing the soluble species.  The solid residue remaining on the 
bottom of the sample holder was dried at room temperature for 1 hr before analysis.  The 
PXRD patterns of the residue and a crystalline DZP standard were obtained using a Bruker 
D8 ADVANCE X-ray Powder Diffractometer with Diffrac-Plus data acquisition and 
analysis software package.  Scan parameters: 2θ range 8-35, number of steps 1373, 
time/step 0.5 sec.  
 
2.3.5 Differential scanning calorimetry (DSC) 
 
Precipitate from the reaction of 20 mg AVF with 8.0 U/mL AOP in 500μL of 20 
mM phosphate buffer pH 7.4 at 32 oC was collected by filtration and dried under high 
vacuum at room temperature for 5 hr.  Approximately 3.5 mg of the collected solid was 
placed in an aluminum Tzero pan.  Measurements were performed in triplicate from 0-190 
oC at a rate of 10 °C/min under nitrogen purge (50 mL/min) using a TA Instruments Q2000 
V24.11 Build 124 DSC with a standard cell and Universal V4.5A software.  Glass 
transition temperatures (Tg) were determined at the inflection point.  Melting temperature 
ranges (Tm) were determined by the onset and peak of the melting endotherm.  Similar 
measurements were made with crystalline DZP. 
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2.4 Results 
 
2.4.1 Governing equations for the reaction and parameter identification 
 
The following equations were assumed to describe enzymatic conversion of AVF 
to ORI followed by cyclization of ORI to aqueous DZP, as depicted in Figure 3: 
 
max
M
V [AVF]d[AVF]
dt K [AVF]
= −
+
        (3) 
 
 
max
2
M
V [AVF]d[ORI]
k [ORI]
dt K [AVF]
= −
+
      (4) 
 
 
2 aq aq,limaq
aq aq,lim
k [ORI] [DZP] [DZP]d[DZP]
0 [DZP] [DZP]dt

= 

    (5) 
 
 
where KM and Vmax are the usual Michaelis-Menten parameters and k2 is a first order rate 
constant. The initial conditions at t = 0 were [AVF] = [AVF]0 and [ORI] = [DZP] = 0.  
Equation 5 assumes an upper limit to the DZP concentration ([DZP]aq,lim) and that any DZP 
produced in excess of this limit will phase separate as an amorphous precipitate with 
negligible crystallization.  In this article, Cind is distinct from [DZP]aq,lim since the 
concentration at which DZP begins to phase separate does not necessarily coincide with 
the concentration in quasi-equilibrium with the amorphous precipitate. 
 
In previous work, where the disappearance of AVF in the presence of AOP was 
tracked using HPLC, we found KM = 3.38 ± 0.34 mM and Vmax = 0.518 ± 0.030 mM/min 
(± SEM) with 0.25 U/mL AOP in pH 7.4 buffer at 32 oC.42  Using these values, the only 
parameter requiring adjustment to fit the data was k2.  Equations 3-5 were integrated, and 
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the method of least squares fitting to DZP concentration-time profile data was used to 
provide the best estimate for k2. 
 
Figure 5 shows the best fit of Equations 3-5 obtained with [AVF]0 = 65 µM 
converted by 0.25 U/mL AOP in pH 7.4 PBS at 32 oC.  The cyclization rate constant, k2
 ± 
SD, was determined to be 0.470 ± 0.012 min-1 (half-life t1/2 = 1.47 min).  The fit is quite 
good, excepting minor systematic deviations at early times, which suggest slight 
overestimation of k2.  Better fits might have been obtained by re-estimating KM and Vmax, 
but we did not pursue this route.  In addition to the [DZP]t curve, we plot the inferred values 
of [ORI]t and [AVF]t.  As expected, the substrate AVF is depleted by the enzyme, while 
the intermediate ORI’s concentration rises and falls with increasing time. 
 
 
Figure 5.  Kinetics of conversion of AVF to DZP, with ORI intermediate.  Blue points: 
[DZP]aq measured at 315 nm during conversion of 65 µM AVF by 0.25 U/mL AOP in pH 
7.4 PBS at 32 οC.  Grey curve: fit of Equations 3-5 used to determine k2.  Red curve: [AVF] 
predicted using Equation 3.  Green curve: [ORI] predicted using Equations 4 and 5 with 
determined k2.     
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2.4.2 Varying prodrug (AVF) concentration 
 
Figure 6A displays the concentration-time profiles of DZP at different initial AVF 
concentrations.  Increasing [AVF]0 increased the rate of the reaction as expected but did 
not significantly affect Cind.  Solid curves are predictions based on Equations 3-5, with KM, 
Vmax, and k2 all fixed.  Given the uncertainties in these parameter values, the predictions 
can be regarded as satisfactory, despite minor nonrandom residuals.  For [AVF]0 = 3.90, 
3.00, 2.00, and 1.25 mM, Cind was found to be constant at 1.22 ± 0.01 mM DZP (± SD).  
Samples with [AVF]0 at or exceeding 2.00 mM became visibly turbid and there was a 
substantial increase in measured Ext at 338 nm at tind (Figure 6B).  Turbidity from the 
precipitation of DZP is demonstrated in Figure 7 (note that these images were captured at 
room temperature).   
 
For [AVF]0 = 1.25 mM, which is a molar concentration near [DZP]aq,lim, the 
[DZP]aq plateau occurred at 1.22 mM.  After reacting for 1 hr, the 1.25 mM [AVF]0 samples 
appeared completely translucent to the naked eye; however, light scattering was detectable 
at tind = 30 min (corresponding to Cind = 1.21 mM) when the axis of the Ext measurements 
at 338 nm or 400 nm was sufficiently scaled (Figure 6C inset).  For samples with [AVF]0 
< Cind, completion of the reaction was evident by the [DZP]aq plateaus near [AVF]0.  In 
these sub-Cind samples, supersaturation persisted with no precipitate detectable for more 
than 24 hr.     
 
With high [AVF]0 (3.90 and 3.00 mM) there were oscillations accompanied by a 
dip in [DZP]aq observed immediately after tind.  When the AVF substrate was exhausted, 
[DZP]aq recovered from these dips and rose to a plateau near Cind (Figure 6D).  It is unclear 
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if this behavior was due to depletion of aqueous DZP by precipitate particle growth 
outpacing dissolution and enzymatic DZP production, or an artifact in the measurement 
due to excessive precipitate in these samples.  Precipitate suspended in the reaction mixture 
eventually settled to the bottom of the sample cuvette after about 2 hr, leading to reduced 
turbidity and a decrease in the Ext measurements.   
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Figure 6.  Effect of varying AVF concentration.  (A) Concentration-time profiles of 
aqueous DZP following enzymatic conversion from 0.500, 1.00, 1.25, 2.00, 3.00, and 3.90 
mM initial AVF converted by 0.25 U/mL AOP in pH 7.4 PBS at 32 oC, n = 3.  Averages 
of experimental data shown as points with model predictions overlaid as lines.  (B) Ext 
measurements corresponding to data in A.  (C) 1.25 mM AVF experimental data from A, 
n = 1.  Grey arrow: 98% conversion of [AVF]0 to DZP at t = 30.3 min.  Inset shows light 
scatting from DZP phase separation was detected at t = 30.0 min.  (D) 3.90 mM AVF 
experimental data from A, n = 1.  Green arrow: 98% conversion of [AVF]0 to DZP at t = 
35.3 min.  
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Figure 7.  Time-lapse images of DZP precipitation.  Turbidity due to precipitation of 
DZP appears suddenly, with 17.0 < tind < 17.5 min at room temperature (~24 
oC).  Left vial: 
2.00 mM AVF control.  Right vial: 2.00 mM AVF with 0.25 U/mL AOP in pH 7.4 PBS.  
Times indicated above the images are in minutes.     
 
 
Concentrations above Cind were not sustainable for more than a few minutes as 
[DZP]aq quickly dropped to or below the upper limit of the metastable zone.  After the 
enzymatic conversion of AVF was complete, [DZP]aq persisted at high concentrations in 
the metastable zone (Figure 8).  The concentrations began to decrease after 24 hr standing 
at room temperature, but stayed well above [DZP]aq,sat.  This decrease was attributed to the 
slow crystallization of DZP, a separate process from the rapid precipitation, i.e. phase 
separation, of amorphous DZP.  For [AVF]0 = 1.00, 1.25, and 1.50 mM; [DZP]aq,26days = 
0.79, 0.95, and 1.16 mM with S = 6.10, 7.34, and 8.89 respectively.  It should be noted that 
the relevant time frame for IN delivery is on the order of tens of minutes.  Thus, 
crystallization would not be relevant in the therapeutic context.  More evidence that the 
immediate precipitate is amorphous will be presented below. 
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Figure 8.  Kinetic stability of supersaturated DZP left standing.  Extended time points 
for concentration-time profiles of 1.00, 1.25, and 1.50 mM AVF converted to DZP by 0.25 
U/mL AOP in pH 7.4 PBS, n = 3.  The enzymatic reactions were conducted at 32 oC for 1 
hr, after which the samples were allowed to stand at room temperature.  Blue dashed line: 
spectrum of DZP in buffer at [DZP]aq,sat = 0.130 mM (S = 1.00).     
 
 
2.4.3 Varying enzyme (AOP) concentration 
 
Increasing the concentration of the AOP also increased the rate of the reaction 
(Figure 9A) and the onset of turbidity (Figure 9B) as expected, but only for [AOP] ≤ 4.0 
U/mL.  The rate of DZP production saturated at ~3.6 mM/min with 4.0 U/mL AOP due, in 
part, to the finite value of k2.  With [AOP] > 4.0 U/mL, increasing the enzyme concentration 
resulted in progressively slower rates of DZP production as shown in Figure 9C.  This 
‘hook effect’ was attributed to unspecified interactions between the reaction species and 
components of the AOP preparation (refer to the Discussion section for more details).  
These interactions sequester AVF, effectively reducing the concentration of AVF available 
to enter the active site of the enzyme.  In a similar fashion, binding of ORI hinders its 
cyclization.  If we introduce scaling factors α and β, then an empirical correction for the 
effective concentrations for AVF and ORI can be obtained by 
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  
 
 eff
AVF
AVF
1 AOP
=
+
        (6) 
 
  
 
 eff
ORI
ORI
1 AOP
=
+
        (7) 
 
Modifying the right-hand side of Equations 3-5 with the effective concentrations of AVF 
and ORI provided a more accurate prediction of the change in solution concentrations of 
DZP when the amount of AOP was varied.  The values of the scaling factors, α and β, were 
determined concurrently by performing a least-squares fit of the modified differential 
equations to a matrix of DZP concentration-time profiles for t = 0.00 – 4.75 min generated 
by reacting AOP = 0.075 – 8.0 U/mL with 2.00 mM AVF in PBS pH 7.4 at 32 oC to give 
α = 0.629 and β = 0.00813.  
 
The isosbestic point at 338 nm remained consistent prior to precipitation when 
[AOP] was varied (Figure 9B), confirming that ε for each of the reaction species was not 
affected by AOP in this region.  With faster rates of DZP production there were decaying 
oscillations in [DZP]aq near Cind observed immediately after tind.  At very low AOP 
concentrations, thus slow reaction rates, these oscillations were imperceptible and C ind 
more closely reflected [DZP]aq,lim. 
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Figure 9.  Effect of varying AOP concentration.  2.00 mM AVF converted by AOP in 
pH 7.4 PBS at 32 oC, n = 3.  Averages of experimental data shown as points with model 
predictions overlaid as lines.  (A) Concentration-time profiles with AOP = 0.075, 0.15, 
0.25, 0.50, 1.0, 2.0, or 4.0 U/mL.  (B) Ext measurements corresponding to data in A.  (C) 
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The rate of DZP production decreased when the concentration of AOP was increased from 
4.0 to 8.0 U/mL.   
 
 
2.4.4 Varying temperature 
 
Ideally, a nasal spray device containing AVF and a converting enzyme would be 
operated near room temperature.  The components would be combined in a mixing 
chamber and then sprayed into the nasal cavity where nasal mucosal temperatures range 
from 30.2 ± 1.7 oC to 34.4 ± 1.1 oC and fluctuate with the respiratory cycle.54  Because 
portable devices might be used at different temperatures, we looked at the effect of 
temperature over the range 20 – 40 oC on the AVF/AOP system.  Within this temperature 
range, d2ε/dλ2 at 338 nm for AVF and ORI had negligible temperature dependence while 
d2ε/dλ2 for DZP decreased with increasing temperature (Appendices A1, Figure A1.54).  
Slopes for the linear portion of the DZP concentration-time profiles increased with 
increasing temperature (Figure 10A).  At each temperature, there was an abrupt increase in 
Ext measurements at 338 nm, corresponding to phase separation of DZP when [DZP]aq 
reached Cind.  With lower temperatures, both Cind and [DZP]aq,lim decreased, although the 
effect of temperature was less prominent for Cind (Figure 10B).          
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Figure 10.  Effect of varying temperature.  (A) Concentration-time profiles of 2.00 mM 
AVF converted by 0.25 U/mL AOP in pH 7.4 PBS at 20 - 40 oC.  Precipitation occurred at 
tind,40C = 4.75 min, tind,35C = 6.5 min, tind,30C = 13.3 min, tind,25C = 18.0 min, and tind,20C = 24.5 
min.  (B) Cind and [DZP]aq,lim decreased with temperature.     
    
 
2.4.5 Varying pH 
 
The average anterior pH of the nasal cavity is 6.40 (range: 5.17 – 8.13) and average 
posterior pH is 6.27 (range: 5.20 – 8.00).55  Nasal sprays should be formulated within the 
normal pH range in order to avoid irritating the mucosa and reduce the amount of buffer 
needed to overcome the natural buffering capacity of nasal mucus.  The identity of the 
buffering agent used to control pH for the AVF/AOP system did not markedly affect the 
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enzyme activity, Cind, or [DZP]aq,lim (Figure 11A).  However, there was a reduction in the 
rate of DZP production (188 to 23.6 µM/min) when pH was lowered from 7.4 to 6.0 (Figure 
11B).  Lowering pH to 6.0 did not affect Cind or [DZP]aq,lim since these concentrations are 
related to the intrinsic solubility of the amorphous form and the pKa of DZP is ~3.    
 
 
Figure 11.  Effect of buffing agent and pH.  Concentration-time profiles (solid lines) of 
2.00 mM AVF converted by 0.50 U/mL AOP at 32 oC overlaid with zero order Ext 
measured at 338 nm (dashed lines).  (A) Reactions performed at pH 7.0 with 20 mM of the 
indicated buffer agent.  Solutions were made isotonic by adding NaCl.  (B) Reactions 
performed in PBS pH 6.0 – 7.4.   
 
 
 
37 
2.4.5 Nature of the precipitate 
 
DSC (Figure 12A) and PXRD (Figure 12B) comparisons between crystalline DZP 
standards and DZP precipitate formed from the enzymatic conversion of AVF indicated 
that the initial precipitate was amorphous.  The melting temperature (Tm) range observed 
for the crystalline DZP standard was 130.8 – 132.4 oC (onset to peak) with molar heat of 
fusion Hf = 26.0 kJ/mol.  These measurements agree with the literature, which reports Tm 
= 131.5 – 134.5 oC and Hf = 25.8 – 27.1 kJ/mol.56-58  Melting endotherms were not 
observed in the DSC curves of the precipitate samples.  Instead, a glass transition (Tg) was 
found with an inflection point at 45.3 ± 0.8 oC (± SD), close to previously reported values 
of  Tg for amorphous DZP, 46.8 ± 0.2 
oC 57 and 42.1 ± 0.4 oC.58  The characteristic 
diffraction peaks that would be expected for a crystalline sample of DZP were observed in 
the PXRD pattern of the DZP standard, while only an amorphous halo was observed for 
the reaction precipitate.  Polarized light microscope images of crystalline DZP standard in 
buffer showed irregular, angular particles with birefringence (Figure 12C).  However, 
images of the precipitate formed by enzymatic conversion of AVF display spherical 
particles and a lack of birefringence, confirming the amorphous nature of the precipitate 
(Figure 12D). 
 
Further evidence that the DZP precipitate was non-crystalline was obtained by 
demonstrating its rapid dissolution and high solubility (Figure 13).  Samples with [AVF]0 
= 2.00 mM and 0.25 U/mL AOP were allowed to generate DZP beyond tind (11 min) to 
accumulate precipitate.  At t = 20 min, conversion of AVF to DZP was expected to be 89% 
complete by enzyme kinetics and [DZP]aq,20min was measured to be 1.21 ± 0.02 mM, S = 
38 
9.34 (i.e. 68% of the generated DZP was in solution and 32% was phase separated).  At 
this time point, the volume of the reaction mixture was doubled by adding buffer.  DZP 
precipitate immediately returned to solution upon dilution of the reaction mixture, as was 
evident by the elimination of light scattering and determination of a new solution 
concentration, ([DZP]aq,20.5min = 0.852 ± 0.009 mM, S = 6.56, experimentally compared to 
0.890 mM, S = 6.85, theoretical).  These observations also confirm that the Lys 
endopeptidase activity of AOP was unaffected by the presence of the DZP precipitate. 
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Figure 12.  Characterization of DZP precipitate.  (A) Overlaid DSC curves.  Crystalline 
DZP standard (blue) with Tm = 131.5 – 134.5 °C, Hf = 26.0 kJ/mol.  Amorphous reaction 
precipitate (red) with Tg = 45.3 ± 0.8
 °C, n = 3.  (B) PXRD patterns.  Crystalline standard 
shows characteristic peaks for DZP (blue).  Amorphous halo of reaction precipitate (red).  
(C) Polarized light microscope image of crystalline DZP standard in buffer.  Scale bar: 100 
μm.  (D) Polarized light microscope images of reaction mixture with precipitate particles.  
Image at t = 1 hr.  Scale bar: 50 μm. 
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Figure 13.  Dissolution of DZP precipitate.  Concentration-time profiles of 2.00 mM 
AVF converted by 0.25 U/mL AOP in pH 7.4 PBS at 32 oC, n = 3.  Initial reaction mixture 
volume: 200 µL.  At t = 20 min, 200 µL of buffer was added to the reaction mixture and 
the precipitate went back into solution.  Blue points: measured [DZP]aq.  Grey line: 
theoretical [DZP]aq with and without dilution.  Orange points: zero order extinction at 338 
nm. 
 
 
2.5 Discussion and conclusion  
 
Using a second derivative UV spectroscopic method to monitor the conversion of 
AVF to DZP offers several distinct advantages over chromatographic techniques such as 
HPLC.  Foremost, it eliminates the need to filter or centrifuge precipitated DZP in order to 
obtain the solution concentration.  Monitoring of [AVF], [ORI], [DZP]aq, and tind can be 
accomplished in real time with short time intervals between data points.  The time interval 
is limited only by the scan rate of the instrument in the region of the analytical wavelength.  
Chromatographic techniques require stopping the enzymatic reaction to preserve substrate 
and product concentrations at a particular time point.  This is commonly accomplished by 
adding a miscible organic solvent to denature the enzyme.  However, denaturing the 
enzyme does not prevent ORI from progressing to DZP, resulting in measurements that 
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reflect the sum of [ORI]t and [DZP]aq,t.  Furthermore, adding organic solvent to denature 
the enzyme may also solvate precipitated DZP and lead to an erroneous measurement of 
the solution concentration.  Nevertheless, HPLC is critical in determining the rate of 
conversion of AVF to ORI.  Using HPLC data and enzyme parameter identifications from 
our previous publication in tandem with the spectroscopic determination of DZP 
accumulation achieved in the present work enabled us to determine the rate constant for 
ring closure.  While Bayesian fitting of all parameters might have been a better procedure, 
the small improvement in fits would be unlikely to justify the added effort.  
 
Second derivative spectra are derived from zero order spectra.  Zero order spectral 
data can provide additional information about phase separation of solutes from 
supersaturated solutions.  Often, a wavelength beyond the tail of the absorbance peak is 
chosen to determine tind for systems that form such precipitates.  For example, Ext 
measurements at 400 nm have been used to detect precipitation upon dilution of injectable 
DZP formulations.59  By selecting an isosbestic point to simultaneously measure 
concentration and tind, we eliminate error associated with correlating tind to Cind that would 
arise from the time lag between measurements made by scanning between the analyte peak 
and tail wavelengths, such as 315 nm and 400 nm, respectively, for DZP.  Error 
compounding in the determination of [DZP]aq due to the combined uncertainty in 
(d2ε/dλ2)AVF and (d2ε/dλ2)DZP should also be considered when selecting an analytical 
wavelength.  At 338 nm, this error compounding is mitigated since AVF contributes < 5% 
to the combined calibration curve sensitivity (Appendices A1, Figure A1.55).   
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In addition to methodology for monitoring the conversion of AVF to DZP in real-
time, an accurate predictive model was needed to scale-up the reaction for formulation at 
therapeutically relevant concentrations.  The basic reaction model described by Equations 
3-5 was successfully used to model the sigmoidal behavior of concentration-time profiles 
at higher substrate concentrations (Figure 6A) with k2 = 0.470 min
-1 for 0.25 U/mL AOP 
in PBS pH 7.4 at 32 oC.  However, directly scaling Vmax to model different AOP 
concentrations resulted in substantial deviations from experimental data with slower than 
predicted rates of DZP production observed at higher [AOP].  Increasing [AOP] leads to 
an accumulation of ORI; thus, it was thought that perhaps ORI was inhibiting the AOP 
enzyme.  Incorporating traditional enzyme inhibition models for cases where ORI, DZP, 
or Lys was the inhibiting species did not result in better agreement between the model and 
the data set.  The lack of inhibition from DZP or Lys was also confirmed experimentally 
(Appendices A1, Figure A1.60).  Instead, the AOP preparation itself was found to slow the 
reaction.   
 
Commercially available AOP is a protein mixture that has endoprotease, 
exopeptidase, and amylase activity from at least 8 different enzymes.60  In addition to 
proteins, the stock solution of AOP from the manufacturer contains 42.8% w/w water, 30% 
w/w sucrose, 10% w/w potassium chloride, and 0.20% w/w potassium sorbate.61  
Benzophenones and benzodiazepines tend to bind non-specifically to proteins, with the 
fraction unbound in plasma (fu) estimated to be 0.21 for AVF and 0.19 for ORI based on a 
quantitative structure–activity relationship calculation62,63 and fu = 0.01 – 0.04 for DZP 
reported in the literature.64  It was thought that intermittent binding of AVF and ORI to 
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proteins in the AOP preparation was responsible for the attenuation of the reaction rate 
observed when [AOP] was increased.   Binding of AVF reduces the free concentration of 
AVF available to the enzyme, and binding of ORI inhibits the formation of DZP by 
restricting the degrees of freedom necessary for the molecule to cyclize.  However, 
equilibrium dialysis of 130 µM DZP with 4 U/mL AOP did not result in a reduction of free 
DZP, suggesting that the concentration of proteins in AOP was too low for non-specific 
binding interactions to be significant.  The expressions in Equations 6 and 7 remain 
empirical corrections to the model since the binding of ORI to AOP could not be verified 
experimentally and it is unknown which component of AOP could be causing this effect. 
 
Although it is unlikely that a nonhuman enzyme preparation, such as AOP, would 
be chosen as the biocatalyst in a pharmaceutical product, the counterproductive rate of DZP 
production observed with high concentrations of AOP (Figure 9C) exemplifies the need 
for careful characterization of these prodrug/enzyme systems.  When the enzymatic 
conversion of AVF is fast, the rate of ORI cyclization becomes reaction rate limiting.  
Adding excessive amounts of enzyme beyond the amount needed to achieve an optimal 
DZP absorption rate may also increase the possibility of an allergic reaction or other 
adverse effects from the enzyme.          
 
One of the more interesting aspects of the AVF/AOP system is that [DZP]aq was 
sustained at the upper limit of the metastable zone even in the presence of precipitate and 
after the DZP production had ceased.  A solute’s amorphous solubility has been proposed 
to correspond to the maximum achievable free solute concentration.65-67  Based on our 
observations, the amorphous solubility does indeed correspond to the upper limit of the 
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metastable zone.  Polarized light microscopy, DSC, and PXRD analysis indicated that the 
DZP precipitate was amorphous.  This means that the absorption rate enhancement 
afforded by supersaturated formulations is limited by the amorphous solubility.  The 
amorphous solubility of DZP, hence [DZP]aq,lim, was found to be 1.22 ± 0.03 mM (S = 
9.38) at 32 oC.   
 
This concentration limit was unaffected by pH in the range 6.0 – 7.4, but the rate 
of DZP production decreased with decreasing pH.  The rate of DZP production also 
decreased with temperature.  These behaviors were consistent with the pH- and 
temperature-dependent aminopeptidase activity of AOP reported in the literature;60 
however, the intramolecular cyclization of ORI is expected to be pH- and temperature-
dependent as well.  While k2 would increase with increasing temperature according to the 
Arrhenius reaction rate equation, the reaction temperature for the drug product is 
essentially fixed at the average temperature of the nasal cavity (32 oC).  On the other hand, 
pH can be controlled.  The basic amine group of ORI, with a predicted pKa of 7.7,
68 must 
be neutral to react with the ketone (Figure 3).  At pH 6.0 only 1.7% would exist as the free 
base compared to 30% at pH 7.4, so t1/2 of ORI is expected to be shorter at higher pH.   
 
The ionization state of ORI would may also affect its membrane permeability.  
While AVF and Lys would have negligible absorption across nasal epithelium due to their 
hydrophilicity, ORI is somewhat hydrophobic and may undergo passive transcellular 
diffusion (pH 7.4 cLogD = -1.71 for AVF, -4.98 for Lys, 1.69 for ORI, and 3.08 for DZP).68  
Membrane permeability to ORI is expected to contribute to the delivery of DZP into 
systemic circulation, so controlling the concentration of ORI may be important.  As an 
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intermediate, ORI reaches peak concentrations at early time points.  In our experiments the 
highest [ORI] reached was 1.8 mM with no detectable precipitation in the vicinity of that 
time point.  Thus, adjusting the formulation parameters to produce higher [ORI] may be 
desirable from a drug delivery perspective.  Although the toxicological profile of ORI is 
unknown, the overall in vivo exposure would be low because the lifetime of ORI is short.  
Investigations to characterize the biopharmaceutical significance of ORI are ongoing in 
our lab.    
 
At the outset of these studies, our goal was to understand how formulation 
parameters such as pH, buffering agent, temperature, and enzyme concentration affected 
the maximum level of DZP supersaturation that could be obtained and the time course of 
precipitation.  We intended to use this information to balance the DZP production rate with 
the rate of DZP diffusion across cell membranes to afford rapid absorption while avoiding 
precipitation.  However, we found that the amorphous precipitate, lacking long-range 
crystalline order and the accompanying crystal lattice energy barrier to dissolution, readily 
underwent dissolution (Figure 13).  Therefore, precisely controlling the prodrug conversion 
rate to avoid precipitation of DZP is moot.  The non-crystalline precipitate acts as a source 
for DZP and serves a useful function in the formulation by maintaining maximum 
supersaturation during the absorption process.  It may also contribute directly to permeation 
across the membrane.  In general, a high and consistent supersaturation was obtained at 
each experimental condition, demonstrating that the co-administration of AVF with a 
converting enzyme is a robust strategy to generate predictable levels of supersaturated 
DZP.   
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We conclude by reiterating that AOP, while inexpensive and therefore useful in 
conducting the studies reported in this contribution, is unsuitable for human use due to its 
fungal origin.  Furthermore, as purchased, it is a mixture of several enzymes.  We do not 
know how each fraction contributes to the conversion of AVF to ORI, and ultimately DZP.  
Recently we discovered that a human enzyme, aminopeptidase B (APB) is also active 
against AVF.  A purified stock has been produced and characterized.  A report of in vivo 
DZP pharmacokinetic studies in rats receiving intranasal AVF/APB solutions is in 
preparation. 
 
  
47 
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3.1 Summary 
 
Intranasal administration is an attractive route for systemic delivery of small, 
lipophilic drugs because they are rapidly absorbed through the nasal mucosa into systemic 
circulation.  However, the low solubility of lipophilic drugs often precludes aqueous nasal 
spray formulations.  A unique approach to circumvent solubility issues involves co-
administration of a hydrophilic prodrug with an exogenous converting enzyme.  This 
strategy not only addresses poor solubility, but also leads to an increase in the chemical 
activity gradient driving drug absorption.  Herein, we report plasma and brain 
concentrations in rats following co-administration of a hydrophilic diazepam prodrug, 
avizafone, with the converting enzyme human aminopeptidase B.  Single doses of 
avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered 
intranasally, resulting in 77.8 ± 6.0, 112 ± 10, and 114 ± 7 % bioavailability; maximum 
plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/mL; and times to peak plasma 
concentration 5, 8, and 5 min for each dose level respectively.  Both diazepam and a 
transient intermediate were absorbed.  Enzyme kinetics incorporated into a physiologically 
based pharmacokinetic model enabled estimation of the first order absorption rate 
constants: 0.0689 ± 0.0080 min-1 for diazepam and 0.122 ± 0.022 min-1 for the 
intermediate.  Our results demonstrate that diazepam, which is practically insoluble, can 
be delivered intranasally with rapid and complete absorption by co-administering 
avizafone with aminopeptidase B.  Furthermore, even faster rates of absorption might be 
attained simply by increasing the enzyme concentration, potentially supplanting 
intravenous diazepam or lorazepam or intramuscular midazolam in the treatment of seizure 
emergencies. 
49 
 
3.2 Introduction 
 
Status epilepticus and acute repetitive seizures are serious medical emergencies that 
can cause lasting neurological damage and other life-threatening complications.  Prolonged 
seizure activity associated with these conditions may lead to hypoxia, metabolic acidosis, 
hyperthermia, aspiration, pulmonary edema, brain injury, and an increase in the likelihood 
of experiencing additional seizures in the future.69  The risk of injury, medical 
complications, or death can be mitigated by prompt medical treatment.2,7  Benzodiazepines 
are the drugs of choice for treating seizure emergencies.  Intravenous (IV) diazepam (DZP), 
IV lorazepam, or intramuscular midazolam (MDZ) are the preferred first-line rescue 
therapies.10  However, drug delivery by injection can be problematic, especially when 
administered by non-medical personnel.  Injection is difficult to carry out on obese or 
emaciated individuals, in the presence of multiple layers of clothing, or in public places.  
Furthermore, treatment of seizure emergencies can be significantly delayed if the patient 
must wait for medical personnel or transportation to the emergency room. Therefore, there 
is a need for outpatient treatments that can be administered immediately at the onset of a 
seizure by non-medical personnel.  
    
Currently, the only outpatient treatment of a seizure emergencies approved by the 
United States Food and Drug Administration (FDA) is rectally administered DZP 
(Diastat®).  Patients often object to this route of administration despite its effectiveness.70  
Off-label alternatives to rectal diazepam including intranasal (IN) and buccal MDZ using, 
respectively, injectable and oral solution formulations.71  Other routes to deliver 
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benzodiazepines for the treatment of seizure emergencies currently under development 
include buccal DZP films72 and IN sprays for DZP or MDZ.37,73  
 
Intranasal DZP is an attractive treatment option because administration is easily 
performed by non-medical personnel, and it has an extended duration of action with low 
risk of adverse events.71  However, the poor aqueous solubility of benzodiazepines presents 
a challenge in formulating them as nasal sprays because they require co-solvents or other 
additives to improve solubility.29  These solubilizing excipients can be highly irritating to 
nasal mucosa.  Transient epistaxis, nasal discomfort, nasal congestion, and rhinitis have 
been reported as side effects with some of these formulations, including those with 
DZP.30,31,37  Further, the time to reach the maximum plasma concentration (tmax) for IN 
DZP formulations utilizing solubilizing excipients is relatively slow, ranging from 0.75-
1.5 hrs.12,37,74     
 
 One strategy to overcome these challenges is to formulate a nasal DZP spray in an 
aqueous vehicle employing a water-soluble lysine prodrug of DZP, avizafone (AVF).  
While prodrug formulations typically rely on endogenous enzymes for in vivo 
biotransformation to the active drug,41 unpublished results from a pilot canine study 
performed by our group suggested that exogenous enzyme would need to be included in 
the formulation to achieve the desired prodrug conversion rate and bioavailability.  A series 
of in vitro experiments combining water soluble benzodiazepine prodrugs with the fungal 
converting enzyme Aspergillus oryzae protease (AOP) demonstrated that the formulations 
were capable of producing supersaturated solutions of the active drug, leading to an 
enhanced permeation rate of drug across cultured cell monolayers.28,42,43,49  Further in vitro 
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studies characterized the conversion kinetics of AVF to DZP,75 which first involves 
enzymatically catalyzed release of the lysine and formation of an open ring intermediate 
(ORI), followed by spontaneous closure of ORI to form DZP (Figure 14).  These studies 
also showed that supersaturated DZP undergoes liquid/liquid phase separation at a critical 
degree of supersaturation, and resists crystallization over periods of days.   
 
 
Figure 14.  Prodrug/enzyme reaction scheme.  Formation of DZP by enzymatic 
hydrolysis of AVF with APB progresses through an intermediate, ORI. 
 
 
Based on these in vitro results, we hypothesized that intranasal administration of 
prodrug/enzyme formulations should result in rapid and complete in vivo absorption of 
DZP, with rapid distribution into the brain.  In the present study, we tested this hypothesis 
in a rat model, in which we replaced AOP with a human enzyme, aminopeptidase B (APB), 
and compared the plasma and brain pharmacokinetics of IN AVF/APB with IN AVF and 
IV DZP.  In addition to standard noncompartmental pharmacokinetic analyses, we 
augmented an established physiologically based pharmacokinetic (PKPB) model to 
incorporate mechanistic components, including enzyme reaction kinetics, absorption of 
both ORI and DZP across the nasal mucosa, supersaturation of DZP, and liquid-liquid 
phase separation of DZP.  Finally, we carried out preliminary histological studies to 
determine whether acute damage would result from the AVF/APB formulations.   
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3.4 Materials and methods 
 
3.4.1 Experimental design 
 
The primary aim of this study was to determine whether IN administration of an 
AVF/APB combination to rats would result in rapid absorption of DZP without damaging 
the nasal mucosa.  In brief, single doses of admixed solutions of AVF and APB equivalent 
to DZP at either 1.50 mg/kg, 1.00 mg/kg, or 0.500 mg/kg were deposited in the nasal 
cavities of rats.  Plasma samples and brains were collected at time points ranging from 2 to 
90 min.  DZP concentrations measured in these tissues were compared against 
concentrations measured in samples collected from rats that were administered a 1.00 
mg/kg dose of DZP intravenously (IV).  Nasal tissue samples collected from rats sacrificed 
at the 90 min time point were examined for lesions.  Details about the dosing and sample 
collection schedule are given in the sections that follow and summarized in the Appendices 
A2, Table A2.5. 
 
3.4.2 Animals 
 
All animal experiments were approved by the Institutional Animal Care and Use 
Committees of the University of Minnesota (protocol 1508-32889A, principal investigator: 
J.C. Cloyd) and HealthPartners (protocol 14-073, principal investigator: L.R. Hanson).  
The experiments were conducted at the HealthPartners Animal Care Facility and in 
accordance with the Guide for the Care and Use of Laboratory Animals (U.S. National 
Institutes of Health).  Sixty-six male Sprague Dawley rats 8-9 weeks old (0.271 ± 0.023 
kg) from Envigo RMS, Inc. (Indianapolis, IN) were used for this study.  Rats were housed 
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under controlled environmental conditions with a standard 12 hr light/dark cycle and free 
access to food and water. 
 
 
3.4.3 Formulation components 
 
S-avizafone dihydrochloride (AVF•2HCl) was synthesized with > 99% purity, 99% 
ee from 5-chloro-2-methylaminobenzophenone according to the procedure described 
previously.42  Recombinant human aminopeptidase B enzyme (APB) was produced by 
inserting the RNPEP DNA sequence encoding for APB and a His tag into a pQE-30 Xa 
vector, transforming JM109 E. coli with the resultant plasmid, inducing APB expression 
with IPTG, and purifying the expressed APB by affinity capture chromatography.76,77  
Purity of APB was >80% by gel electrophoresis.  Phosphate buffered saline (PBS) IN 
delivery vehicle was prepared at pH 7.4 and concentration 20 mM using sodium phosphate 
dibasic and sodium phosphate monobasic purchased from Fisher Scientific, Inc. (Hampton, 
NH: cat# BP332 and BP329), made isotonic with sodium chloride purchased from EMD 
Millipore (Burlington, MA: cat# 567440), and sterile filtered during formulation.  For the 
IV control arm of the study, a commercial formulation of injectable diazepam USP (5 
mg/mL DZP, 40% propylene glycol, 10% alcohol, 5% benzoate-benzoic acid, and 1.5% 
benzyl alcohol) was purchased from Hospira, Inc. (Rocky Mount, NC: NDC 0409-3213-
12, lot 58-257-EV).   
 
3.4.4 Enzyme kinetics 
 
The Michaelis constant (KM) and maximum reaction velocity (Vmax) for the 
hydrolysis of AVF by APB in pH 7.4 PBS at 32 °C were determined by fitting the 
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Michaelis-Menten equation to the initial rates of substrate consumption for a series of AVF 
concentrations.  Reactions with 62.5 – 4000 µM AVF and 15 µg/mL (0.203 µM) APB were 
carried out in an Eppendorf Thermomixer 5436 at 500 rpm.  After 1 min, APB was 
denatured by addition of methanol.  Cyclization of ORI to DZP was allowed to progress to 
completion before measuring UV spectra of the quenched reaction mixtures in a Cary 100 
Bio UV/Vis spectrophotometer (Agilent Technologies, Inc., Santa Clara, CA).  The second 
derivative of the spectrum at 338 nm was used to quantify DZP, and this quantity was taken 
to be the molar equivalent to the amount of AVF consumed.  A curve was fit to the AVF 
consumption versus initial AVF concentration with KM and Vmax as fitting parameters using 
the nlinfit function in MATLAB® version R2017b by The MathWorks, Inc. (Natick, MA). 
 
3.4.5 Dosing 
 
For IN dosing, rats were anesthetized, placed in the supine position, and cannulated.  
Rats designated for nasal tissue histology were not cannulated.  Solutions of AVF and APB 
prepared in PBS were admixed to the appropriate concentration for each animal 
immediately prior to administration.  See Table 1 for dose levels.  After mixing, the 
formulation was quickly instilled into the nasal cavity using an Eppendorf pipettor with a 
gel loading pipette tip inserted to a depth of 14 mm past the nares.  A total volume of 30 
µL was delivered, 15 µL into the right nostril followed by 15 µL into the left nostril within 
0.5 min.  There were four IN dose groups: AVF/APB at low, medium, and high doses, and 
an AVF-only group at the medium dose.  These doses were chosen because DZP near 1 
mg/kg is commonly used in rat studies and results in plasma concentrations in rats that are 
clinically relevant.   
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Table 1.  IN doses.  
Dose 
level 
Equivalent DZP 
(mg/kg) 
AVF•2HCl 
(mg/kg) 
APB 
(µg/kg) 
high 1.50 2.66 91.4 
med 1.00 1.77 60.7 
low 0.500 0.885 30.4 
    
For IV dosing, a commercial formulation of DZP was injected directly into the 
femoral vein.  A small incision was made in the skin along the mid line of the left hind leg 
of anesthetized rats that were already cannulated in the right femoral vein.  The incision 
was enlarged by blunt dissection to expose the left femoral vein.  A 30-gauge needle was 
inserted into the vein to deliver a bolus dose of 1 mg/kg (medium dose level, ~54 µL) of 
DZP using a 100 µL syringe.  Upon withdrawal of the needle, moderate pressure was 
applied to the site of injection with a cotton swab for 5-10 seconds to facilitate coagulation 
and seal the puncture.   
 
3.4.6 Sample collection 
 
Prior to cannulation for serial blood draws, rats were anesthetized with a 1.0 mL/kg 
subcutaneous ketamine cocktail containing 43 mg/mL ketamine HCl, 8.6 mg/mL xylazine 
HCl, and 1.4 mg/mL acepromazine.  Anesthesia was maintained throughout surgery, 
dosing, and sample collection by administering subcutaneous boosters of 50 mg/kg 
ketamine alternating with boosters of ketamine cocktail.  Blood was drawn from the right 
femoral vein through an PU 3Fr 25cm catheter (Instech Laboratories Inc., Plymouth 
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Meeting, PA: cat# C30PU-RFV1308).  Leapfrog sampling was performed, with one cohort 
of 3 rats sampled at 2, 10, 20, 30, and 60 min and another cohort of 3 rats sampled at 5, 15, 
45, 75 and 90 min for each dosing group.  Each blood draw was 500 µL, with a 500 µL 
saline replacement volume pushed following every other draw.  Whole blood was 
centrifuged at 2000 g for 3 min in BD MicrotainerTM Tubes (Becton Dickinson Co., 
Franklin Lakes, NJ: cat# 365974) containing EDTA to obtain plasma.  Additional cohorts 
of 3 rats each were designated for destructive sampling to obtain 2, 5, 8, and 10 min brain 
samples for the medium dose IV DZP and medium dose IN AVF/APB groups.  At the final 
time points, blood samples were collected by cardiac puncture.  The rats were then 
euthanized by transcardial perfusion with 120 mL saline.  Brains, including the olfactory 
bulbs, were removed by gross dissection and hemisected sagittally.  Brain and plasma 
samples were snap-frozen in liquid nitrogen and stored at -80 °C until analysis.   
 
3.4.7 LC-MS/MS method 
 
DZP and AVF were extracted from plasma and brain samples and quantified by 
LC-MS/MS.  For extraction, brain tissue was first combined with two volumes (w/v) of 
lysis buffer and homogenized.  The lysis buffer was composed of 25% methanol in PBS.  
An internal standard, tolbutamide, was spiked into 50 μL aliquots of plasma and 200 μL 
aliquots of brain lysates.  The aliquots were then extracted with 2.5 mL ethyl acetate.  The 
supernatant was removed by centrifugation at 2500 rpm for 10 min and evaporated to 
dryness under nitrogen at 37 °C.  The dried extract was resuspended in 150 μL of mobile 
phase for LC–MS/MS analysis.   
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A DionexTM UltiMateTM 3000 LC and TSQ QuantumTM Access MAX triple 
quadrupole mass spectrometer (MS/MS) with electrospray ionization (ESI) manufactured 
by Thermo Fisher Scientific, Inc. (Waltham, MA) was used for the analysis.  Analyte 
separation was performed at a flow rate of 0.2 mL/min through a Zorbax Eclipse XDB C18 
(3.0 x 150 mm x 3.5µm) column (Agilent Technologies, Inc., Santa Clara, CA: cat# 
963954-302) with a step gradient mobile phase.  Retention times for AVF, DZP, and 
internal standard were 3.4, 9.3, and 7.6 min, respectively.  The mobile phase consisted of 
acetonitrile (solvent A) and 0.1% acetic acid in water (solvent B).  The composition of the 
mobile phase was held for 2 min at 5:95 A/B, increased to 60:40 A/B for 8 min, and finally 
decreased to 5:95 A/B for 3 min to condition the column before the next injection.  The 
mass spectrometer was operated in multiple reaction monitoring (MRM) mode with a 
capillary voltage of 3200 V and capillary temperature of 2500 °C.  Precursor and product 
ions for the analytes were detected in positive ion mode with m/z 431 [MH]+ → 246 for 
AVF and 286 [MH]+ → 193 for DZP; the internal standard was detected in negative mode 
with m/z 269 [M-H]- → 170.  The concentration ranges for DZP were 25.0–1600 ng/mL 
in plasma and 6.25–400 ng/mL in brain lysate. 
 
3.4.8 Nasal tissue histology 
 
A separate cohort of rats was utilized to assess potential trauma to the nasal mucosa 
from the prodrug/enzyme formulation.  This cohort did not receive catheters and no blood 
or brain samples were collected, but the animals did receive anesthesia and were dosed 
intranasally in the same manner as the others.  Three rats at each dose level (vehicle-only, 
low, medium, and high, n = 12) were euthanized 90 min post-dose by perfusion with 120 
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mL saline followed by 120 mL of 10% neutral buffered formalin (NBF).  The heads were 
removed, fixed in 10% NBF, and submitted to Colorado Histo-Prep (Fort Collins, CO) for 
histopathological evaluation by a board-certified veterinary pathologist.  The samples were 
decalcified, trimmed, processed, embedded, and sectioned.  Five sections of the nasal 
turbinates from each of the rats were stained with hematoxylin and eosine for microscopic 
imaging.  Slides of the sections were read without knowledge of the dose group.  The 
observed tissue changes were categorized using standardized toxicological pathology 
criteria.78,79 
 
3.4.9 Noncompartmental analysis 
 
Naïve pooled noncompartmental analysis (NCA) of plasma and brain 
concentration-time profiles was performed using WinNonlin® software version 8.0.0.3176 
by Certara USA, Inc. (Princeton, NJ).  Maximum concentration (Cmax) and the tmax were 
determined from the average concentrations at nominal time points.  The apparent terminal 
rate constant (λz) was estimated by regression of the log-linear portion of the concentration-
time profiles.  The apparent terminal half-life (t1/2,z) was calculated as ln(2)/λz.  
Concentrations measured from animals subjected to destructive and repeated sampling 
were pooled.  Data was treated as sparse and the linear trapezoidal method was used for 
calculating the area under the curve (AUC) from the time of dosing to 90 min.  Intranasal 
bioavailability (F) was calculated by 
F =
AUCIN,plasma/DoseIN
AUCIV,plasma/DoseIV
× 100 (1) 
 
Drug targeting efficiency (DTE) was used to assess direct nose-to-brain transport via the 
olfactory or trigeminal pathways.80  DTE represents the time average partition ratio 
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between brain and plasma for IN administration versus IV administration.  Data from the 
medium dose level from time of dosing to 90 min was used to calculate DTE from the 
following equation  
DTE =
(AUCbrain/AUCblood)IN
(AUCbrain/AUCblood)IV
× 100 (2) 
 
 
3.4.10 PBPK model 
 
A physiologically based pharmacokinetic (PBPK) model was used for further 
analysis.  The model’s structure and parameters for DZP disposition in rats were originally 
reported by Igari et al.81  Variants of the model have been utilized by other researchers, 
such as Gueorguieva et al.82 and Thompson et al.,83 to explore aspects of predicting DZP 
concentration in tissues.  We have appended the model with a nasal compartment for IN 
delivery of AVF and APB as illustrated in Figure 15. 
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Figure 15.  PBPK model schematic.  An established PBPK model for DZP disposition in 
rats was modified to include a nasal cavity compartment.  ORI and DZP absorb from the 
nasal cavity into circulation after IN administration of AVF and APB.     
 
 
 The conversion rate for AVF to DZP in the nasal cavity is governed by enzyme 
kinetics and the rate of ORI cyclization.  To characterize the enzyme reaction, KM and Vmax 
were measured in vitro in the formulation vehicle (pH 7.4 PBS) at 32 °C.  This temperature 
is approximately the average temperature of rodent nasal passages.84  The catalytic rate 
constant (kcat) for enzymatic hydrolysis was then calculated from Vmax, i.e. kcat = 
Vmax/Cnasal,APB where Cnasal,APB is the concentration of enzyme in the nasal cavity.  Thus, 
the rate of AVF hydrolysis in vivo can be predicted by   
dCnasal,AVF
dt
= −
kcatCnasal,APBCnasal,AVF
KM + Cnasal,AVF
 (3) 
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where Cnasal,AVF is the concentration of AVF in the nasal cavity.  ORI, the immediate 
product of AVF hydrolysis, can accumulate in the nasal cavity and has physicochemical 
properties such that this species has the potential to passively diffuse across nasal 
epithelium.  Transport of ORI was modeled as unidirectional due to the relatively small 
volume of the nasal cavity.  The volume of the nasal cavity (Vnasal) was assumed to be the 
volume of the deposited formulation, 30 µL.  Thus, the rate of change in the concentration 
of ORI (Cnasal,ORI) in the nasal cavity can be expressed as  
dCnasal,ORI
dt
=
kcatCnasal,APBCnasal,AVF
KM + Cnasal,AVF
− (k2 + ka,ORI)Cnasal,ORI (4) 
 
where k2 is the first order intramolecular cyclization rate constant of ORI and ka,ORI is the 
nasal absorption rate constant of ORI.  Similarly, DZP has an associated absorption rate 
constant (ka,DZP).  However, DZP generated in excess of CDZP,lim forms an amorphous phase 
separate from the solution phase.  Assuming drug transport only occurs from the solution 
phase, the rate of change in the concentration of DZP (Cnasal,DZP) in the nasal cavity can be 
expressed as  
dCnasal,DZP
dt
= k2Cnasal,ORI − ka,DZPCnasal,DZP,sol (5) 
   
where Cnasal,DZP,sol is the concentration of DZP in the solution phase and Cnasal,DZP,sol ≤ 
CDZP,lim.   
 
This PBPK model assumes perfusion rate-limited distribution and tissue 
compartment concentrations that are in instantaneous equilibrium with venous blood flows.  
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A general expression for the rate of change in concentration of DZP in non-eliminating 
organ or tissue compartments can be written as   
dCtissue
dt
=
Qtissue
Vtissue
[Cartery −
Ctissue
KP,tissue
] (6) 
 
where Ctissue is the concentration in the specified tissue, Vtissue is the volume of that tissue, 
Qtissue is the blood flow rate, Cartery is the concentration in the arterial blood, and KP,tissue is 
the partition coefficient.      
 
DZP is extensively metabolized in the liver and minimally excreted unchanged, so 
elimination was assumed to be solely by hepatic metabolism.  The hepatic extraction ratio 
for DZP in rats is approximately unity, even for doses as high as 4 mg/kg.85  Therefore, the 
concentration of DZP in the liver was assumed to stay well below KM for metabolism by 
liver enzymes.  An expression for the rate of change in the concentration of DZP in the 
liver can be written as 
dCliver
dt
=
1
Vliver
[
QstomachCstomach
KP, stomach
+
QsplanchnicCsplanchnic
KP, splanchnic
+ QliverCartery
−
CLintCliver(fu/R)
KP,liverR
−
(Qstomach + Qsplanchnic + Qliver)Cliver
KP, liver
] 
(7) 
 
where CLint is intrinsic clearance, fu is the fraction unbound in plasma, and R is the blood 
to plasma ratio.  In rats, the blood to plasma DZP concentration ratio has been reported to 
be R = 1.037 ± 0.007 with the fraction unbound in plasma fu = 0.14 ± 0.003.
81,86   
 
Expressions for the rate of change in the concentration of DZP in the venous and 
arterial blood compartments are 
63 
dCvein
dt
=
1
Vvein
[∑
QiCi
KP, i
i
+ Vnasal(ka,ORICnasal,ORI + ka,DZPCnasal,DZP,sol)
− QlungsCvein] 
(8) 
dCartery
dt
=
1
Vartery
[
QlungsClungs
KP, lungs
− ∑ Qj
j
Cartery] (9) 
 
where i represents each tissue compartment that has an outflow to the venous pool and j 
represents each tissue compartment that has an inflow from the arterial pool.  At pH 7.4, 
the half-life for cyclization of ORI is 1.47 min,75 so we assume most of the conversion to 
DZP occurs in the nasal cavity.  Absorbed ORI would continue to transform into DZP in 
the mucosa and in the blood.87  Therefore, systemic exposure to ORI was limited, and any 
ORI that did reach the circulation was regarded as DZP for the purposes of 
pharmacokinetic analysis. 
 
The PBPK model, represented by Equations 3-9, was constructed in MATLAB®.  
Values for the parameters of interest (CLint, ka,ORI, ka,DZP, and CDZP,lim) were determined by 
fitting numerically solved solutions of the differential equations to experimental data using 
the ode45 function in conjunction with the lsqcurvefit function.  Experimental data was 
input as averages of the DZP concentrations measured at the nominal time points, with data 
from animals subjected to destructive and repeated sampling pooled.  Fitting was 
performed in two stages.  First, CLint was determined by fitting the model to DZP 
concentrations measured in plasma from rats administered IV DZP.  Tissue compartment 
volumes, blood flow rates, and partition coefficients were fixed at the values reported by 
Gueorgieva et al.82 and Thompson et al.83  These constants are listed in Appendices A2, 
Table A2.6.  Then, CLint was fixed and in vivo values for ka,ORI, ka,DZP, and CDZP,lim were 
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determined by fitting the model to a matrix of DZP concentrations measured in plasma 
from rats administered IN AVF/APB at the low, medium, and high dose levels.  
 
3.4.11 Statistical methods  
 
Naïve pooled noncompartmental analysis was performed using sparse sampling 
computations.88  Concentrations of DZP measured below the limit of quantification were 
retained in the data set.89  Squared correlation coefficients adjusted (R2adj) for the number 
of points used in the estimation of λz were >0.7 for all treatment groups.  For AUC, standard 
error (SE) of the mean estimate was calculated using WinNonlin®, which employs 
equations described by Nedelman and Jia90 and unbiased sample covariance estimation 
described by Holder.91  The SEs associated with F estimates were calculated by 
propagating the SEs from the AUCs.  Similarly, the SEs of DTEs were calculated by 
propagating the SEs from the AUCs.  Descriptive statistics for the variability in tmax are not 
reported because leapfrog serial and destructive sampling data were pooled.  The standard 
deviation (SD) of measured concentrations at tmax was used to describe the dispersion of 
Cmax.  SEs reported for determined PBPK parameter estimates were obtained from 
MATLAB® by back-calulating from 95% confidence intervals computed using the nlparci 
function with the Jacobian from the lsqcurvefit function.  Root mean square error (RMSE) 
for the model fits were calculated from the average concentrations at the nominal time 
points. 
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3.5 Results 
 
3.5.1 Noncompartmental analysis 
 
As shown in Figure 16, DZP generated from IN administration of the AVF/APB 
formulation appeared rapidly in plasma.  Plasma and brain tissue samples were also 
analyzed for AVF, but concentrations were below the limit of quantification.  The short 
half-life of ORI did not allow for its quantification.  The average plasma concentration of 
DZP at the first measured time point, 2 min, was greater for IN AVF/APB than for IV DZP 
at an equivalent dose due to rapid distribution following IV dosing (Figure 16A).  Plasma 
concentrations from IN administration continued to rise, reaching Cmax = 388 ± 31 ng/mL 
at tmax = 8 min for the medium dose level.  Similar tmax values were observed at each dose 
level, but Cmax was not proportional to the dose.  In fact, Cmax for the high dose was not 
statistically different from that of the medium dose (Figure 16B).  When AVF was 
administered without APB, there was a prominent decrease in the rate of DZP absorption.  
As shown in Table 2, Cmax was nearly fourfold lower without co-administered enzyme.    
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Figure 16.  DZP concentration-time profiles measured in plasma.  Error bars are SD.  
For IV DZP and IN AVF/APB at the medium dose level (equivalent to DZP at 1.00 mg/kg), 
n = 6 at 2, 5, and 10 min time points; n = 3 for all other data points.  (A) IN-administered 
AVF/APB compared with IV-administered DZP indicated high bioavalability of the IN 
formulation, F = 112 ± 10 % (±SE).  The IN-administered AVF/APB formulation has a 
pharmacokinetic advantage with regards to Cmax and AUC0-15min when compared to the 
AVF-only control.  (B) Saturation of the absorption process resulted in nearly identical 
initial rates of absorption for IN-administered AVF/APB at the medium and high dose 
levels.  
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There was complete absorption of DZP from IN AVF/APB at the medium and high 
dose levels, as was evident by bioavailabilities of 112 ± 10 and 114 ± 7 % respectively.  
The AVF-only control group and low dose APB/AVF group had nearly identical 
bioavailability (F = 77.8%) based on exposure from 0 to 90 min.  However, there was a 
notable difference between these groups at early time points (Figure 16B).  Dose 
normalized AUC0-15min was twice as large for the AVF/APB low dose group compared to 
the AVF-only control (Table 2).  AUC0-15min for the IN AVF/APB medium and high dose 
groups were similar, suggesting saturation of the DZP absorption rate. 
 
Table 2.  Noncompartmental analysis of plasma DZP concentrations. 
Formulation DZP AVF AVF/APB AVF/APB AVF/APB 
Route IV IN IN IN IN 
Equiv. DZP 
dose (mg/kg) 
[dose level] 
1.00 
[medium] 
1.00 
[medium] 
0.500 
[low] 
1.00 
[medium] 
1.50 
[high] 
Tmax (min) 0 a 10 5 8 5 
Cmax ± SD 
(ng/mL) 
441 a 108 ± 30 71.5 ± 9.3 388 ± 31 355 ± 187 
t1/2,z (min) 32.9 33.4 136 b 26.7 37.8 
AUC0-15min 
(min.ng/mL) 
1910 ± 70 837 ± 28 793 ± 54 3250 ± 190 3850 ± 270 
AUC0-90min ± SE 
(min.ng/mL) 
5430 ± 190 4230 ± 120 2110 ± 150 6080 ± 510 9280 ± 470 
F % ± SE n/a 77.8 ± 3.5 77.8 ± 6.0 112 ± 10 114 ± 7 
a Cmax reported for IV DZP is the concentration extrapolated to t = 0 min (i.e. the initial 
concentration C0) as calculated by WinNonlin
® NCA analysis.  b Overestimation of t1/2,z 
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due to inherent variability of data below limit of quantification in terminal phase of low 
dose group.   
 
NCA results for DZP measured in brain tissue are listed in Table 3.  For the IN 
AVF/APB medium dose group, tmax was reached at 8 min in both plasma and brain tissue.  
However, the concentration of DZP measured in plasma at the first time point (Cplasma,DZP 
= 270 ± 181 ng/mL ±SD at t = 2 min) was already greater than the therapeutic concentration 
that is expected to lead to seizure threshold elevation in rats, Cplasma,DZP ≥ 70 ng/mL.92  Brain 
concentrations were not measured at time points between 10 and 60 min, but comparable 
concentrations were observed at 8 and 10 min (415 ± 32 and 404 ± 35 ng/g respectively), 
suggesting the true maxima were in this region.  Brain Cmax for IV DZP was recorded at 
the first time point, 2 min.  Rapid transport from blood into brain tissue is normal for small, 
lipophilic drugs.  DTE, a metric commonly used to assess nose-to-brain transport, was less 
than unity, negating significant transport of DZP through direct nose-to-brain pathways.   
 
Table 3.  Noncompartmental analysis of brain DZP concentrations.   
Formulation 
Equiv. 
DZP dose 
(mg/kg) 
tmax 
(min) 
Cmax ± SD 
(ng/mL) 
AUC0-90min ± 
SE 
(min.ng/mL) 
DTE  
% ± SE 
IV DZP 1.00 2 938 ± 142 18600 ± 200 n/a 
IN AVF/APB 1.00 8 415 ± 33 15400 ± 500 74.0 ± 7.3 
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3.5.2 PBPK model 
 
Concentration-time profiles were well described by a PBPK model with the rate of 
drug input controlled by enzyme kinetics.  At 32 °C in pH 7.4 PBS, the Michaelis-Menten 
enzyme kinetic parameters for APB measured in vitro were KM = 370 ± 63 µM and kcat = 
1250 ± 60 min-1 ±SE (see Appendices A2, Figure A2.67).  The rate constant, k2 ±SD, for 
cyclization of ORI, previously measured in vitro under the same conditions 75, was assumed 
to remain constant at 0.470 ± 0.012 min-1 in vivo.  As listed in Table 1, the APB 
concentrations were scaled with the AVF concentration so that hydrolysis of AVF would 
be complete at t ≈ 4 min, regardless of the dose level.  This also means that the predicted 
mole fraction of the total dose that had been converted to DZP was the same for each dose 
level at a given time point.  For example, approximately 75% of the dose was expected to 
be converted to DZP at t = 5 min regardless of the dose level.   
 
Fitting the PBPK model to DZP concentrations measured in plasma samples from 
the IV DZP group resulted in CLint = 15.4 L/min, which was expected since DZP is well 
known to have a hepatic extraction ratio of approximately one in rats93 and confirms the 
assumption that DZP clearance from the liver was flow-limited in this PBPK model.  
Subsequent fitting of the model to DZP concentrations measured in plasma samples from 
the IN APB/AVF groups allowed estimation of the parameters governing in vivo absorption 
from the nasal cavity: ka,ORI = 0.122 ± 0.022 min
-1, ka,DZP = 0.0689 ± 0.0080 min
-1, and 
CDZP,lim = 20.8 ± 3.1 mM (±SE).  Conversion of AVF to DZP was faster than the combined 
absorption of ORI and DZP, leading to an accumulation of DZP in the nasal cavity.  Since 
the aqueous equilibrium solubility of DZP is only 130 µM, concentrations entered the 
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supersaturated region.  The apparent concentration at which supersaturated DZP began to 
phase separate from solution in the nasal cavity, CDZP,lim, was a useful parameter to model 
the nonlinear absorption kinetics observed at early time points.  However, the value of 
CDZP,lim should be interpreted within the context of the assumptions that Vnasal was equal to 
the dose volume and only DZP in the solution phase could be absorbed. 
 
 Well-stirred PBPK models predict high initial plasma concentrations with IV 
administration because the initial volume of distribution is assumed to be the volume of 
the venous blood compartment.  This is illustrated in Figure 17A where the predicted 
plasma concentration for the IV DZP group decreases dramatically from the time of dosing 
as it distributes out of the venous compartment to reach the first measured plasma 
concentration at t = 2 min.  The high concentrations of DZP measured in the brain at the 
first time point were predicted more accurately with this PBPK distribution behavior 
compared to a modeling approach which relied on a standard two-compartment model 
function to drive brain concentrations.  In general, concentrations of DZP in the brain were 
predicted reasonably well by the PBPK model.  For the IN AVF/APB medium dose group, 
brain concentrations lagged behind plasma concentrations during the first few min.  This 
observation provided additional evidence that transport of DZP through direct nose-to-
brain pathways was not significant.     
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Figure 17.  DZP concentration-time profiles in plasma and brain tissue.  Experimental 
data (points) and model predictions (lines) at the medium dose level (equivalent to DZP at 
1.00 mg/kg).  For plasma concentrations, n = 6 at 2, 5, and 10 min time points; n = 3 at all 
other time points for plasma and brain.  Error bars are SD.  (A) IV-administered DZP.  
RMSE of the predicted curve was 44 ng/mL for plasma and 246 ng/g for bain.  The open 
purple triangle at the origin is a marker to highlight the steep initial increase in brain DZP 
concentration; it is not a measured data point.  (B) IN-administered AVF/APB.  Predicted 
curve RMSE = 66 ng/mL for plasma and 67 ng/g for bain.   
 
 
Although there was significant variablity in the data, similar average plasma 
concentrations were observed for the medium and high IN AVF/APB dose groups at early 
time points (Figure 18A).  This indicated the absorption process was saturable.  The 
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nonlinearity was likely caused by phase separation of DZP from solution when CDZP,lim was 
reached in the nasal cavity, a phenomenon that has been observed in vitro.75  Phase 
separation attenuated DZP absorption and produced a shoulder at t = 10 min in the 
predicted concentration-time profile for the high dose group (Figure 18A, green curve).  
The peak preceding the shoulder comes from the absorption of ORI, which contributes to 
the concentration of DZP observed in plasma.  In the first few min after administration, the 
amount of DZP produced by the reaction is relatively low compared to ORI.  Predictions 
for the relative amount of each reaction species in the nasal cavity are shown in Figure 
18B.  Decomposition of the plasma concentration-time profile for the medium IN 
AVF/APB dose group, shown in Figure 18C, illustrates how absorption of ORI contributes 
to the rate at which DZP enters the circulation.             
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Figure 18.  DZP concentration-time profiles in plasma from IN administration of 
AVF/APB at each dose level.  Experimental data (points) and model predictions (lines).  
For medium dose level (equivalent to DZP at 1.00 mg/kg), n = 6 at 2, 5, and 10 min time 
points; n = 3 for all other data points.  Error bars are SD.  (A)  Saturation of absorption rate 
observed with the high dose.  Predicted curve RMSE = 43 ng/mL for low dose, 66 ng/mL 
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for medium dose, and 61 ng/mL for the high dose.  (B) Predicted amounts of each reaction 
species in the nasal cavity.  Solid lines represent the low dose, dashed lines medium dose, 
and dotted lines high dose level for a 0.250 kg rat.  Inset shows expanded view of the first 
10 min.  (C) Absorption of ORI contributes to the rate of DZP delivery into the systemic 
circulation.            
 
 
3.5.3 Nasal tissue histology 
 
No inflammatory response was observed in the nasal tissue samples.  Lesions 
(changes) found in the samples were few, with severities graded as either minimal or mild.  
These were located in the anterior portion of the nasal cavity and were consistent with 
mechanical trauma from insertion of the pipette tip used for dosing.  There were some 
small, focal areas of missing epithelium on the wall of the nasal septum and/or 
nasoturbinate, and occasionally the maxilloturbinate.  Cellular debris, consisting of small 
clusters of sloughed epithelial cells and cellular fragments, were found on the wall of the 
nasal septum or the nasoturbinate and anterior meatus.  Other than two instances of minimal 
focal hemorrhage, the blank vehicle control group was unremarkable.  There were no 
lesions observed in the ethmroid turbinates, olfactory nerves, and olfactory bulbs.  The low, 
medium, and high dose groups (IN AVF/APB equivalent to 0.500, 1.00, and 1.50 mg/kg 
DZP respectively) did not display a dose response with regard to location, frequency, or 
severity of the lesions.  Some examples of the tissue sections are shown in Figure 19.  A 
detailed enumeration of the locations and severity of the observations can be found in 
Appendices A2, Table A2.8.  
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Figure 19.  Representative examples of nasal tissue section images.  Minor mechanical 
trauma from insertion of the dosing pipette tip was observed in some animals.  There were 
no lesions attributed to the drug formulation.  (A) Normal tissue.  (B)  Hemorrhage.  (C) 
Necrosis.  
 
 
 
3.6 Discussion and conclusion 
 
Intranasal co-administration of AVF and APB resulted in rapid absorption of DZP 
with excellent bioavailability, thus demonstrating that a prodrug/enzyme combination in 
an aqueous vehicle efficiently delivers a hydrophobic drug.  PBPK analysis indicated that 
both DZP and transient ORI were readily absorbed through the nasal mucosa into the 
systemic circulation.  There was no evidence of transport through direct nose-to-brain 
pathways.  Histological analysis of the nasal tissues post-dose did not reveal significant 
differences between the vehicle-only control group and treatment groups, suggesting that 
the formulation was well tolerated.   
 
Although aminopeptidases capable of hydrolyzing Lys from AVF to produce DZP 
exist in the nasal mucosa and blood of both rats and humans,94-96 exogenous APB is 
necessary to ensure complete and rapid conversion of AVF.  In Figure 16B, the appearance 
of DZP in plasma at early time points for the IN AVF-only control group suggests that 
some AVF conversion occurred in the nasal cavity by endogenous enzymes.  However, the 
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therapeutic concentration of DZP that is expected to lead to seizure threshold elevation in 
rats (Cplasma,DZP ≥ 70 ng/mL)92 was not reached until t = 10 min and was not sustained 
thereafter.  AVF also converts to DZP when absorbed into the circulation.  Upshall et al.87 
found the half-life for conversion of AVF in blood was 0.49 ± 0.06, 3.17 ± 0.09, and 3.85 
± 0.26 min for guinea pig, rhesus monkey, and human, respectively (blood and plasma 
were not significantly different).  However, substantial transport of AVF across nasal 
epithelium is unlikely since it does not readily partition into membranes.  Using wild type 
Madin-Darby canine kidney epithelial cell (MDCKII-wt) monolayers as an in vitro model 
for nasal epithelium to estimate apparent permeability coefficients (Papp), we observed 
negligible permeation of AVF (Papp = 1.0-1.5×10
-6 cm/s) compared to DZP (Papp = 2.2×10
-
5 cm/s).28   
 
IN-administered drugs tend to exhibit variable absorption rates and bioavailabilities 
when mucociliary clearance to the digestive tract competes with absorption though the 
nasal mucosa.  The high bioavailability calculated for the medium and high IN AVF/APB 
dose groups suggests that those doses were fully converted and absorbed through the nasal 
mucosa of the rats (Table 2).  The lower bioavailability observed for the low dose IN 
AVF/APB and AVF-only groups may have been due to a portion of the dose being cleared 
from the nasal cavity before complete conversion could occur.  The first order rate constant 
for mucociliary clearance is roughly 0.035 min-1 in healthy adult humans97 and 0.14 min-1 
in Sprague-Dawley rats.98  However, the rate of clearance depends on many factors 
including dose volume, viscosity, pH, tonicity, component concentrations, and 
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pharmacodynamic effects on the cilia.  A separate study to assess the effects of dose level 
on the beat frequency of cilia may be warranted to reconcile the discrepant bioavailabilities. 
 
From the plasma DZP concentration-time profiles measured at each dose level 
(Figure 18A), absorption during the first 15 min displayed nonlinear pharmacokinetics 
while concentrations at later time points were approximately dose proportional.  This 
behavior was not entirely unexpected since it was known that phase separation of DZP 
would occur if the accumulation of DZP in the nasal cavity exceeded CDZP,lim.  However, 
it was surprising that the in vivo estimate of CDZP,lim (20.8 ± 3.1 mM ±SE), determined by 
fitting the PBPK model, was nearly 17 times greater than CDZP,lim measured in vitro (1.22 
± 0.03 mM ±SD).75  The in vivo estimation is conspicuously high because Vnasal was 
assumed to be equivalent to the dosed formulation volume.  However, the total volume 
would increase when the deposited dose mixes with nasal mucus.   
 
Absorption of DZP directly from phase separated DZP could also cause 
overestimation of CDZP,lim.  Transcytosis of the precipitated DZP colloidal particles presents 
one possible mechanism of transport across the nasal epithelium.  Brooking et al.99 reported 
size dependent transcytosis of latex nanoparticles through the nasal mucosa and into the 
blood of rats.  Another potential mechanism invokes an increase in driving force for 
absorption arising from higher local concentrations of DZP in the diffuse layer of particles 
that are proximal to cell membranes.  Both mechanisms require that DZP precipitate 
particles be close to cell membranes.  Confounding of DZP absorption from solution with 
absorption from the precipitated phase is exacerbated by the small volume-to-surface area 
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ratio that results when the formulation spreads across the surface of the mucosa, 
minimizing the distance particles need to travel to reach the cell membranes.          
 
 The hydrophobic reaction intermediate, ORI, can accumulate in the nasal cavity as 
well, so there is potential for phase separation of this species.  Since we did not observe 
precipitate formation at time points where there was expected to be high concentrations of 
ORI during our in vitro experiments,75 phase separation of ORI was not considered in this 
PBPK model.  However, it was necessary to incorporate absorption of ORI into the model 
to account for the rapid appearance of DZP in plasma and the shape of the concentration-
time profiles.  Satisfying Lipinski's rule of five, with cLogD = 1.69 at pH 7.4,68 ORI can 
partition into membranes and permeate epithelium.  Papp for ORI across MDCKII-wt 
monolayers was predicted to be 1.77×10-5 cm/s using structure activity relationship 
calculations.100,101  Since ORI quickly transforms into DZP, absorption of ORI fortuitously 
contributes to the rate at which DZP appears in plasma.  This contribution is illustrated by 
the dotted curve in Figure 18C, but the area under the ORI curve is not representative of 
exposure.  Exposure to ORI was miniscule due to its short half-life. 
 
Exposure to the other reaction species, AVF and APB, was similarly short and most 
likely only topical.  Based on enzyme kinetic calculations, AVF was completely 
hydrolyzed in the nasal cavity in less than 4 min and increasing the amount of APB could 
easily speed up its consumption.  The residence time of APB in the nasal cavity is 
controlled by mucociliary clearance and possibly by proteases in the mucus.  Once APB or 
its degradation products reach the digestive tract, they would be digested like any other 
protein.  Histological analysis of the posterior, absorptive nasal tissue sections suggested 
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that the formulation was innocuous.  However, the histological findings are incomplete.  
Collection of tissue samples 90 min post-dose does not provide sufficient time to develop 
an inflammatory response.  Future in vivo studies will incorporate later time points to more 
fully assess acute nasal toxicology.    
 
Approximately 50% of the nasal surface in a rat is olfactory epithelium.102  
Although dosing did not specifically target the olfactory epithelium, rats were in the supine 
position during treatment.  Presumably the formulation spread across the olfactory 
epithelium, providing ample opportunity for direct nose-to-brain transport via the olfactory 
bulb.  However, there was no evidence that direct nose-to-brain transport was an important 
pathway for delivery of DZP to the brain, in agreement with the findings of Kaur and 
Kim.103  DTE was only 74% (Table 3) and DZP concentrations in plasma preceded brain 
concentrations (Figure 17B), indicating absorption into the blood and subsequent advection 
to the brain was faster than diffusive transport along olfactory or trigeminal nerves. 
         
In conclusion, the pharmacokinetic results presented here demonstrate that IN co-
administration of AVF with APB is a viable method to rapidly deliver DZP into the 
systemic circulation and, subsequently, the brain.  Since the highly concentrated 
formulation does not contain organic solvents, it is expected to be better tolerated and 
absorb faster than IN formulations of DZP that utilize solubilizing excipients.  
Administered as a noninvasive nasal spray, IN AVF/APB could be used to quickly 
terminate seizure emergencies in humans, resulting in reduced emergency department 
visits and an improved quality of life for patients who experience seizure emergencies.  
Further progress necessitates development of a device which can store the prodrug and 
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enzyme separately, and then combine them as into sprayed solution at the time of 
administration. 
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Chapter 4: Substrate stabilizes human aminopeptidase B 
during lyophilization 
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4.1 Summary 
 
Human aminopeptidase B (APB) is a hydrolytic zinc metalloenzyme currently 
being investigated as a biocatalyst for intranasal delivery of prodrug/enzyme combinations.  
APB is known to be unstable in solution, with significant degradation over the course of 
24 hr at room temperature.  Therefore, enzyme stability is a major concern to ensure a 
viable drug product.  Lyophilization is one technique commonly used to increase the 
activation energy for denaturization of proteins and confer an extended shelf-life.  
However, the lyophilization process itself can cause conformational changes and 
aggregation, leading to inactivation of the enzyme.  In this study, we demonstrate the use 
of the substrate avizafone (AVF), a prodrug for diazepam, as a stabilizer to minimize 
inactivation of APB during lyophilization.  Permutations of APB samples combined with 
AVF, trehalose, and/or mannitol were snap frozen and lyophilized at 0.016 mbar and 24 
°C for 18 hr.  The lyophilizates were then reconstituted in pH 7.4 PBS at 32 °C to measure 
the activity of APB.  Of the permutations, an APB+AVF+trehalose combination resulted 
in minimum degradation with 71% retention of activity.  This was followed by APB+AVF 
and APB+trehalose with 60% and 56% retention of activity respectively.  In comparison, 
APB+mannitol and APB alone retained only 16% and 6.4% activity.  Lyophilizates of the 
APB+AVF+trehalose formulation were subjected to a 6-month accelerated stability study, 
at the end of which negligible reduction in activity was observed.  These results suggest 
co-lyophilization of an enzyme with its substrate can impart stability on par with the 
commonly used lyoprotectant, trehalose, but the combination of substrate and trehalose 
provides a greater stabilizing effect than either additive alone. 
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4.2 Introduction 
 
Stabilization of enzymes by lyophilization is a common process that is used 
ubiquitously across many industries, from textiles to food processing.104  Enzymes tend to 
lose activity during the lyophilization process and many can become completely 
inactivated.  To prevent inactivation, cryo- and lyo-protecting excipients are added to the 
enzyme formulation before lyophilization.   A variety of excipients can be used for this 
purpose, but the quantity and combination required for adequate stabilization can differ for 
a given enzyme and lyophilization cycle.  Some common additives are trehalose (Tre), 
polyvinylpyrrolidone, and serum albumin.  These excipients are not substrates, so they do 
not naturally dock into the active sites of enzymes.  They are added in high concentrations 
relative to the concentration of the enzyme in order to limit molecular mobility, thereby 
minimizing perturbations in the protein structure that can lead to denaturation during the 
freezing and drying steps.105  Conscientious selection and reduction of excipient is 
especially important in pharmaceutical preparations where the physicochemical properties 
(e.g. viscosity, rate of dissolution, volume) and biocompatibility (e.g. tonicity, pH, toxicity, 
immunogenicity) of the formulation are critical.106,107     
 
 Herein, we report the use of an enzyme’s substrate as a stabilizer for lyophilization.  
We hypothesized that substrate occupation of the active site (i.e. substrate binding pocket) 
during lyophilization would prevent collapse of the active site in a similar fashion as 
traditional excipients.  Furthermore, substrates offer the potential to preserve enzymatic 
activity at lower concentrations than other excipients because they have high binding 
affinity and are structurally complimentary to the arrangement of amino acid residues in the 
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active site.  Our experiments suggest that substrate alone can be as effective at stabilizing 
enzymes as non-substrate excipients.  A cooperative effect was also observed in which the 
inclusion of both substrate and the common stabilizing excipient, Tre, resulted in greater 
enzyme stability than the use of either additive by itself.   
 
This work was born out of a desire to stabilize human aminopeptidase B (APB) in 
a pharmaceutical preparation.  We have been developing pharmaceutical formulations that 
allow intranasal delivery of poorly soluble drugs via co-administration of a soluble prodrug 
with an exogenous converting enzyme.42,108  One such formulation contains the diazepam 
prodrug avizafone (AVF) and APB.  When combined and sprayed into the nasal cavity, 
hydrolysis of AVF by APB produces an open ring intermediate (ORI) species that 
spontaneously cyclizes to form supersaturated, rapidly permeating diazepam (DZP) 
(Figure 3).  This drug delivery strategy requires AVF and APB to be in an inactivated state 
during storage.  Segregating the two reactive components in a nasal spray device as two 
separate solutions was not feasible because APB is unstable in solution and AVF is 
marginally stable in solution.  Storing AVF and APB as solids and reconstituting them at 
the time of administration seemed to be the most expedient way to achieve an acceptable 
shelf-life.  It was thought that co-lyophilizing AVF and APB would improve the overall 
stability of the formulation, reduce the need for high concentrations of stabilizing 
excipients, and result in a homogeneous mixture that produces DZP upon reconstitution in 
a nasal spray.      
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Figure 20.  Reaction scheme for the hydrolysis of AVF by APB.  Transformation of 
AVF to DZP progresses through an open ring intermediate, ORI. 
 
 The process of combining AVF and APB in a pre-lyophilization solution relies on 
reduced enzymatic activity of APB at low temperatures.  When solutions of the two 
components were cooled in an ice bath, they could be mixed without generating DZP.  The 
mixtures were then cooled further to freeze for lyophilization.  After drying under vacuum, 
the resulting lyophilizates contained both AVF and APB in a stable, unreactive solid state.  
Reconstitution of the lyophilizates at room temperature activated the reactive system, 
producing DZP and allowing quantification of active APB.  This process and the concept 
of using substrates as stabilizers for lyophilizing enzymes may be applicable to a variety 
of substrate/enzyme pairs.  
 
4.3 Methods 
 
4.3.1 Materials 
 
S-avizafone dihydrochloride (AVF) was synthesized with > 99% purity, 99% ee 
from 5-chloro-2-methylaminobenzophenone according to the procedure described 
previously.42  Recombinant human aminopeptidase B enzyme (APB), expressed and 
isolated with > 80% purity from JM109 E. coli cells, was produced by the procedure 
described previously.108  Aspergillus oryzae protease, S-Lys-para-nitroanilide 
dihydrobromide (LpNA), and para-nitroaniline (pNA) were purchased from Sigma-
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Aldrich, Inc. (St. Louis, MO: cat# P6110, L7002, and 31569).  D-trehalose (Tre) as a 
dihydrate and D-mannitol (Man) were purchased from MP Biomedicals, LLC (Solon, OH: 
cat# 103097 and 102248).  Tris(hydroxymethyl)aminomethane (Tris) and pH 7.4 
phosphate buffered saline (PBS) were purchased from Fisher Scientific (Hampton, NH: 
cat# BP152 and 10010-023).  The mass of the anhydrous form of Tre was reported for the 
sample concentrations.   
 
4.3.2 Lyophilization procedure 
 
Aqueous stock solutions of APB, AVF, Tre, Man, pH 7.4 Tris, and pure water were 
cooled in an ice bath to ~ 0 °C.  Aliquots of the stock solutions were pipetted into cold 2 
mL glass vials in the appropriate ratios to give the indicated component concentrations and 
an equal final volume for each sample.  For samples that contained AVF, the AVF solution 
was added last.  These cold pre-lyophilization solutions were mixed briefly with a pipette 
before placing the vials in liquid nitrogen for 5 min to snap freeze the contents.  The vials 
were then removed from the liquid nitrogen, transferred to a lyophilization flask, and dried 
at room temperature under 0.016 mbar vacuum for 18 hrs using a Labconco, Inc. (Kansas 
City, MO) FreeZone 6 manifold freeze dryer.  The vials containing the lyophilizates were 
capped and stored in desiccators until analysis.  Storage was at room temperature unless 
otherwise stated.       
 
4.3.3 Measurement of active enzyme 
 
The amount of active enzyme remaining after sample processing, lyophilization, 
and storage was determined using spectroscopic techniques.  Absorbance (Abs) 
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measurements to track the hydrolysis of substrates were made using an Agilent 
Technologies, Inc. (Santa Clara, CA) Cary 100 Bio UV/Vis double beam 
spectrophotometer equipped with a temperature controller.  Unless stated otherwise, the 
temperature controller was set to 32 °C, which is the average temperature of the human 
nasal cavity.54  Samples were analyzed in a quartz ultra-microcuvette with 1 cm pathlength 
(ℓ) and 50 µL minimum fill volume.  Solutions of APB, Tre, Tris, and Man at the 
concentrations used in this study were transparent at the wavelengths used for 
spectroscopic quantification of the substrate and product concentrations.   
 
To measure specific enzyme activity, lyophilizates were reconstituted with 1.00 
mM LpNA in PBS that had been warmed to 32 °C.  The resulting solutions were 
immediately transferred to a cuvette already positioned in the temperature-controlled block 
of the spectrophotometer.  The change in Abs due to hydrolysis of LpNA was monitored 
at 405 nm.  Readings were taken every 100 ms.  The slope of the absorbance change 
(dAbs/dt) during the first 0.25 min was used to calculate the reaction rate (d[pNA]/dt) by 
 
d[𝑝NA]
dt
= (
ℓ−1
ε𝑝NA − εL𝑝NA
)
dAbs
dt
 (1) 
 
 
where ε denotes molar absorptivity.  In pH 7.4 PBS at 32 °C, εpNA = 9860 M−1cm−1 and 
εLpNA = 55.9 M−1cm−1 at 405 nm.  (Refer to Appendices Table A3.9 for the temperature 
dependence of ε.)  Specific enzyme activity was calculated by (d[pNA]/dt)/[APB].             
 
The chromogenic substrate, LpNA, could not be used to measure the amount of 
active APB in samples that contained the prodrug substrate, AVF.  To measure active APB 
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in these samples, the lyophilizates were reconstituted with 100 µL of either PBS or 1.00 
mM AVF in PBS that had been warmed to 32 °C, and the resulting solutions were 
immediately transferred to a cuvette embedded in the spectrophotometer as described 
above.  The change in Abs due to conversion of AVF to DZP was monitored for 20 min at 
315 nm.  Readings were taken every 0.25 min.   The concentration of DZP at time t was 
calculated by 
 
[DZP]t =
Abst − Abs0
(εDZP − εAVF)ℓ
 (2) 
 
 
where Abs0 is the initial absorbance of the sample and Abst is the absorbance measured at 
time t.  In pH 7.4 PBS at 32 °C, εDZP = 2040 M−1cm−1 and εAVF = 753 M−1cm−1 at 315 nm.  
The temperature dependence of εDZP and εAVF, and the validity of neglecting εORI in the 
calculation of DZP concentrations from absorbance measurements, have been discussed 
previously.75  After obtaining DZP concentration-time profiles, the following set of 
coupled differential equations was fit to the data with [APB] as the lone fitting parameter: 
 
d[AVF]
dt
= −
kcat[APB][AVF]
KM + [AVF]
 (3) 
d[ORI]
dt
=
kcat[APB][AVF]
KM + [AVF]
− k2[ORI] (4) 
d[DZP]
dt
= k2[ORI] (5) 
 
Fitting was performed using the ode45 function in conjunction with the lsqcurvefit function 
in MATLAB® version R2017b by The MathWorks, Inc. (Natick, MA).  The catalytic rate 
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constant (kcat), Michaelis constant (KM), and cyclization rate constant (k2) for conversion 
of AVF to DZP by APB in pH 7.4 PBS at 32 °C were reported previously: KM = 370 μM, 
kcat = 1250 min
-1, k2 = 0.470 min
−1.108 
 
4.3.4 Accelerated stability studies  
 
Accelerated stability studies were performed at three storage temperatures for solid 
state APB and solution state AVF.  Each study was 6 months long with measurements of 
active analyte remaining in the samples taken every 30 days.  For AVF, the natural log of 
the ratios of AVF concentration remaining at time t to the initial concentration were plotted 
as a function of time.  Linear regression was performed, and the degradation rate constant 
(kdeg) at each temperature was determined from the slopes according to the integrated first 
order rate equation: 
 
ln (
[AVF]t
[AVF]0
) = −kdegt (6) 
 
 
4.4 Results 
  
The enzymatic activity of APB was temperature dependent.  For hydrolysis of 
LpNA, the maximum enzyme activity was observed at 25 °C (Figure 21A, blue circles).  
At 1 °C, the rate of hydrolysis was more than 34 times slower.  Solutions of LpNA and 
APB could be held at 1 °C for several minutes without causing substantial product 
formation as demonstrated by a lack of increase in Abs from 0-2.5 min in Figure 21B.  
When temperature was increased to 32 °C at the 2.5 min time point, enzyme activity 
recovered, and Abs measurements began to increase due to production of pNA.  A similar 
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rate of Abs increase was observed for a control reaction initiated at 32 °C (Figure 21B, red 
line) compared to the reaction that had been initiated at 1 °C and subsequently brought to 
32 °C, indicating that stalling the reaction at low temperatures did not cause loss of enzyme 
activity.  The reaction could be successfully stalled at low temperatures for longer periods, 
but the maximum duration a reaction could be stalled without adverse effect was not 
determined.   
 
 Similarly, the rate of DZP production increased with increasing temperature, with 
the highest rate observed at the highest temperature condition tested, 40 °C (Figure 21A, 
red diamonds).  However, the trend was not strictly due to temperature effects on the rate 
of enzymatic hydrolysis.  Conversion of AVF to DZP is a two-step reaction (Figure 3).  
The rate of the second step, cyclization of to form the diazepine, is known to increase with 
increasing temperature.48,109  No DZP production was observed over the course of 20 min 
at 1 °C.  In order to determine if the low temperature had stalled the enzymatic hydrolysis 
reaction step or the ring closing reaction step, the enzymatic reaction was quenched by 
denaturing APB with the addition of 2x volume of methanol after being held at 1 oC for 20 
min.  Subsequently raising and holding the temperature at 32 oC did not result in the 
formation of DZP in the quenched solution.  This observation suggested that ORI had not 
accumulated, and the enzymatic reaction was indeed stalled at 1 oC. 
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Figure 21.  Temperature dependence of APB enzyme activity.  (A) Slow rate of product 
formation at 1 °C allowed APB and AVF to be combined in the pre-lyophilization solution 
without substantial changes in the species concentrations.  Reaction conditions: 1.00 mM 
LpNA or 2.00 mM AVF with 5.0 µg/mL APB in pH 7.4 PBS, n = 3, ±SD.  The rate of DZP 
production was determined by regression of the linear portion of measured concentration-
time profiles.  (B) 1.00 mM LpNA with 0.50 µg/mL APB in pH 7.4 PBS did produce the 
chromophore product pNA when held for 2.5 min at 1 °C.  The enzymatic activity of APB 
fully recovered when the temperature was brought to 32 °C.  n = 1.   
 
 
 APB was not stable when stored in solution.  Aliquots from solutions of APB stored 
at 4 °C in PBS were taken at specified time points and combined with a solution of LpNA 
in PBS to measure the change in enzyme activity over the course of a day (Figure 22A).  
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Production of pNA in the analytical samples, containing 1.00 mM LpNA and 12 µg/mL 
APB, was measured at 32 °C.  A comparison of the average enzyme activity at each time 
point by one-way ANOVA indicated that statistically significant degradation had occurred, 
F(3,8) = 35.2, p < 0.0001.  A Tukey HSD post hoc test revealed that the average enzyme 
activity ±SD was significantly lower at the 4 hr time point (8.9 ± 0.3 U/mg, p = 0.0396) 
and 16 hr time point (7.7 ± 0.2 U/mg, p < 0.0001) compared to the 1 hr time point (9.5 ± 
0.1 U/mg).  There was no statistically significant difference between the 1 hr and 2 hr time 
points, p = 0.174.   
 
A large initial drop in enzyme activity was observed when APB solutions were 
lyophilized (Figure 22B).  The loss in activity was most dramatic when no excipient was 
added (i.e. stock solutions of APB diluted to pre-lyophilization sample concentrations with 
just water), with only 6.4% recovery of active enzyme after lyophilization.  Adding Tre to 
the formulation stabilized APB during the lyophilization process.  The extent of 
stabilization was dependent on the Tre concentration, with concentrations 12.5 mg/mL or 
greater providing ~57% recovery of active APB.  Co-lyophilizing APB with LpNA, also 
had a stabilizing effect.  There were no statistically significant differences between the 
average enzyme activity for APB lyophilized in the presence of 1.00 mM LpNA, 12.5 
mg/mL Tre, or 25.0 mg/mL Tre as determined by one-way ANOVA, F(2,6) = 0.853, p = 
0.472. 
 
The pre-lyophilization controls, shown as blue bars in Figure 22B, demonstrate that 
enzyme activity was unaffected by the presence of Tre or Man.  Although the addition of 
the bulking agent, Man, produced elegant cakes, it did not markedly stabilize APB during 
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the lyophilization process.  The cakes produced by samples with APB and 12.5 and 25.0 
mg/mL Tre were uniform, but samples with 6.25 or 3.13 mg/mL Tre were non-uniform 
and wispy.  Similarly, the low mass contained in lyophilizates produced from samples of 
APB lyophilized in the presence of LpNA resulted in diminutive, non-uniform, wispy 
cakes.  The lyophilized samples that contained only APB did not contain enough mass to 
produce visible cakes.  However, changes in cake appearance do not necessarily impact 
product quality.110  
    
 
 
Figure 22.  Pilot stability studies for APB.  The chromogenic substrate, LpNA, was used 
to measure enzyme activity for preliminary formulation studies.  Reactions performed in 
pH 7.4 PBS at 32 °C, n = 3, ±SD.  (A) Solution state stability of 50 µg/mL APB stored in 
pH 7.4 PBS at 4 °C.  Statistically significant degradation was observed over the course of 
a day.  (B) Stability of APB upon lyophilization.  Lyophilizates made from solutions 
containing 15 µg/mL APB with mannitol (Man) and/or trehalose (Tre) were stored for 2 
days at room temperature before analysis.  Reconstitution of APB only lyophilizates with 
1.00 mM LpNA in PBS showed nearly complete loss of enzyme activity, while those 
containing 12.5 mg/mL or greater Tre provided optimum stabilization of APB.  
Lyophilizing APB in the presence of 1.00 mM LpNA substrate resulted in equivalent 
stabilization compared to the high concentration Tre formulations. 
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 Inclusion of the prodrug substrate, AVF, in the lyophilizate formulation had a 
stabilizing effect against degradation of APB during the lyophilization process (Figure 
23A).  A two-way ANOVA conducted to examine the effect of formulation composition 
and time on active APB concentration in the lyophilizates indicated there were significant 
differences between the formulation groups [F(2,18) = 90.6, p < 0.0001], significant 
differences over time [F(2,18) = 21.5, p < 0.0001], and a significant interaction effect 
[F(4,18) = 3.59, p = 0.0255].  Tukey HSD post hoc analysis comparing the formulation 
groups revealed that the AVF+APB+Tre formulation provided statistically significant 
better stabilization than the AVF+APB (p < 0.0001) or APB+Tre (p < 0.0001) 
formulations, but no significant difference between the AVF+APB and APB+Tre 
formulation groups (p = 0.928).  Therefore, the combination of AVF and Tre had a greater 
stabilizing effect against degradation during the lyophilization process than either additive 
alone.   
   
As was observed with APB only lyophilizates, the low concentration of the 
AVF+APB lyophilizates did not allow visible cakes to form.  Instead, the collapsed 
material appeared as residue adhering to the surface of the vial.  There was a gradual loss 
in enzyme activity observed over the course of 6 months with the AVF+APB formulation, 
as can be seen in Figure 23A.  Tukey HSD analysis comparing the average active APB 
concentration in the AVF+APB lyophilizates stored for 2 days with concentrations 
measured after storage for 90 and 180 days confirmed that there was significant 
degradation of APB over time (p < 0.0001 for both comparisons).  When Tre was included 
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in the formulation, uniform cakes were formed and the loss of enzyme activity over the 
course of 6 months was not statistically significant.  For the AVF+APB+Tre formulation 
on day 2 compared to day 90 and 180, p = 0.502 and 0.356, respectively.  For the APB+Tre 
formulation on day 2 compared to day 90 and 180, p = 0.523 and 0.120, respectively.       
 
 
 
 
Figure 23.  Room temperature stability studies.  Error bars are SD with n = 3.  (A) 
Optimum stability was achieved by co-lyophilization of APB with AVF and Tre.  
Concentrations of active APB in the lyophilizates were measured in pH 7.4 PBS at 32 °C 
after storage for the specified time at 24 °C.  Pre-lyophilization solutions contained AVF 
= 1.00 mM, APB = 50 µg/mL, and/or Tre = 12.5 mg/mL.  (B) Controls of 1.00 mM AVF 
lyophilized with 12.5 mg/mL Tre and subsequently reconstituted with 50 µg/mL APB in 
pH 7.4 PBS at 32 °C produced an equimolar concentration of DZP, indicating AVF was 
stable in the lyophilizate. 
 
 
The concentration of active APB was also measured in a series of lyophilizate 
formulation controls in order to rule out potential mechanisms of degradation or 
stabilization.  Lyophilizate controls containing AVF and Tre, but no APB, indicated that 
AVF was stable during the lyophilization process and upon subsequent storage as a solid 
96 
at room temperature (Figure 23B).  The addition of pH 7.4 Tris buffer to the pre-
lyophilization solutions did not result in greater enzyme stability (Appendices, Figure 
A3.73).  Likewise, formulations containing pH 5.5 PBS or phosphate buffer without salt 
did not result in greater enzyme stability. 
 
 The lyophilizate formulation showing the greatest stability at room temperature, 
that which contained AVF+APB+Tre, was subjected to an accelerated stability study 
(Figure 24A).  The production of DZP upon reconstitution of the lyophilizates was 
measured, and curve fitting the coupled differential equations (Equations 3-5) to the 
resulting concentration-time profiles allowed the concentration of active APB to be 
determined.  A two-way ANOVA conducted to examine the effect of temperature and time 
on active APB concentration in the lyophilizates indicated that there were no significant 
differences over time [F(6,42) = 1.93, p = 0.0977] and that the interaction of the factors 
was not significant [F(12,42) = 0.243, p = 0.994].  However, there were significant 
differences observed between the temperature groups [F(2,42) = 6.28, p = 0.00412].  Tukey 
HSD post hoc analysis indicated storage at 4 oC was not statistically different than storage 
at 24 oC (p = 0.840), while statistically significant lower active APB concentrations were 
observed upon storage at 40 oC compared to 4 oC (p = 0.00533) and 24 oC (p = 0.0234).  
The results suggest APB was highly stable in the AVF+APB+Tre lyophilizates even 
though there was an initial loss of active enzyme from the lyophilization procedure.   
 
 The solution state stability of the prodrug, AVF, was also investigated (Figure 24B).  
The initial AVF concentration and subsequent concentrations remaining in samples 
prepared for the stability study were determined by measuring the total DZP produced after 
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hydrolysis with 2.0 U/mL of Aspergillus oryzae protease.  (APB was not used here as it 
was unnecessary and more expensive.)  The degradation of AVF was found to follow first 
order kinetics with degradation rate constants, kdeg ±SE = 0.31 ± 0.03, 0.44 ± 0.04, and 2.9 
± 0.1 yr-1 for 4, 24, and 60 °C, respectively. 
 
 
Figure 24.  Accelerated stability studies.  Error bars are ±SD.  (A) Solid state stability of 
50 µg/mL APB co-lyophilized with 1.00 mM AVF and 12.5 mg/mL Tre.  (B) Solution 
state stability of 2.00 mM AVF in pH 7.4 PBS.   
 
4.5 Discussion 
   
Aminopeptidase B (BRENDA:EC3.4.11.6) has been isolated from animals, plants, 
bacteria, and fungi.111  It is an endopeptidase with catalytic activity confined to the cleavage 
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of basic amino acids from the N-terminus of certain oligopeptides or synthetic substrates 
by hydrolysis of the peptide bond.  There are conflicting reports in the literature regarding 
the stability of this enzyme that seem to depend on the source species and expression 
system, but the consensus is that purified enzyme preparations tend to be unstable.112,113  
We found that recombinant human aminopeptidase B, referred to here as APB, was stable 
enough in PBS to work with at room temperature for several hours, but there was a 
noticeable decrease in enzyme activity by the end of the day.  Figure 22A demonstrates the 
solution state instability of APB.  The enzyme did not tolerate freeze/thaw cycles well 
either.  Considerable reduction in enzyme activity was observed after thawing from 
overnight storage at -20 °C.  It may be that the difference in enzyme activity between the 
pre-lyophilization solutions and day 2 lyophilizates shown in Figure 23A was due to 
insufficient cryoprotection.   
 
 AVF is a Lys-Gly dipeptide derivative of a 2-methylamino-5-chlorobenzophenone 
and substrate for APB (Figure 3).  There are conflicting reports in the literature regarding 
the stability of AVF.  Clair et al. measured the solution state stability of a combination drug 
product over a 6 month period at pH 4 and temperatures as high as 40 °C and found only 
5% degradation of AVF.114  Breton et al. performed 24 hr photolytic, oxidative, hydrolytic, 
and thermal stress testing of solid and solution state AVF.115  The latter authors concluded 
that AVF in solution was susceptible to photolytic and thermal degradation but was stable 
in the solid state.  Both stability studies utilized chromatographic techniques that would 
not be able to distinguish between the S and R isomers of AVF.  Therefore, degradation by 
enantiomerization to the inactive isomer would not be detected.42  In the present study, 
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active AVF was measured by product formation from enzymatic hydrolysis.  Using this 
technique, we found that AVF was stable in the solid state (Figure 23B) but predicted only 
42% active AVF would remain after room temperature storage in solution at pH 7.4 for 2 
yr based on kdeg at 24 °C determined from the data represented by red diamonds in Figure 
24B.   
 
Since the intention was to use both APB and AVF in a nasal spray formulation, we 
began investigating ways to prepare them as a mixture of stable, unreactive solids that 
could be rapidly reconstituted and subsequently atomized for deposition in the nasal cavity.  
Co-lyophilizing the components into a single lyophilizate offered several advantages in 
this regard: homogeneous mixtures of the components could be made in the pre-
lyophilization solutions, the increased surface area due to cake formation would facilitate 
rapid dissolution, and the solid state of the lyophilizates would extend the shelf-life of the 
drug product.116  The AVF+APB+Tre formulation provided the most stabilization, with 
71% recovery of active APB immediately after lyophilization and minimal degradation 
thereafter (Figure 23A).  In comparison, APB+Tre provided 56% and AVF+APB provided 
60% recovery of active APB immediately after lyophilization.  Interestingly, lyophilization 
of APB in the presence of a chromogenic substrate, LpNA, also conferred stabilization on 
par with Tre (Figure 22B).  The relatively high initial recovery observed with just substrate 
and enzyme was an impressive result, even though the amount of active APB in the 
AVF+APB lyophilizate steadily decreased over time (Figure 23A).  Presumably enough 
molecular mobility remained in the samples to slowly turnover the docked substrate that 
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was supporting the active site structure, thus leading to eventual degradation.  Further 
studies are needed to investigate this behavior.   
 
The effect of varying substrate concentration on the stabilization of APB during the 
lyophilization process was not examined here, but the exceptionally low concentration of 
substrate used for the experiment (1.00 mM, i.e. 0.504 mg/mL of AVF or 0.428 mg/L of 
LpNA) demonstrates the remarkable potential to stabilize enzymes with the addition of far 
less material than is normally required with the use of traditional cryoprotectant or 
lyoprotectant excipients.  For example, the molar concentration of APB in the samples 
shown in Figure 23A was 0.68 µM based on the molecular mass of APB (74 kDa), giving 
a mole ratio of 1,500 AVF:APB.  In comparison, the molar concentration of Tre was 36.5 
mM, giving a mole ratio of 54,000 Tre:APB.  The prevailing theories used to explain the 
stabilization of proteins by sugars such as Tre involve maintenance of the native protein 
structure through vitrification and water replacement.117  The sugars are thought to act as 
scaffolding, preventing molecular mobility that can lead to unfolding and chemical 
degradation.  Smaller, flexible oligosaccharides that can more easily occupy the cavities 
within a protein structure have been shown to be more effective stabilizers than rigid, 
polymeric sugars.118  In this view, a large number of excipient molecules would be needed 
to provide structural support to the entire protein.  Thus, the high mole ratio of Tre to APB 
needed for stabilization seems reasonable.    
 
Preservation of the peripheral protein structure is not as critical to the retention of 
enzyme activity as preserving the structure of the active site.119,120  Docking of a substrate 
in the active site of APB provides a well-tailored support scaffold, preventing misalignment 
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of the binding/catalytic residues and collapse of the active site pocket as water molecules 
are removed during the drying step.  This mechanism for the stabilization of APB does not 
rely on protection of the entire protein, which explains why stabilization was observed with 
a much lower concentration of substrate compared to Tre.  In the solution state, the degree 
of enzyme stabilization has been shown to depend on substrate structure.  Better substrates 
(those with lower KM values) were better stabilizers.
121  The trend is likely to extend to 
improved stabilization during lyophilization. 
   
Reports of the inclusion of an enzyme substrate as a stabilizer for lyophilization are 
scant, presumably because substrate turnover complicates the process and would need to 
be controlled to produce consistent lyophilizates.  However, the technique we describe for 
limiting substrate turnover by combining the formulation components at low temperature 
can be generalized to a wide variety of enzymes.122  For example, Dai and Klibanov 
described snap freezing substrate/enzyme pairs during the lyophilization process to 
improve enzyme activity upon reconstitution of the lyophilizates in organic solvents.123  
They tested four different oxidases with several substrates and observed complete 
elimination of lyophilization-induced activity loss in some cases.  There are some reports 
of using enzyme inhibitors for stabilization of lyophilizates, but inhibitors have the 
potential to imprint an altered conformation for the active site thereby changing the 
selectivity and specificity of the enzyme.124   
 
We conclude by recognizing that this study, while demonstrating the effect of 
substrate on the stability of an enzyme during lyophilization, was limited in scope to APB.  
The primary goal of these experiments was to assess the feasibility of co-lyophilizing the 
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AVF/APB pair to stabilize the pharmaceutical formulation for further translational 
development and guide design requirements for a specialized nasal spray device.  
Additional experiments for scale-up to therapeutically relevant concentrations, 
optimization of the lyophilization process parameters, full characterization of the 
lyophilizates, and performance testing in the delivery device are ongoing.              
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Chapter 5: Reactive formulations for intranasal delivery of midazolam 
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5.1 Summary 
 
Systemic delivery of many lipophilic drugs can be achieved quickly and 
conveniently by intranasal administration.  However, the low aqueous solubility of these 
drugs can make it difficult to formulate a therapeutic dose in the small volume required for 
nasal sprays.  One formulation strategy to circumvent solubility issues relies on in situ 
production of drug from co-administration of soluble reactants.  Herein, we describe how 
a prodrug/enzyme reaction or an acid/base reaction could be used to formulate the 
lipophilic drug, midazolam, in an aqueous solution for intranasal delivery.  In both 
formulation approaches, the reactions progress through an intermediate open ring form of 
midazolam.  The half-life of the open ring form was measured at 32 °C by UV spectroscopy 
and found to be pH dependent, with a local minimum of 3.45 ± 0.27 min at pH 5.0 and 
local maximum of 17.2 ± 1.7 min at pH 6.5.  In vitro drug transport studies were performed 
at pH 5.5, 6.5, and 7.4 using MDCKII-wt cell monolayers as a model for nasal epithelium.  
Apparent permeability coefficients respective to each pH condition were found to be 33 ± 
20, 40 ± 14, and 145 ± 64 nm/s for the open ring form.  Permeability of midazolam was 
also pH dependent and over twofold greater than that of the open ring form.  Generation of 
midazolam in these low volume reactive formulations led to metastable supersaturated 
solutions and an upper limit to the supersaturation was observed.  The upper limit of 
supersaturation for unionized midazolam was determined to be 1.15 mM.  Above this limit, 
amorphous midazolam phase separated from solution.  The prodrug/enzyme reaction was 
less flexible in regard to setting the formulation pH for optimum enzyme activity and drug 
absorption, whereas the final pH of the acid/base formulation can be adjusted by choosing 
the appropriate base concentration.  Absorption of midazolam generated from these 
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reactive formulations would be controlled by the upper limit of supersaturation and 
cyclization rate of the open ring form. 
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5.2 Introduction 
 
Midazolam (MDZ) is a short-acting central nervous system depressant with 
hypnotic, sedative, anxiolytic, amnesic, muscle relaxant, and anticonvulsant properties.  It 
is the most common sedative administered prior to anesthesia in the United States, and it 
is a drug of choice for first-line rescue therapy in the treatment of seizure emergencies, 
such as status epilepticus.10,125  Considered safe and effective for addressing a variety of 
public health needs globally, MDZ has been deemed an essential medication by the World 
Health Organization.126  The dosage forms currently available on the market are oral 
tablets, oral syrups, oromucosal solutions (only available in Europe), and solutions for 
intravenous or intramuscular injection.127,128  Several intranasal (IN) formulations have 
been investigated35,129-134 or are under development,135 but a dosage form specifically 
designed for IN delivery has not yet become commercially available.     
 
IN delivery of MDZ is attractive because it offers many important advantages over 
other routes of administration, especially in emergency situations.14  A therapeutic plasma 
concentration can be attained quickly due to the large absorptive surface area, high 
vascularization, and thin epithelium of the nasal mucosa.  Orally administered MDZ 
reaches a peak plasma concentration in approximately 1 hr and has low bioavailability 
(~30%) due to extensive gastrointestinal and hepatic first-pass metabolism.136,137  In 
comparison, peak plasma concentrations have been reported in the 10-20 min range with 
bioavailabilities ranging from 50-90% for IN formulations.29,34,133  Furthermore, IN 
administration is convenient and noninvasive.  Operation of nasal spray devices does not 
require special skills and is generally intuitive.  There is no need to remove articles of 
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clothing or puncture the skin, posing a lower risk of injury to the patient compared to 
parenteral routes of administration. 
 
For three decades, caregivers have been administering commercially available 
injectable MDZ formulations ‘off-label’ through the IN route by using a needleless syringe 
or attaching a nasal mucosal atomization device (MAD) to a syringe and spraying the 
solution into the nose of the patient.138-140  An IN dose of 0.2 mg/kg (max 10 mg) is often 
used for treating status epilepticus and 0.4-0.5 mg/kg (max 10 mg) for sedation in pediatric 
patients.10,141  Although generally effective, the injectable MDZ formulations are not ideal 
for IN delivery.  A large volume of the injectable formulation (2 mL split between each 
nostril) is required to administer a 10 mg dose.  The volume of liquid that can be deposited 
in the human nasal cavity without causing significant loss of drug by drainage from the 
nostril or into the nasopharynx is less than 200 µL,22,24 and low bioavailability due to runoff 
is a well-known issue with IN administration of injectable MDZ formulations.129,142  
Therefore, a highly concentrated MDZ nasal spray is needed to reliably deliver the intended 
dose.   
 
Although MDZ has been touted as the first water-soluble benzodiazepine, its 
solubility is pH dependent.143  The lipophilic, neutral microspecies predominates at pH 7.4 
and has a thermodynamic aqueous solubility of only 0.018 ± 0.001 mg/mL (55 ± 4 µM).42  
The nitrogen at position 2 of the imidazole ring has an estimated pKa of 6.2,
68 producing a 
somewhat water-soluble cation when protonated.  At pH < 5, protonation of the imine in 
the diazepine ring leads to a reversable ring-opening reaction and a highly soluble open 
ring species (MDZopen) that is in equilibrium with the closed ring species.  The oromucosal, 
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intravenous, and intramuscular dosage forms are formulated to a concentration of 5 mg/mL 
by lowering the pH to ~3 and contain up to 25% MDZopen.
128,144,145  Reducing the pH further 
would permit higher concentrations; however, the pH of an IN formulation should be close 
to the physiological pH range of the nasal cavity to avoid causing discomfort, inducing 
secretion, hampering absorption, and damaging the mucosa.146,147  The average anterior pH 
of the nasal cavity is 6.40 (range: 5.17 – 8.13) and average posterior pH is 6.27 (range: 
5.20 – 8.00).55  Temporary distress, a burning unpleasant taste, stinging, sneezing, 
coughing, swallowing, watery eyes, and other mild adverse events reported from IN 
administration of aqueous MDZ formulations have been attributed to low pH.148-150  
Concentrated formulations of MDZ have been made by utilizing organic co-
solvents130,134,151,152 to increase the thermodynamic solubility or by sequestering the drug 
in carriers like emulsions,131 polymeric particles,132 or inclusion complexes.129  However, 
these additives can reduce the driving force for permeation of drug across 
membranes38,39,153 and irritate sensitive nasal tissues.34,40   
 
Our group has been developing a new approach to formulate drugs that have low 
solubility or poor stability in an aqueous vehicle.  The strategy involves co-administration 
of a two-part, reactive system to generate drug in situ.  In the case of small lypophilic drugs, 
such as MDZ, a metastable supersaturated solution of the drug can be produced at the site 
of administration and result in rapid absorption.  We previously reported in vitro28,42,43,49,75 
and in vivo108 experiments that demonstrated enhanced permeation of drug across cell 
membranes using reactive prodrug/enzyme formulations to generate supersaturated 
solutions of phenytoin, diazepam, or MDZ.  The MDZ prodrug/enzyme formulation 
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consisted of MDZopen derivatized at the primary amine with lysine (Lys-MDZpro) and a 
fungal converting enzyme, Aspergillus oryzae protease (AOP).  Cleavage of the N-terminal 
lysine from Lys-MDZpro is catalyzed by AOP through enzymatic hydrolysis of the peptide 
bond and liberates MDZopen.  MDZopen can then undergo spontaneous intramolecular 
cyclization to form MDZ.  In the current report, an analogous version of the prodrug 
derivatized with phenylalanine (Phe-MDZpro) is introduced.  Phe-MDZpro can be 
hydrolyzed by a human enzyme, aminopeptidase N (APN).   
 
The MDZpro/enzyme formulations were compared to a reactive acid/base 
formulation approach that combines the dihydrochloride salt of MDZopen (MDZopen•2HCl) 
with an aqueous base at the time of administration to produce a supersaturated solution of 
MDZ with a pH and volume appropriate for IN delivery.  Figure 25 illustrates the 
relationship between these reactive formulation approaches.  Both approaches rely on 
water-soluble forms of MDZopen that do not undergo cyclization during storage because the 
amine is occupied, either by a covalent bond with an amino acid or as a primary ammonium 
salt.  We hypothesized that recovery of the free amine through deprotonation of 
MDZopen•2HCl with a strong base would result in faster reaction rates and more rapid 
delivery of MDZ than could be achieved by cleavage of an amino acid moiety with an 
enzyme.  However, further investigation revealed that the ring closing step was rate 
limiting.  Thus, rapid liberation of MDZopen from the precursor species would result in 
accumulation of MDZopen in the nasal cavity.  These observations prompted a series of 
experiments aimed at determining the pH dependence of the first-order cyclization rate 
constant (k2), supersaturation behavior of MDZ, and permeation of each reaction species 
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across epithelium to evaluate the viability of using an open ring precursor for rapid IN 
delivery of MDZ.                
 
 
 
Figure 25.  Reactive IN formulations produce MDZ in situ.  Potential two-part, reactive 
formulations for IN delivery of MDZ include a prodrug/enzyme pair or an acid/base pair.  
The reactants would be stored in separate compartments of a specially designed nasal spray 
device.  Upon actuation of the device, the reactants are rapidly mixed and atomized into a 
spray to be deposited as a single solution onto the surface of the nasal mucosa.  Production 
of MDZ from the mixed formulation proceeds in the nasal cavity.  AA = amino acid moiety.   
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5.3 Materials 
 
5.3.1 Prodrugs 
 
The trihydrochloride salt of the S-lysyl-midazolam prodrug (Lys-MDZpro•3HCl) 
was synthesized with > 99% purity and > 94% ee from MDZ by opening the diazepine ring 
and adding a lysine group.  Similarly, the dihydrochloride salt of the S-phenylalanyl-
midazolam prodrug (Phe-MDZpro•2HCl) was synthesized with > 99% purity and 98% ee 
by adding a phenylalanine group to the open ring form of MDZ.  Details for the synthesis, 
purification, and characterization of Lys-MDZpro were described previously.
42 
 
5.3.2 Converting enzymes 
 
Recombinant human aminopeptidase N (APN), expressed and isolated with > 95% 
purity from an NS0 murine cell line, was purchased from R&D Systems (Minneapolis, 
MN: cat# 3815-ZN, lot PQP011809A).  Recombinant human aminopeptidase B enzyme 
(APB), expressed and isolated with >80% purity from a JM109 E. coli cell line, was 
produced in house by the procedure described previously.76  Purity of APB was >80% by 
gel electrophoresis.  Aspergillus oryzae protease (AOP) was purchased from Sigma-
Aldrich, Inc. (St. Louis, MO: cat# P6110, lot SLBQ4182V).  
 
5.3.3 Midazolam open ring salt 
 
 MDZopen was isolated as a solid dihydrochloride salt (MDZopen•2HCl) by opening 
the diazepine ring of MDZ in acidic medium using a procedure first described by Walser 
et al.154  MDZ (253 mg, 777 µmol), purchased from MEDISCA Pharmaceutique Inc. 
(Plattsburgh, NY: NDC 38779-2519-06, lot 888378/G), was dissolved in 140 µL of 12 N 
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HCl.  Then, 2 mL of isopropanol (IPA) was added, and the mixture was azeotropically 
dried by reducing the volume to approximately 0.5 mL with a rotovap.  The solids were 
collected by filtration and purified by co-solvent recrystallization.  Recrystallization was 
performed by dissolving the crude in a minimum volume of MeOH.  IPA was added slowly 
until the cloud point was reached.  After cooling to -20 °C, the purified material was 
collected by filtration, washed with cold IPA, and dried under vacuum to yield 87% (281 
mg, 674 µmol) of (2-(5-(aminomethyl)-2-methyl-1H-imidazol-1-yl)-5-chlorophenyl)(2-
fluorophenyl)methanone dihydrochloride as shiny, white, hygroscopic crystals.  Mp: 247 
°C dec.  ATR-FTIR neat: imidazole 3100-2300 cm-1 (s, br), aromatic overtones 1956 and 
1799 cm-1 (w), C=O 1651 cm-1 (s, sh).  1H NMR (400 MHz, D2O) δ 7.92 (dd, 1H), 7.89 (s, 
1H), 7.72-7.47 (m, 4H), 7.31 (t, 1H), 7.23 (q, 1H), 4.10 (s, 2H), 2.37 (s, 3H).  See 
Appendices A4, Section A4.1 for ART-FTIR and 1H NMR spectra.  
 
5.4 Methods 
 
5.4.1 Determination of ring closing reaction rate 
 
To obtain the cyclization reaction rate dependence with respect to pH, UV 
absorbance (Abs) spectra were measured using an Agilent Technologies, Inc. (Santa Clara, 
CA) Cary 100 Bio UV/Vis double beam spectrophotometer equipped with a temperature 
controller.  The temperature controller was set to the average temperature of the nasal 
cavity, 32 °C.54  Prior to data collection, solutions of 23 mM phosphate buffered saline 
(PBS) or 23 mM citrate buffered saline (CBS), 8.00 mM MDZopen•2HCl in water, and 1 
cm pathlength (ℓ) quartz ultra-microcuvettes were warmed to 32 °C.  A 25.0 µL aliquot of 
the MDZopen•2HCl solution was mixed with 175 µL of buffer in the sample cuvette to 
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obtain a 1.00 mM total analyte concentration ([total]) in 20 mM of buffer.  The 
concentration of MDZopen at the start of data collection ([MDZopen]0) was not 1.00 mM 
because MDZopen began to equilibrate with MDZ as soon as solid MDZopen•2HCl was 
dissolved to make the stock solution.  The reaction progress was monitored by collecting 
scans over time from 300-400 nm at a scan rate of 600 nm/min using the Cary WinUV 
version 3.10(246) Scan Application.  The molar absorptivities (ε) of MDZopen and MDZ at 
300 nm were used to calculate concentrations of each species at time t.        
 
[MDZopen]t =
Abst/ℓ − εMDZ[total]
εMDZopen − εMDZ
 (1) 
[MDZ]t = [total] − [MDZopen]t (2) 
 
Linear regression of ln([MDZopen]t/[MDZopen]0) versus t, plotted from t = 0-15 min, gave 
the first-order ring closing rate constant (k2) as the slope according to the integrated 
reaction rate law. 
 
ln (
[MDZopen]t
[MDZopen]0
) = −k2t (3) 
 
The half-life (t1/2) of MDZopen was calculated by t1/2 = ln(2)/k2.   
 
 
5.4.2 Polarized light microscopy  
 
MDZopen•2HCl (100 µL, 8.00 mM) was combined with 100 µL of 16.0 mM NaOH 
in a small glass vial.  The solution became turbid as MDZ phase separated.  Aliquots of the 
turbid reaction mixture were removed at regular intervals to view under a Nikon, Inc. 
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(Tokyo, Japan) P-1 microscope equipped with a Nikon 40x/0.65 NA - WD 0.65 Pol 
objective, Nikon Digital Sight DS-Fi1 camera, and temperature-controlled stage.  Images 
were captured using NIS-Elements F 3.0 software. 
 
5.4.3 Differential scanning calorimetry (DSC) 
 
Samples for DSC were placed in hermetically sealed aluminum Tzero pans.  
Measurements were performed from 40-300 oC at a heating rate of 10 °C/min under 
nitrogen purge (45 mL/min) using a TA Instruments Q2000 V24.11 Build 124 DSC with 
a standard cell and Universal V4.5A software.  Glass transition temperatures (Tg) were 
determined at the inflection point.  Melting temperature (Tm) and cold crystallization (Tcc) 
ranges were determined by the onset and peak of the melting endotherm or crystallization 
exotherm.  For the MDZ precipitate samples, MDZopen•2HCl (14.2 mg) in 100 µL of water 
was combined with 100 µL of 0.681 M NaOH to form MDZ which subsequently phase 
separated from solution.  The precipitate from the reaction was allowed to sediment before 
the supernatant containing soluble species was removed.  The precipitate was then washed 
once with 50 µL of water and dried under high vacuum at room temperature for 3 hr before 
performing measurements.  There were no special preparation steps for the MDZ standard 
or MDZopen•2HCl sample.   
 
5.4.4 Liquid Chromatography (HPLC)  
 
Measurements of Phe-MDZpro and MDZ concentrations were performed using an 
Agilent 1260 Infinity LC system: quaternary pump G1311B, autosampler G1329B, 
thermostatted column compartment G1316A, diode-array detector G4212B, and Agilent 
OpenLAB CDS software.  The isocratic mobile phase was 10 mM acetate buffer pH 5.0 
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and acetonitrile (60:40 v/v) with a flow rate of 0.65 mL/min through an Agilent ZORBAX 
Eclipse XDB-C18 column (3.0 x 150 mm, 3.5 μm particle size).  Diazepam was used as 
the internal standard (IS).  Aqueous samples were spiked with IS prepared in acetonitrile 
to obtain 8.00 μM (2.28 μg/mL) IS.  Analytes from 25 μL injections of each sample were 
detected at 310 nm with retention times of 3.6, 6.3, and 8.4 min observed for Phe-MDZpro, 
MDZ, and IS respectively.  Calibration curves were constructed in triplicate using MDZ 
standard solutions prepared in the mobile phase with IS.  For Phe-MDZpro, LOD 
(3.3×SEy/slope) was 0.297 µM (0.146 µg/mL), and LOQ (10×SEy/slope) was 0.901 µM 
(0.443 µg/mL).  For MDZ, LOD was 0.0696 µM (0.0227 µg/mL), and LOQ was 0.211 µM 
(0.0687 µg/mL).  Representative examples of the chromatograms and calibration curves 
can be found in Appendices A4, Section A4.1.  The peak area ratios (Phe-MDZpro or 
MDZ/IS) and dilution factors were used to calculate the analyte concentrations in the 
samples.  
 
5.4.5 Enzyme kinetics 
 
The Michaelis constant (KM) and maximum reaction velocity (Vmax) for hydrolysis 
of Phe-MDZpro by APN in pH 5.5 CBS at 32 °C were determined by fitting the Michaelis-
Menten equation to the initial rates of product formation for a series of Phe-MDZpro 
concentrations.  Reactions with 62.5 – 2000 µM Phe-MDZpro and 15 µg/mL APN were 
carried out at a volume of 50 µL in an Eppendorf Thermomixer 5436 at 500 rpm.  After 1 
min, the enzymatic reaction was quenched by denaturing APN with 100 µL of acetonitrile.  
Cyclization of the liberated MDZopen to MDZ was allowed to progress to completion before 
measuring MDZ in the reaction mixtures by HPLC.  A curve was fit to the MDZ production 
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versus initial Phe-MDZpro concentration with KM and Vmax as fitting parameters using the 
nlinfit function in MATLAB® version R2017b by The MathWorks, Inc. (Natick, MA).     
 
5.4.6 Cell culture 
 
Madin-Darby canine kidney II-wild type (MDCKII-wt) epithelial cells provided by 
The Netherlands Cancer Institute, Amsterdam were used as a model for nasal epithelium.  
Cells were cultured in DMEM media with 10% FBS and antibiotics (100 mg/ml 
streptomycin, 100 U/mL penicillin, and 250 ng/mL amphotericin B) in T-25 flasks at 37 
°C with 5% CO2 atmosphere.  Only cells between passages 10-20 were used for 
experiments.  Confluent cells were trypsinized and seeded at 0.5×105 cells/mL into cell 
culture plates for drug transport experiments.  Media was replaced every second day until 
cell monolayers had formed.  The media was removed, and the cells were rinsed with PBS 
prior to treatment with drug formulations.   
 
5.4.7 Drug transport studies 
 
 MDCKII-wt cell monolayers were cultured on the apical insert of Transwell® 12-
well tissue culture plates from Corning Inc. (Corning, NY: cat# 3460).  Transepithelial 
electrical resistance (TEER) was monitored regularly using an EVOM Epithelial 
Voltohmmeter with STX2 electrode from World Precision Instruments, Inc. (Sarasota, FL).  
The monolayers were considered confluent and ready for experiments when the TEER 
measurements were no longer increasing, which took approximately 5 days.  For transport 
experiments, the wells and confluent monolayers were first rinsed with assay buffer 
(specified by the apical well treatment group).  Then 1.50 mL of assay buffer was added to 
the basal well and 0.500 mL of the drug formulation was added to the apical well.  The 
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apical wells contained either: pH 7.4 PBS only, pH 6.5 PBS only, pH 5.5 PBS only, pH 5.5 
CBS only, 500 µM MDZopen•2HCl solution in each buffer, 500 µM supersaturated solution 
of MDZ in each buffer, 500 µM Phe-MDZpro in CBS, 200 µg/mL APN in CBS, or 500 µM 
Phe-MDZpro with 200 µg/mL APN in CBS.  Each condition was performed in triplicate.  
The treated cells were placed in an incubator at 32 °C with a 150 rpm orbital shaker.  At t 
= 5, 15, and 30 min, a 65 µL sample for analysis was removed from the basal wells.  After 
the last sample was collected, the cells were rinsed with pH 7.4 PBS and checked for 
confluency by confirming that TEER had not decreased and by performing a standard 
Lucifer yellow dye permeability assay.155  MDZ and Phe-MDZpro were quantified in the 
basal well samples by HPLC.   
 
To infer the permeation of each reaction species across the cell monolayers, a 
mathematical model of drug transport was constructed using MATLAB®.  A schematic of 
the model is shown in Figure 26, where k1 and k-1 are rate constants for reversible binding 
of Phe-MDZpro to the active site of APB, and kcat is the enzyme catalytic rate constant for 
conversion of Phe-MDZpro to MDZopen.  The relationship of these rate constants to 
Michaelis–Menten enzyme kinetic parameters is given by KM = (k-1+kcat)/k1 and Vmax = 
kcat[APN].  In the prodrug/enzyme formulation pathway, endogenous enzyme activity was 
assumed to be small and negligible.  In the acid/base formulation pathway, deprotonation 
of cationic MDZopen to the ionization state prescribed by the buffer pH was assumed to be 
fast and negligible. 
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Figure 26.  Schematic of transport in Transwell assay.   
 
Values for the apparent permeability coefficient (Papp) of Phe-MDZpro, Papp of 
MDZopen, and rate constants for transport of MDZ through the cell monolayer (kin and kout) 
were determined by fitting numerical solutions of the following differential equations to 
experimental data: 
 
dAMDZpro
a
dt
= −
kcatAAPN
a AMDZpro
a
VaKM + AMDZpro
a − Papp,MDZpro S (
AMDZpro
a
Va
−
AMDZpro
b
Vb
) (4) 
dAMDZopen
a
dt
=
kcatAAPN
a AMDZpro
a
VaKM + AMDZpro
a − k2AMDZopen
a
− Papp,MDZopen S (
AMDZopen
a
Va
−
AMDZopen
b
Vb
) 
(5) 
dAMDZ
a
dt
= k2AMDZopen
a − kinAMDZ
a  (6) 
dAMDZ
c
dt
= kinAMDZ
a − koutAMDZ
c  (7) 
dAMDZpro
b
dt
= Papp,MDZpro S (
AMDZpro
a
Va
−
AMDZpro
b
Vb
) (8) 
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dAMDZopen
b
dt
= −k2AMDZopen
b + Papp,MDZopen S (
AMDZopen
a
Va
−
AMDZopen
b
Vb
) (9) 
dAMDZ
b
dt
= k2AMDZopen
b + koutAMDZ
c  (10) 
 
where A is mole amount with the species denoted by subscripts and the compartment (‘a’ 
for apical well, ‘b’ for basal well, and ‘c’ for cell monolayer) denoted by superscripts, V is 
the volume of the compartment denoted by the superscript, and S is the surface area of the 
cell monolayer.  Experimental data was input as averages of the concentrations measured 
in the basal well at each sampling time point.  Model fits were obtained using the ode45 
function in conjunction with the lsqcurvefit function, and standard errors (SEs) for each 
parameter estimate were calculated from confidence intervals given by the nlparci function 
in MATLAB®.   
 
Fitting to estimate the Papp of MDZopen was performed in two stages.  First, 
Equations 6, 7, and 10 were used to estimate kin and kout by adding supersaturated MDZ 
(500 µM) to the apical well and fitting the model to concentrations of MDZ measured in 
the basal well.  The supersaturated solutions of MDZ were created by admixing 
MDZopen•2HCl with assay buffer 1.5 hr before addition to the apical well, so the 
concentration of MDZopen was assumed to be zero.  Then kin and kout were fixed at the 
determined values, and Equations 5, 6, 7, 9, and 10 were used to estimate the Papp of 
MDZopen from the combined transport of MDZopen and MDZ when 500 µM of 
MDZopen•2HCl was added to the apical well.  Concentrated stock solutions of 
MDZopen•2HCl were prepared immediately before addition to assay buffer in the apical 
wells, so the initial concentration of MDZ was assumed to be zero.  Since cyclization of 
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MDZopen continued to completion in the samples removed from the basal wells for analysis, 
the concentrations of MDZ measured at each time point were considered to be equivalent 
to the sum of the basal MDZopen and MDZ concentrations.                    
 
 
5.5 Results 
 
5.5.1 Rate limitation for MDZpro/enzyme formulations 
 
A fungal enzyme, AOP, was used to convert lysyl derivatives of the open ring forms 
of diazepam and MDZ in our previous work, although the catalytic efficiency (kcat/KM) for 
hydrolysis of the Lys-diazepam prodrug was 36 fold greater than for Lys-MDZpro.
42  Co-
administering an exogenous human enzyme with an amino acid derivatized prodrug is 
preferable over the fungal enzyme to avoid potential immune responses.156  A human 
enzyme, APB, was found to efficiently convert the Lys-diazepam prodrug (KM = 0.370 
mM and Vmax = 0.254 mM/min with 15 µg/mL APB at 32 °C in pH 7.4 PBS, determined 
by HPLC).108  However, there was essentially no conversion of Lys-MDZpro with 15 µg/mL 
APB under the same conditions, and incomplete conversion with 500 µg/mL APB.  
Therefore, a different MDZpro/enzyme combination was sought.  Various peptido-2-
aminobenzophenone prodrugs have been shown to convert to their respective 
benzodiazepine parent drugs in vivo by endogenous enzymes.46,157  The rate of hydrolysis 
was dependent on the amino acid moiety, with Phe and Lys derivatives cleaving faster than 
Gly and Glu derivatives.  It was thought that APN, a human endopeptidase that catalyzes 
cleavage of neutral amino acids, would efficiently convert a phenylalanyl version of 
MDZpro.  Indeed, Phe-MDZpro was found to be fully converted to MDZ by APN, but 
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cyclization of the intermediate species MDZopen was slow at pH 7.4.  Figure 27 illustrates 
this point.  The absorbance for each reaction mixture started near 2.5 and progressed to 1.3 
as a molar concentration of MDZ equivalent to the initial MDZpro concentration was 
formed.  The time course of the absorbance change was the same for the Phe-MDZpro/APN 
combination and the Lys-MDZpro/AOP combination regardless of enzyme concentration, 
suggesting that the ring closing step was rate limiting.                
  
 
Figure 27.  MDZpro/enzyme reactions tracked by UV spectroscopy.  Identical time 
courses were observed for Lys-MDZpro/AOP and Phe-MDZpro/APN, regardless of enzyme 
concentration.  Incomplete conversion to MDZ was observed with the Lys-MDZpro/APB 
combination.  Reactions performed with the indicated enzyme and 1.00 mM MDZpro at 32 
°C in pH 7.4 PBS, n = 1.  
 
 
5.5.2 pH dependence of MDZopen cyclization 
 
A dynamic equilibrium exists between MDZopen and MDZ when the pH is below 
5.158  Above pH 5, equilibrium is completely in the direction of MDZ.  MDZopen can be 
isolated as a solid in the form of a dihydrochloride salt, MDZopen•2HCl, by bringing the pH 
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very low and removing the solvent.  This salt was convenient for studying the ring closing 
rate as a function of pH by UV spectroscopy.  Aqueous solutions of the salt are acidic with 
predicted pKas of 5.7 at the imidazole nitrogen and 8.4 at the primary amine.
68  Aliquoting 
a stock solution of the salt into a buffer led to rapid deprotonation of the MDZopen cation 
and an absorbance change at 300 nm corresponding to the formation of MDZ.  The 
cyclization rate constant, k2, was measured by tracking this absorbance change.  Figure 28 
shows the t1/2 of MDZopen calculated from k2.  The slowest ring closing rate occurred at pH 
6.5 with t1/2 = 17.2 ± 1.7 min, ±SD.  The fastest ring closing rate occurred at pH 5.0 with 
t1/2 = 3.45 ± 0.27 min.                               
 
 
Figure 28.  pH dependence of MDZopen half-life.  Formation of MDZ from cyclization 
of MDZopen became slow between pH 6.5-7.4, 32 °C, n = 3, ± SD. 
 
5.5.3 Phase separation of MDZ from supersaturated solutions 
 
 Cyclization of MDZopen produced supersaturated solutions of MDZ.  When the 
MDZ concentration was driven sufficiently high, an upper limit of supersaturation was 
reached, and spontaneous phase separation of amorphous MDZ occurred throughout the 
liquid.  This process, known as ‘oiling out’ or liquid-liquid phase separation (LLPS),52,53 
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caused the samples to become turbid.  The total extinction (absorbance + scattering) of 
transmitted light was monitored at a wavelength beyond the tail of analyte absorbance 
peaks (λ = 400 nm) to detect the onset of light scattering and LLPS.  Figure 29A shows the 
abrupt increase in extinction that was observed when solution concentrations of MDZ 
generated from the cyclization of MDZopen reached the upper limit of supersaturation.  The 
reactions were performed under alkaline conditions by adding an excess of strong base to 
solutions of MDZopen•2HCl, so the resultant MDZ was unionized.  Samples that produced 
a final concentration of 1.14 mM MDZ or less did not undergo LLPS.  For higher 
concentration samples, LLPS consistently initiated when the reactions progressed to about 
1.15 mM MDZ.  Therefore, the upper limit of supersaturation or amorphous solubility was 
estimated to be 1.15 mM for the neutral MDZ microspecies. 
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Figure 29.  Precipitation of MDZ observed by UV spectroscopy.  (A) Light scattering 
from precipitation of amorphous MDZ was observed when the concentration reached the 
upper limit of supersaturation: ~1.15 mM MDZ.  Reaction conditions: 1.30, 1.20, 1.15, or 
1.14 mM MDZopen•2HCl(aq), 4.34 mM NaOH, 32 °C, n = 2 for 1.30 mM condition and n = 
3 for all other conditions.  (B) Occasional crystal nucleation and growth led to a continual 
drop in absorbance for some samples (green diamonds).  Reaction conditions: 1.00 mM 
MDZopen•2HCl(aq) in PBS, 32 °C, n = 1 for pH 7.4 sample that began to form crystals and 
n = 3 for all other data.  Error bars are SD.  
 
 
Crystallization events were also observable by UV spectroscopy.  Figure 29B 
shows absorbance measurements for MDZopen cyclization upon the addition of a 
MDZopen•2HCl stock solution to buffer.  The reactions, at a concentration of 1.00 mM, 
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were below the upper limit of supersaturation but above the equilibrium solubility of MDZ.  
When crystallization occurred, the measured absorbance of the reaction continued to 
decrease after the reaction was complete (Figure 29B, green diamonds).  Sequestering of 
MDZ in the crystalline phase caused the absorbance to fall below that which was expected 
for the final supersaturated MDZ solution (1.00 mM), towards the absorbance of MDZ at 
its thermodynamic equilibrium solubility (55 µM MDZ at pH 7.4 and 32 °C with Abs ≈ 
0.07 at 300 nm).  Crystallization was also observed with irregularity in higher concentration 
samples that had already undergone LLPS.             
 
Images of the amorphous precipitate from MDZopen cyclization reactions performed 
above the upper limit of supersaturation for MDZ were captured by polarized microscopy.  
When the LLPS process initiated, an abundance of very small colloidal particles distributed 
homogeneously throughout the reaction mixture was observed.  These particles coalesced 
and continued to grow, eventually forming aggregates (Figure 30A).  The lack of 
birefringence under polarized light and the spherical shape of the MDZ precipitate particles 
from LLPS indicated that the precipitate was amorphous.  Figure 30B demonstrates that 
crystals can be formed from the amorphous precipitate by introducing nucleation sites.  As 
the crystals grew, the amorphous precipitate particles began to shrink.  Samples that did 
not have crystal nucleation sites introduced would sometimes spontaneously form crystals 
early on, while others remained amorphous for more than 24 hr.     
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Figure 30.  Polarized microscope images of MDZ precipitate.  (A) Amorphous 
precipitate in the reaction mixture at t = 40 min after turbidity was observed.  (B) Induced 
MDZ crystal formation.   
 
Calorimetry performed on precipitates collected from a reaction mixture that had 
undergone LLPS showed a glass transition at Tg = 60.2 °C, cold crystallization exotherm 
at Tcc = 127-136 °C, and characteristic melting endotherm for MDZ at Tm = 159-163 °C 
(Figure 31A).  The Tm of a crystalline MDZ standard (162-163 °C, Figure 31B) was similar 
to the Tm of the precipitate and in agreement with values that have been reported for MDZ 
in the literature, 158-160 °C and 161-164 °C.56,159  There were no other features present in 
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the MDZ standard thermogram besides the melting endotherm.  The thermogram of 
MDZopen•2HCl did not reveal a Tg and did not have a melting endotherm corresponding to 
MDZ, suggesting there was no MDZ in the sample (Figure 31C).  The observed melting 
range was broad due to fusion of a metastable modification overlapping with fusion of a 
stable form that had Tm = 146-147 °C.   
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Figure 31.  DSC thermograms.  (A) MDZ precipitate from reaction of MDZopen•2HCl 
with NaOH solution.  (B) MDZ standard.  (C) MDZopen•2HCl.   
 
5.5.4 Drug transport studies 
 
To investigate the permeation of MDZopen across epithelium and the ability of this 
species to contribute to the rate of MDZ delivery, transport studies were performed with 
MDCKII-wt cell monolayers using Transwell® plates.  Freshly prepared, concentrated 
stock solutions of MDZopen•2HCl were added to buffer on the apical side of the monolayers 
in order to expose the cells to a known initial concentration of MDZopen at a specified pH.  
Since MDZopen is a transient species, the basal well MDZ concentrations shown in Figure 
32A are the result of cyclization with simultaneous transport of both species.  Any MDZopen 
present in the samples removed from the basal well for analysis would have continued to 
form MDZ, so only MDZ was observed by the time the samples were processed. 
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Figure 32.  Transport of MDZ across MDCKII-wt cell monolayers from acid/base 
formulation approach.  n = 3, averages ±SD.  (A) pH dependence of MDZopen transport 
from 500 µM MDZopen in apical well.  MDZ measured in the basal well represents the sum 
of MDZopen and MDZ at each time point.  Lines are model fits with kin, kout, and k2 as fixed 
parameters and Papp for MDZopen as a fitting parameter.  (B) pH dependence of MDZ 
transport from 500 µM MDZ (supersaturated) in apical well.  Lines are model fits with kin 
and kout as fitting parameters.  
 
The permeation of MDZ at each pH was needed to deconvolute the permeation of 
MDZopen from MDZ.  Previously we had reported Papp = 2.65 ×10
-5 cm/s for MDZ 
measured at pH 7.4 with 55 µM MDZ in the apical well.42  However, there was a lag 
observed for the appearance of MDZ in the basal wells of monolayers treated with 
supersaturated MDZ (Figure 32B).  To account for this lag, the cell monolayers were 
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modeled as a separate compartment where MDZ could accumulate (Figure 26).  The rate 
constants determined for MDZ transport from the apical compartment into the monolayer 
compartment, kin, and out of the monolayer compartment to the basal compartment, kout, 
are listed in Table 4.  (For reference, Papp ±SE for MDZ would have been 1.54 ± 0.19 ×10
-
5 cm/s at pH 5.5, 2.15 ± 0.44 ×10-5 cm/s at pH 6.5, and 3.24 ± 0.56 ×10-5 cm/s at pH 7.4 in 
this data set if the lag had been ignored.)  Literature values for Papp of MDZ across MDCK 
cells at pH 7.4 are generally higher, ranging from 4.2-7.0 ×10-5 cm/s.160-164  With kin, kout, 
and k2 as fixed parameters, Papp of MDZopen could be estimated as a fitting parameter from 
the data shown in Figure 32A.     
 
Table 4.  Parameters for transport of each reaction species across MDCKII-wt cell 
monolayers.    
Species 
Parameter ± 
SE 
pH 
5.5 6.5 7.4 
Phe-
MDZpro 
Papp (× 10
5 cm/s) 0.545 ± 0.056 * ND ND 
MDZopen Papp (× 10
5 cm/s) 0.326 ± 0.195 0.396 ± 0.135 1.45 ± 0.64 
MDZ 
kin (min
-1) 0.144 ± 0.080 0.0405 ± 0.0056 0.105 ± 0.036 
kout (min
-1) 
0.00284 ± 
0.00051 
0.00783 ± 
0.00079 
0.00674 ± 
0.00100 
ND = not determined, * Phe-MDZpro transport measured in CBS, all other species measured 
in PBS.   
 
Phe-MDZpro and MDZ were found in the basal wells when Phe-MDZpro without 
enzyme was added to the apical wells of the cell monolayers (Figure 33A).  MDCK cells 
express small amounts of endogenous APN that is localized to the apical side of the 
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membrane.165  So some hydrolysis of Phe-MDZpro likely occurred in the apical well and 
MDZ subsequently permeated to the basal well.  When conversion of Phe-MDZpro by 
endogenous enzymes is ignored, the Papp for Phe-MDZpro at pH 5.5 was 0.545 min
-1 (Table 
4).  The Michaelis–Menten parameters for enzymatic hydrolysis of Phe-MDZpro by 15 
µg/mL APN in pH 5.5 CBS at 32 °C were KM = 336 ± 39 μM and Vmax = 16.5 ± 0.6 μM/min 
(±SE).  APN is a 104 kDa enzyme, so this Vmax gave kcat = 114 ± 5 min
-1.  Under the same 
conditions, measured k2 was 0.126 ± 0.015 min
-1 ±SD.  When all of the model parameters 
(KM, kcat, k2, Papp for Phe-MDZpro, Papp for MDZopen, kin, and kout) were fixed, the basal well 
concentrations resulting from a Phe-MDZpro/APN reaction in the apical well could be 
predicted remarkably well by numerically solving Equations 4-10.  Curves of the 
predictions are shown in Figure 33B.       
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Figure 33.  Transport of MDZ across MDCKII-wt cell monolayers from 
prodrug/enzyme formulation approach.  n = 3, averages ±SD.  (A) Transport of Phe-
MDZpro and MDZ in pH 5.5 CBS from 500 µM Phe-MDZpro in apical well.  Line is model 
fit with Papp of Phe-MDZpro as a fitting parameter.  Some conversion to MDZ from 
endogenous enzymes occurred.  (B) Transport of Phe-MDZpro and MDZ in pH 5.5 CBS 
from 500 µM Phe-MDZpro combined with 200 µg/mL APN in apical well.  Lines are 
predicted concentrations with all model parameters fixed. 
 
 
5.6 Discussion 
 
The cyclization rate of MDZopen is an important factor to consider when using an 
open ring precursor to generate MDZ in a two-part, reactive formulation for rapid IN 
delivery.  Cyclization was slow in pH 7.4 buffer at 32 °C, with t1/2 = 16.1 ± 1.5 min.  Other 
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researchers have reported similar t1/2 for the cyclization of MDZopen.  Walser et al. estimated 
the t1/2 to be ~10 min at neutral pH, although the temperature was not specified.
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also estimated ~10 min in pH 7.4 buffer at 37 °C.158  Loftsson et al. reported t1/2 > 2 min at 
pH 7.4 in human serum at 37 °C by HPLC.129   Differences in temperature and analytical 
technique likely account for the discrepancy between these measurements.  The fastest 
rates for cyclization of MDZopen were observed near pH 5; however, transepithelial 
transport of both MDZ and MDZopen was found to be optimal at alkaline pH.  Note that 
slow cyclization of MDZopen will delay the pharmacodynamic effect of MDZ regardless of 
whether the cyclization occurs in the nasal cavity or in the body.   
 
The polynomial like profile observed for the pH dependent cyclization rate (shown 
in terms of t1/2 in Figure 28) can be explained by a change in the protonation state of 
functional groups at different locations on the MDZopen molecule, thereby changing the rate 
determining step for imine formation.  Deprotonation of the primary ammonium cation in 
the basic region increases the concentration of the free amine, which is a better nucleophile 
to attack the carbonyl carbon of the benzophenone moiety.  In the acidic region, the 
carbonyl can be activated by protonating the oxygen, and dehydration of the carbinolamine 
intermediate is facilitated by subsequent protonation of the hydroxyl (i.e. imine formation 
is acid catalyzed).  Alprazolam, a triazolo-benzodiazepine, and oxazolam, a 
benzodiazepine derivative, also display polynomial like pH dependence to their cyclization 
rates.109,166,167    
 
 Cyclization of MDZopen in the nasal cavity will lead to supersaturation of MDZ if 
production of MDZ outpaces absorption.  Supersaturated solutions are metastable50,51 and 
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can phase separate to form crystalline or amorphous precipitates.  Crystallization is 
undesirable because drug trapped in the crystal lattice is of lower activity and could be 
transported from the nasal cavity to the digestive tract by mucociliary clearance, 
diminishing the bioavailability.  Our in vitro experiments suggest crystallization of MDZ 
is a sporadic process at short time scales, requiring a nucleation event that only occurred 
in some samples.  When MDZ concentrations were driven beyond the upper limit of 
supersaturation, LLPS was spontaneous and the dispersed phase was amorphous MDZ.  
The amorphous precipitate has no crystal lattice energy barrier to dissolution; therefore, it 
exists in quasi-equilibrium with the supersaturated solution.  This allows the amorphous 
precipitate to act as a source for MDZ and maintains the solution concentration at the upper 
limit of supersaturation during the absorption process.  In other words, LLPS effectively 
caps the driving force for absorption of MDZ from the solution phase at the upper limit of 
supersaturation, but MDZ in the amorphous precipitate is still bioavailable.   
 
Supersaturated solutions of MDZ had a greater propensity to crystalize than 
supersaturated solutions of diazepam generated from Lys-diazepam prodrug/enzyme 
reactions.  This difference between the two benzodiazepine drugs was also manifest in DSC 
analysis of the dried reaction precipitates.  Diazepam reaction precipitates showed a glass 
transition, but no cold crystallization or melting peaks.75  In contrast, MDZ reaction 
precipitates showed a glass transition, cold crystallization exotherm, and melting 
endotherm (Figure 31A).  The presence of a cold crystallization peak suggested that MDZ 
readily underwent rearrangement in the amorphous regions to form a crystalline phase.  
Furthermore, the molar heat of solidification (ΔHs) was often slightly lower than the molar 
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heat of fusion (ΔHf).  For the sample shown in Figure 31B, ΔHs = 24.1 kJ/mol and ΔHf was 
26.5 kJ/mol, indicating the MDZ precipitate was initially only 91% amorphous.   
 
The rate at which MDZ could be delivered systemically by IN administration of an 
open ring precursor would be primarily controlled by the absorption rate of MDZ, 
absorption rate of MDZopen, and cyclization rate of MDZopen, all of which are pH dependent.  
Both MDZ and MDZopen exhibited higher permeation at higher pH.  The charge of the 
predominate microspecies reflected the differences in permeation observed at each pH as 
well as differences observed between the two species.  Based on a pKa of 6.2, about 94% 
of MDZ is expected to exist as the neutral microspecies at pH 7.4 while 82% is 
monocationic at pH 5.5.  With pKas at 5.7 and 8.4, about 89% of MDZopen is expected to 
exist as the monocation at pH 7.4 while 60% is dicationic at pH 5.5.  Since MDZ was less 
charged than MDZopen at a given pH, it was more readily transported across the membrane.  
Therefore, the cyclization rate in the nasal cavity is also important.  This is demonstrated 
in Figure 32B.  At pH 5.5 (blue circles), MDZ was ultimately delivered to the basal wells 
at a faster rate than at pH 6.5 (orange triangles) even though MDZ and MDZopen had higher 
permeation at pH 6.5.                  
 
A formulation pH of 7.4 for delivery of MDZ is desirable because it would afford 
rapid absorption and is within the pH range of the nasal cavity.  For MDZpro/enzyme 
formulations, the pH dependent solubility of MDZpro must be taken into consideration.  
Precipitation of Phe-MDZpro from solution was observed at pH 5.8 and concentration of 
160 mM (Appendices A4, Figure A4.86).  At this concentration, which is equivalent to 52 
mg/mL of MDZ, a volume of 192 µL would be needed to deliver a 10 mg dose of MDZ.  
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Transport studies and enzyme kinetics for the Phe-MDZpro/APN formulation were 
performed at pH 5.5 because of this solubility limitation.   
 
 The amount of enzyme required to hydrolyze high concentrations of Phe-MDZpro 
within a reasonable time frame is another factor that must be considered for the 
MDZpro/enzyme formulation approach.  To hydrolyze Phe-MDZpro equivalent to 10 mg 
MDZ in 10 min at pH 5.5, 2.8 mg of APN would be needed.  Even then, the cyclization 
reaction would take additional time to complete.  Slow reaction rates coupled with slow 
absorption could lead to low bioavailability if a significant portion of the dose is carried to 
the digestive tract by mucociliary clearance.  The transit time for mucus in the nasal cavity 
has been reported to be 15-20 min at a rate of 5 mm/min.168  Depending on the scalability 
of enzyme production, the amount of enzyme required for sufficiently fast hydrolysis could 
make the cost per dose prohibitively expensive.  It should be noted that the enzymatic 
activity of APN was suboptimal at pH 5.5 (Appendices A4, Figure A4.84).  Different 
MDZpro/enzyme combinations formulated at different pH may not require such large 
amounts of enzyme.  The stability of the enzyme and level of endogenous enzymes in the 
nasal cavity that can convert MDZpro will also affect the amount of exogenous enzyme 
needed per dose.  
 
At low pH, the open ring forms of benzodiazepines like diazepam undergo chemical 
degradation.169  Open ring forms of triazolo- and imidazo-benzodiazepines such as 
alprazolam and MDZ do not allow for further acid hydrolysis and are chemically stable in 
solution.129  Thus, the stability of MDZopen at low pH presents the possibility of delivering 
MDZ by co-administering MDZopen•2HCl with a solution of base to bring the pH within 
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an acceptable range for IN delivery and rapid absorption.  MDZopen•2HCl is highly soluble 
and undergoes very rapid dissolution.  An amount equivalent to 10 mg of MDZ can be 
dissolved in as little as 50 µL of water.  With this acid/base formulation approach, there is 
no need for amino acid derivatization and subsequent hydrolysis of the amino acid moiety 
to liberate MDZopen as is the case with the MDZpro/enzyme formulation approach.   
 
5.7 Conclusions 
 
Despite a long history of off-label IN administration of MDZ injectable solutions, 
an approved nasal spray formulation has been elusive.  This is because MDZ has low 
aqueous solubility.  Formulations that utilize solubilizing excipients or low pH to achieve 
a dose volume appropriate for IN delivery tend to irritate the nasal mucosa.  However, it is 
possible to generate aqueous MDZ in a volume and at a pH appropriate for IN delivery by 
mixing a precursor with a reactant immediately before administration.  The metastable, 
supersaturated solution of MDZ that results provides an increased driving force for 
enhanced permeation across membranes, but there is a limit to the degree of supersaturation 
that can be reached without causing spontaneous phase separation of MDZ.  Precipitate 
from MDZ generated above the supersaturation limit was found to be amorphous.  MDZ 
in the amorphous precipitate remains available for absorption.  Phase separation of MDZ 
into a crystalline phase was also observed, but only sporadically.  It is unclear if nucleation 
would occur in vivo or if crystallization would sequester a significant amount of MDZ 
before the dose is absorbed.  The most critical barrier to achieve rapid delivery and high 
bioavailability of MDZ using an open ring precursor was found to be the cyclization rate 
of MDZopen.  Cyclization was pH dependent.  A formulation pH of 7.4 was found to be 
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optimal for permeation of MDZ and MDZopen across cell membranes, but the slow 
cyclization rate for MDZopen at this pH would control the rate at which MDZ appears in the 
body.       
 
Different reactions can be used to liberate MDZopen in an aqueous formulation and 
generate MDZ.  The acid/base formulation approach is preferable to the MDZpro/enzyme 
formulation approach, because the latter is more difficult to optimize.  Enzyme stability is 
often an issue, and catalytic activity can be sensitive to changes in pH or temperature.  
Furthermore, the prodrugs themselves may have solubility limits, as was the case with Phe-
MDZpro.  In contrast, an acid/base reaction is robust and straightforward.  The final pH of 
the acid/base formulation can be selected simply by choosing the appropriate base 
concentration, but the acid and base components must be adequately mixed during 
administration to avoid heterogeneous deposition and pH spikes on the surface of the nasal 
mucosa.  Either formulation approach requires the reactants to be kept segregated during 
storage.  This is most conveniently accomplished with a nasal spray device specifically 
designed to store, mix, and atomize two-part reactive formulations.  When the dose is ready 
to be administered, mixing of the two formulation components would be initiated and the 
mixture sprayed into the nasal cavity where formation of MDZ would occur.  Our group is 
currently prototyping and testing nasal spray devices for administration of these types of 
formulations.    
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Chapter 6: Nasal spray device for administration of two-part drug formulations 
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6.1 Summary 
 
Intranasal drug delivery is an attractive route to noninvasively achieve a rapid 
therapeutic effect, avoid first pass metabolism, and bypass the blood brain barrier.  
However, the types of drugs that can be administered by this route have been limited, in 
part, by device technology.  Herein, we describe a pneumatic nasal spray device that is 
capable of mixing liquid and solid components of a drug formulation as part of the 
actuation process during dose administration.  The ability to store a nasal spray drug 
formulation as two separate components can be leveraged to solve a variety of stability 
issues that would otherwise preclude intranasal administration.  Examples of drugs that 
could be delivered intranasally by utilizing this two-part formulation strategy include 
biomolecules that are unstable in solution and low solubility drugs that can be rendered 
into metastable supersaturated solutions.  A proof of concept nasal spray device prototype 
was constructed to demonstrate that a liquid and solid can be rapidly mixed and atomized 
into a spray in a single action.  The primary breakup distance and angle of the spray cone 
were measured as a function of the propellant gas pressure, and silicone nasal cavity molds 
were used to assess the effect of cone angle on formulation deposition within the nasal 
cavity.  Higher pressures produced wider cone angles, but the deposition area within the 
nasal cavity was found to be generally independent of cone angle.  Variations of two-part 
drug formulations for intranasal delivery of insoluble benzodiazepines in an aqueous 
vehicle were tested with the prototype device.  An acid/base formulation that generates 
midazolam demonstrated rapid dissolution of the solid component and effective mixing, 
while a prodrug/enzyme formulation that generates diazepam demonstrated the ability to 
conveniently store and administer labile biomolecules with this device.         
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6.2 Introduction 
 
The intranasal route for systemic drug delivery has been gaining popularity in 
recent years.  This is because it offers several advantages over traditional routes of 
administration.  The highly vascularized nasal mucosa contains fenestrated capillaries and 
has a porous basement membrane, making the tissue an ideal site for rapid drug 
absorption.20  Since the capillaries drain directly into the systemic circulation, the 
bioavailability of drugs that undergo first pass metabolism or gastrointestinal degradation 
by the oral route can be improved by delivery through the intranasal route.  In addition to 
capillaries, the nasal mucosa has a network of lymphatic vessels that can be targeted for 
efficient, needle-free delivery of vaccines.170  The intranasal route also offers the possibility 
of bypassing the blood brain barrier and delivering drugs directly to the brain via the 
olfactory or trigeminal nerve pathways.171   From a patient perspective, convenient and 
essentially painless dosing makes the intranasal route preferable to other parenteral routes.  
Furthermore, the nasal cavity is easily accessible and operation of a nasal spray device is 
generally intuitive, so administration can be performed by untrained individuals even in 
emergency situations.33 
 
Even though intranasal delivery has been shown to be practical and safe for many 
drugs,33 there are challenges that have prevented formulation of certain types of drugs as 
nasal sprays.  Most notably, the volume that can be reliably deposited in the nasal cavity is 
limited to 200 µL.172  Larger volumes tend to drain out of the nostrils and/or into the 
nasopharynx, causing slower absorption and lower bioavailability.  Organic solvents and 
other solubilizers have been investigated to obtain an acceptable dose volume for drugs 
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with low solubility, but these additives tend to cause irritation and can damage sensitive 
nasal tissues.34,40  Another major challenge to formulating some drugs as nasal sprays is 
poor stability.19  Biopharmaceuticals have notoriously short shelf lives when stored in 
solution because they are susceptible to denaturation, aggregation, and chemical 
degradation reactions.  Degradation reactions are also accelerated for small molecule drugs 
stored in solution.  Challenges related to low solubility or poor stability can be overcome 
for a variety of drugs by strategically selecting some components of the formulation to be 
stored separately as solids.  Immediately prior to administration, the liquid and solid parts 
would be combined to make supersaturated or metastable solutions that can be sprayed into 
the nasal cavity without concern for processes that would normally render the formulation 
unstable over a longer timescale.  
 
To our knowledge, there is no marketed nasal spray device that is capable of mixing 
liquid and solid parts of a formulation during administration of the dose.  The availability 
of such a device would revolutionize intranasal delivery by enabling two-part formulation 
strategies and opening up the pharmacokinetic advantages of intranasal delivery to drugs 
that cannot be stored in solution.  Born out of a desire to co-administer reactive 
prodrug/enzyme combinations for intranasal delivery of drugs with low solubility,42,75 we 
have designed a pneumatically driven, dual chamber nasal spray device for rapid mixing 
and atomization of pre-metered doses.  A description of the device mechanism, 
demonstration of a proof of concept prototype, results from preliminary testing of the proof 
of concept prototype with two-part drug formulations, and an example of a functional 
prototype follow.   
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6.3 Device mechanism 
 
6.3.1 Dual chamber drug cartridge  
 
The nasal spray device relies on disposable drug cartridges that contain a single, 
pre-metered dose.  The drug cartridge, illustrated in Figure 34, has two compartments to 
keep the liquid and solid parts of the drug formulation separate during storage.  The liquid 
part of the drug formulation (e.g. buffer, water, solvent, liquid drug, drug that is stable in 
solution, liquid excipients, excipients in solution, etc.) is contained between two pistons in 
the first compartment.  Solids that are reactive or otherwise unstable in solution are 
hermetically sealed in the second compartment between Piston 2 and a check valve or 
breakable membrane near the atomizer tip.   
 
During actuation of the device, a burst of propellant such as compressed air or inert 
gas is released into the aft end of the drug cartridge.  Initially, the force of the propellant 
gas causes Piston 1, the liquid, and Piston 2 to move down the drug cartridge barrel with 
the same displacement.  When Piston 2 reaches the slot near the center of the barrel it 
becomes stationary as the liquid moves around Piston 2, through Channel 1, and into the 
solids compartment.  The liquid and solid parts of the formulation mix as Piston 1 continues 
to advance down the cartridge barrel, pushing liquid into the solids compartment.  When 
Piston 1 reaches Piston 2, they make contact.  This contact forces Piston 2 past the slot 
region, at which point Piston 1 becomes stationary and Piston 2 advances down the barrel 
under the force of the propellant gas.  The movement of Piston 2 causes the mixed drug 
formulation to fill the atomizer tip and exit the drug cartridge as a spray.  When Piston 2 
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reaches the atomizer tip, the propellant gas flows through Channel 2 and expels any 
remaining drug formulation out of the atomizer tip. 
 
6.3.2 Propellant gas system 
 
The drug cartridge can be integrated with a small, mechanical system to generate a 
single burst of propellant as illustrated in Figure 35.  Actuation of the device is as simple 
as pressing the button.  The button moves a compressed gas cartridge toward a flow 
regulating, hollow puncture pin.  When the pin punctures the gas cartridge, the gas is 
released into the drug cartridge.  This iteration of the propellant gas system is for one-time 
use, making the entire device disposable. 
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Figure 34.  Sequence of drug cartridge cross sections demonstrate mechanism for 
mixing and spraying the drug formulation.  The cartridge body is a long, thin, hollow 
cylinder.  (A) Compartment for storing liquid portion of formulation.  (B) Compartment 
for storing solids portion of formulation.  (C) Piston 1.  (D) Piston 2.  (E) Channel 1.  (F) 
Channel 2 with a membrane to seal the solids compartment during storage.  (G) Atomizer 
tip. 
 
 
 
 
Figure 35.  Cross section of disposable, single dose, dual chamber nasal spray device.  
(A) Mechanical button for actuation.  (B) Locking mechanism to keep button depressed.  
(C) Micro sized propellant gas cartridge charged for single use.  (D) Elastomer receiver to 
create seal with gas cartridge.  (E) Hollow piercing pin to puncture gas cannister.  (F) 
Plastic body.  (G) Soft foam tip for contact with nostril. 
 
 
Alternatively, the propellant gas system could be reusable as illustrated in Figure 
36.  In this iteration of the design the drug cartridge is still single use, removable, and 
disposable.  The body of the device is meant to be reused.  The gas cartridge is also 
replaceable and disposable, but it contains enough charge to be used many times before 
replacement.  The device has an electronically controlled solenoid to release a metered 
burst of propellant gas into the drug cartridge when the button is pushed.  A discharge 
counter would keep track of how many times the device was used and be reset every time 
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a fresh gas cartridge is installed.  The status of the device (ready, full, empty, battery 
warning, etc.) can be indicated to the user on a display or with led lights.   
 
 
 
Figure 36.  Reusable nasal spray device that accepts disposable, single use, dual 
chamber drug cartridges.  (A) Propellant gas cartridge charged for multiple doses.  (B) 
Elastomer receiver to create seal with gas cartridge.  (C) Hollow piercing pin to puncture 
gas cannister.  (D) Metered flow solenoid and counter.  (E) Status indicator display.  (F) 
O-ring.  (G) Button for actuation.  (H) Power cell.  (I) Drug cartridge positioning pins.  (J) 
Main plastic body molded to house the components.  (K) Soft foam tip for contact with 
nostril.  (L) Viewing window to determine if cartridge has been spent.  (M) Top shell that 
can be removed to access and replace the internal components (drug cartridge, propellant 
gas cartridge, and power cell).    
   
6.4 Materials and methods 
 
6.4.1 Proof of concept device prototype construction  
 
A fully functional proof of concept nasal spray device was constructed with the 
following basic elements: dual chamber drug cartridge, propellant gas cartridge, flow 
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regulator, valve, and switching mechanism.  A 0.3 mL polypropylene insulin syringe 
(Becton Dickinson Co., Franklin Lakes, NJ: cat. #324702) having an ID of 3.2 mm and 
length of 50 mm was repurposed for the drug cartridge barrel.  Slots, approximately 4 mm 
long, were cut through the wall of the barrel and covered with sections of silicone tubing 
to form Channels 1 and 2 as illustrated in Figure 34.  Polyisoprene pistons 2.5 mm in length 
were fashioned from syringe plunger tips.  The pistons were lightly lubricated with PFPE 
based DuPont Krytox GPL 100 Oil (DowDuPont Inc., Midland, MI), which is compatible 
with elastomeric seal materials and engineering plastics.  After loading the drug cartridge 
with a test formulation, a pressure-swirl type atomizer tip was affixed to one end of the 
drug cartridge using silicone tubing as shown in Figure 37.  The atomizer tip was obtained 
from a generic nasal spray bottle (Pirlo International Co., Zhejiang, China: cat. # 
391333528).  The other end of the drug cartridge was connected to a fast response (< 20 
ms), normally closed solenoid valve (WIC Valve Co., San Jose, CA: cat. #2ACK-1/4).  The 
valve was operated using a triggered relay timer that was programmable in millisecond 
increments with 0.1% precision (QiYuanFei Electronic Technology Ltd., Shanghai, China: 
cat. #JDQSX11SH).  Triggering the relay caused the release of propellant gas into the drug 
cartridge for a specified time interval.  The propellant gas was pressurized CO2 from a 
standard 8 gr cartridge attached to an adjustable regulator with 0-125 psi gauge (Interstate 
Pneumatic Manufacturing, Vista, CA: cat. #WRCO2).   
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Figure 37.  Prototype drug cartridge prior to actuation.  Inset shows examples of the 
elastomer pistons, which are situated in the cartridge but obscured by opaque tubing in the 
main image.  (A) Liquid compartment containing buffer.  (B) Solids compartment 
containing lyophilized prodrug and enzyme.  (C) Location of elastomer piston 1.  (D) 
Location of elastomer piston 2.  (E) Location of channel 1.  (F) Location of channel 2.  (G) 
Atomizer tip.  (H) Barbed connector from solenoid that releases a controlled burst of 
propellant gas, CO2. 
 
6.4.2 Spray cone measurements 
 
Drug cartridges were loaded with 150 µL water in the liquid compartment and 15 
mg mannitol lyophilizate in the solids compartment to simulate a two-part drug 
formulation.  The relay timer and regulator were set to release CO2 into the drug cartridge 
at specified stagnation pressures for a duration of 100 ms.  The resulting spray was filmed 
with a Sony Exmor RS 12 MP camera at a frame rate of 240 fps.  Individual frames were 
examined to locate three representative images of the fully developed spray cone at each 
condition tested.  Examples of the images are shown in Figure 38.  To measure the primary 
breakup distance and cone angle, the features and margins of the spray were identified 
using the Sobel edge detector in the Fiji distribution of ImageJ software version 1.51s.173  
Primary breakup distance (d) was defined as the axial distance from the atomizer tip orifice 
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to the point at which the liquid sheet became unstable and began to form droplets.  Cone 
angle (θ) was defined as the angle between two rays drawn from a vertex located at the 
atomizer tip orifice along the upper and lower margins of the droplet cone. 
      
 
Figure 38.  Images of fully developed spray cone produced by different stagnation 
pressures.  (A) 30 psi.  (B) 35 psi.  (C) 40 psi.  (D) 45 psi. 
 
 
6.4.3 Nasal cavity deposition tests 
 
Human and canine nasal cavity molds were made by 3D printing a cast of the 
interstitial space using a water-soluble polymer, molding clear silicone around the cast, and 
then dissolving out the cast with water.  To print the casts, 3D renderings were required.  
For the human nasal cavity, an STL file (3DPX-002305) was downloaded from the NIH 
3D Print Exchange.174  For the canine nasal cavity, the interstitial space representing the 
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cavity of a 21.6 kg mixed breed canine with a mesocephalic snout was segmented from CT 
scan DICOM files (103 images, voxel spacing 0.449×0.449×3 mm) using ITK-SNAP 
version 3.6.0 developed by Yushkevich et al.175  The STL files were cleaned up to remove 
artifacts and unnecessary sinuses in Meshmixer version 3.5 (Autodesk Inc., San Rafael, 
CA), sliced using Ultimaker Cura version 4.0 (Ultimaker, Geldermalsen, Netherlands) to 
generate the G-code, and subsequently printed on a CR-10 3D Printer (Creality3D 
Technology Co., Shenzhen, China) using Atlas Support water soluble polyvinyl alcohol 
(PVA) blend filament (Formfutura BV, Nijmegen, Netherlands: cat. # 901034). 
 
To create the molds, two-part SYLGARD® 184 Silicone Elastomer (Dow Corning 
Co., Midland, MI) was mixed in a glass container and degassed under vacuum.  Then the 
3D printed nasal cavity casts were submerged in the silicone and the combination placed 
in an oven to cure at 50 °C for 8 hr.  After curing, the glass was fractured for easy removal 
from the outer surface.  The PVA casts were dissolved from the inside of the silicone molds 
using a combination of water bath soaking and periodic pressurized water rinses from a 
Water Flosser (Water Pik Inc., Fort Collins, CO).  Removal of the PVA took about 3 days.      
 
Before each spray test, the nasal cavity molds were prepared by rinsing them with 
an aqueous solution of 100 mg/mL surfactant (Alconox Inc., White Plains, NY: cat# 
MFCD00145747) and dried to leave a thin coat of surfactant on the inner surface.  The 
surfactant mitigated the amount of beading, pooling, and dripping that occurred when dye 
was sprayed into the cavities.  The drug cartridges used for deposition experiments 
contained 150 µL of aqueous erioglaucine dye (FD&C Blue #1) in the liquid compartment 
and 15 mg mannitol lyophilizate in the solids compartment to simulate a two-part drug 
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formulation.  The CO2 propellant gas system set to 30, 35, 40, and 45 psi with a gate interval 
of 100 ms was used to spray the dye formulation into the nasal cavity molds.  The 
anatomical regions where dye deposited was determined by visual inspection through the 
sides of the clear molds, and the penetration depth was measured from the opening of the 
nare to the furthest boundary of bulk solution deposition (light splattering and mists were 
ignored).    
 
6.4.4 Acid/base formulation testing 
 
An acid/base drug formulation was used to assess the ability to mix reactive species 
using the dual chamber drug cartridges.  The acid component was a solid dihydrochloride 
salt of an open ring form of midazolam (MDZopen•2HCl), which is a water-soluble 
precursor to the insoluble drug midazolam (MDZ).  MDZopen•2HCl was synthesized from 
MDZ according to the procedure described in Chapter 5.  To load the drug cartridge, a 
lyophilizate of MDZopen•2HCl was formed and stored within the solids compartment.  The 
lyophilizate was prepared by dissolving MDZopen•2HCl in water at ~0 °C in an ice bath to 
obtain a solution concentration of 0.154 M.  Then, 100 µL of the solution (equivalent to 5 
mg of MDZ) was quickly transferred into a drug cartridge that had a plunger situated near 
Channel 1 to prevent the sample from leaking out of the other end.  The cartridge containing 
the solution was dipped in liquid nitrogen to freeze the liquid, the plunger was removed, 
and the cartridge containing the frozen sample was placed in a lyophilization chamber to 
dry under 0.016 mbar vacuum at room temperature for 18 hr using a FreeZone 6 manifold 
freeze dryer (Labconco Inc., Kansas City, MO).  After lyophilization, the cartridge 
assembly was completed by placing an atomizer tip at the end of the solids compartment, 
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positioning Piston 2 near Channel 1, filling the liquid compartment with 100 µL of pH 13.4 
NaOH in water (0.276 M), capping the end of the liquid compartment with Piston 1, and 
attaching the loaded drug cartridge to the CO2 propellant gas system set to 40 psi with a 50 
ms gate interval.             
 
To test the performance of the drug cartridges that contained this acid/base 
formulation, the pH profile of the spray pattern was visualized on pH indicator paper.  The 
cartridge contents were sprayed onto a sheet of either blue litmus paper or red litmus paper 
from Precision Laboratories, LLC (Waukegan, IL: cat# 280-24-810 and 290-24-8X10).  
The distance between the atomizer tip and the litmus paper was 7 cm.  Images of the spray 
pattern were captured ~10 s after the formulation had been sprayed. 
 
6.4.5 Prodrug/enzyme formulation testing 
 
A prodrug/enzyme formulation was used to assess the ability to reconstitute and 
atomize lyophilized fragile biomolecules using the dual chamber drug cartridges.  The 
prodrug, avizafone (AVF), was synthesized in house according to the procedure described 
previously.42  The enzyme, recombinant human aminopeptidase B enzyme (APB), was also 
produced in house by the procedure described previously.108  In the drug cartridge, both 
AVF and APB were contained in the solids compartment as a lyophilizate.  To prepare the 
lyophilizate, stock solutions of AVF, APB, and the lyoprotectant trehalose were mixed at 
~0 °C in an ice bath to obtain a sample concentration of 1.00 mM AVF, 35 µg/mL APB, 
and 25 or 50 mg/mL trehalose.  Then, 150 µL of the resulting solution was injected into 
the end of a drug cartridge that had a plunger situated near Channel 1 to prevent the sample 
from leaking out of the other end.  The cartridge containing the solution was dipped in 
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liquid nitrogen to freeze the solution, the plunger was removed, and the cartridge 
containing the frozen sample was placed in a lyophilization chamber to dry under 0.016 
mbar vacuum at room temperature for 18 hr.  After lyophilization, the cartridge assembly 
was completed by placing an atomizer tip at the end of the solids compartment, positioning 
Piston 2 near Channel 1, filling the liquid compartment with 150 µL of pH 7.4 phosphate 
buffered saline (PBS), capping the end of the liquid compartment with Piston 1, and 
attaching the loaded drug cartridge to the CO2 propellant gas system set to 45 psi with a 50 
ms gate interval.   
 
To test the performance of the drug cartridges that contained this prodrug/enzyme 
formulation, the concentration of active APB in the spray was calculated from the rate of 
drug production in the ejected solution.  When AVF and APB are combined in solution at 
physiological temperature, they generate the drug diazepam (DZP).108  DZP was measured 
by second derivative UV spectroscopy as described previously.75  In brief, the contents of 
a cartridge were expelled directly into a quartz ultra-microcuvette that was pre-warmed to 
32 °C in the temperature controlled block of Cary 100 Bio UV/Vis double beam 
spectrophotometer (Agilent Technologies Inc., Santa Clara, CA).  Scans from 300-400 nm 
were collected every 0.25 min for 20 min.  The second derivative of the extinction 
measured at 338 nm was used to determine the DZP concentration.  Then the concentration 
of active APB was determined by fitting the differential equations that describe the reaction 
kinetics to the measured DZP concentration-time profiles (Chapter 4, Section 4.3.3).   
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6.5 Results and Discussion 
 
6.5.1 Device functionality 
 
Visual inspection of spent drug cartridges indicated that the prototype device was 
operating properly.  The final position for Piston 1 was at Channel 1, and the final position 
of Piston 2 was at Channel 2.  Nearly all of the formulation was cleared from the cartridge 
and atomizer tip.  The way that the dual chamber drug cartridge functions in this nasal 
spray device is similar to that of prefilled dual chamber syringes.176  Dual chamber syringes 
are marketed for parenteral drug delivery by injection.  These syringes use a mechanical 
plunger, so there will always be some amount of drug left in the dead space between the 
plunger and end of the needle.  Since volumes on the order of milliliters are common for 
injectable formulations, the amount trapped in the dead space of a dual chamber syringe is 
only a small fraction of the dose.  Much smaller dose volumes (25 – 200 µL) are required 
for nasal spray formulations.172  The amount of drug left in the dead space and atomizer tip 
would be a significant fraction of the dose if a mechanical plunger were to be used as the 
driving force.  Unspent drug can be dangerous or abused.  By using compressed air or 
propellent gas as the driving force for actuation, virtually all of the drug can be expelled 
from the drug cartridge.  This means that cartridges do not have to be loaded with excess 
drug, and the empty cartridges can be safely disposed in household trash.  
 
The pre-metered drug cartridges and automated action of this nasal spray device 
reduce the risk of improper dosing, but adequate deposition of the dose in the correct region 
of the nasal cavity is also important for effective intranasal delivery.  Deposition is 
controlled by the atomizer tip insertion depth and angle, as well as spray plume 
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characteristics.  Spray characteristics include cone angle, spray pattern, breakup distance, 
droplet velocity, and droplet size.  As one might expect, the spray characteristics were 
found to be dependent on the type of atomizer tip used, composition of the formulation, 
propellant gas pressure, and duration of the applied pressure.  When these device conditions 
were held constant, the cone angle and primary breakup distance for the jet were 
reproducible.  Other spray characteristics were not measured during preliminary testing.  
Cone angle was approximately proportional and breakup distance was inversely 
proportional to pressure, for pressures between 30 and 45 psi as shown in Figure 39.  Below 
30 psi, erratic spray patterns were observed, and the device occasionally failed to expel the 
entire dose.  Pressures above 45 psi produced a qualitatively finer mist but did not result in 
larger cone angles.   
 
 
Figure 39.  Fully developed spray cone geometry as a function of stagnation pressure.  
Averages +SD plotted, n = 3.  
 
6.5.2 Nasal cavity deposition 
 
Some spray parameters, such as droplet size, have a relatively minor influence on 
deposition efficiency and area of deposition within the nasal cavity compared to cone angle 
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and administration angle.177  For small cone angles, the orientation of the device in the 
nostril becomes more important.  A stream-like spray could impact a surface at the anterior 
of the nasal cavity, limiting the deposition to a smaller area in a region that is not optimal 
for drug absorption.  Conversely, spray plumes with large cone angles may not clear the 
nasal valve (tapered region between the vestibule and atrium) and deposit predominantly 
in the vestibule rather than the nasal cavity.  Ideally the spray would develop beyond the 
valve and deposit on the highly permeable respiratory epithelium at the anterior region of 
the turbinates.32,178  The surface tension of the drug formulation and lateral movement of 
the mucus layer towards the nasopharynx (a process known as mucociliary clearance)97 
will cause the formulation to spread over the surface of the turbinates.177  Deposition too 
deep within the nasal cavity, at the posterior of the turbinates, would limit the residence 
time of the drug in the nasal cavity and may lead to lower bioavailability if absorption 
cannot occur before mucociliary clearance carries the drug to the digestive tract.   
 
Images of a human nasal cavity mold that was used for spray deposition testing are 
shown in Figure 40.  The contents of drug cartridges with a solution of blue dye in the 
liquid compartment and a mannitol lyophilizate in the solids compartment were sprayed 
into the mold using the CO2 propellant gas system set to various stagnation pressures to 
produce a range of spray cone angels (θ = 19, 31, 54, and 67°).  The primary deposition 
area, regardless of spray cone angle, was in the atrium region of the nasal cavity.  Spray 
cone angles of 67° tended to impact the nasal valve, and the buildup of solution in that area 
caused dripping of the formulation back out though the nare (Figure 40D1).  The higher 
pressures used to produce wider cone angles also led to more splattering within the nasal 
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cavity, but the boundaries of the splattered region did not extend much further than the 
atrium region.  This is because the meatus of the atrium and turbinates form a thin, tortuous 
path with no linear route for spray droplets to travel to the deeper recesses of the nasal 
cavity.  Formulations sprayed with the smallest cone angle tested, 19°, deposited beyond 
the nasal valve region and were less likely to drip back out through the nare (Figure 40D2).  
One of the most critical factors affecting the region where dye deposited in the nasal cavity 
was found to be the angle of administration.  Perhaps not surprisingly, greater deposition 
on the respiratory epithelium at the anterior of the turbinates could be achieved by angling 
the spray device towards the turbinates (at about a 40° angle from the plane of the nare).  
These observations and deposition areas are similar to the findings of other researchers.16,17  
Suman et al. noted that benchtop spray plume characterization measurements (droplet size, 
cone angle, ovality ratio, etc.) that can portray two spray devices as having different 
performance does not necessarily equate to differences in performance in vivo.179  
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Figure 40.  Human nasal cavity mold.  (A1-3) Cast of interstitial space of human nasal 
cavity that was 3D printed with soluble PVA filament.  (B) Nasal cavity cast inside of 
silicone mold.  (C) PVA dissolved out of silicone to leave empty mold of nasal cavity.  
(D1-2) Blue dye from drug cartridge sprayed though left nare into nasal cavity mold 
deposited in the atrium region.  Spray impacting the nasal valve tended to drip back out of 
the nare as shown in D1.      
 
 
A canine nasal cavity mold was also made to test the device for preclinical trials 
and potential applications in veterinary medicine (Figure 41).  Again, the deposition area 
was found to be largely independent of spray cone angle.  The narrow meatus of the nasal 
cavity and impact of the dye formulation on the walls of the nasal cavity did not allow for 
fully developed spray plumes even at the smallest cone angle tested, 19°.  The region of 
deposition was at the anterior of the nasal cavity and was well distributed between the 
dorsal, middle, and ventral meatus when the spray was directed toward the common meatus 
and aligned parallel to the rostral axis (Figure 41C).  This is likely the ideal region for 
deposition since mucociliary clearance will carry the formulation across the respiratory 
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epithelium from the anterior to the posterior of the nasal cavity, allowing maximal 
residence time for drug absorption to occur. 
 
 
 
Figure 41.  Canine nasal cavity mold.  (A1-3) 3D rendering of the nasal cavity interstitial 
space obtained from CT scan segmentation.  (B1-3) Empty silicone mold.  (C1-3) Blue dye 
from drug cartridge sprayed though left nare into nasal cavity mold deposited past the 
osseous nasal aperture and spread across the anterior regions of the dorsal, middle, ventral 
meatus.   
 
 
6.5.3 Drug formulation testing 
 
Our group is currently investigating a two-part formulation strategy for the 
intranasal delivery of insoluble benzodiazepines to treat seizure emergencies.  These 
formulations contain reactive species that must be kept separate during storage.  When the 
reactants are combined and sprayed into the nasal cavity, a metastable supersaturated 
solution of the benzodiazepine is created which leads to very rapid absorption across the 
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nasal mucosa into the systemic circulation.108  Two different versions of these two-part 
benzodiazepine formulations were tested in the drug cartridges.  An acid/base formulation 
that generates the benzodiazepine MDZ was used to demonstrate rapid dissolution and 
mixing, and a prodrug/enzyme formulation that generates the benzodiazepine DZP was 
used to demonstrate the applicability of this strategy to the delivery of unstable molecules 
or molecular assemblies.       
 
6.5.3.1 Acid/base formulation 
 
The drug MDZ is insoluble in water at physiological pH.  Formulations that are 
concentrated enough to deliver a therapeutic dose in a volume acceptable for intranasal 
delivery rely on low pH, organic co-solvents, or inclusion complexes.  These formulation 
strategies can irritate sensitive nasal tissues and slow drug absorption.  MDZopen•2HCl is a 
soluble precursor of MDZ.  When dissolved in water at high concentrations, MDZopen•2HCl 
results in an acidic solution and exists predominately as an inactive open ring form of MDZ.  
Increasing the pH of the solution shifts the equilibrium toward MDZ, creating a 
supersaturated solution and a bioavailable amorphous phase.  This slurry of supersaturated 
and amorphous MDZ cannot be stored for long periods of time without leading to 
undesirable crystallization of MDZ.  Therefore, the pH shift should be performed at the 
time of administration.  Refer to Chapter 5 for background and details about this 
formulation. 
 
The dual chamber drug cartridges offer an opportunity to conveniently store 
MDZopen•2HCl separately from a base and the ability to rapidly atomize a mixture of them 
for deposition in the nasal cavity at the time of administration.  In the drug cartridge, 
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MDZopen•2HCl was stored within the solids compartment as a lyophilizate.  The base 
component, aqueous NaOH, was stored in the liquid compartment.  In order to avoid a 
heterogenous mixture and pH spikes on the surface of the nasal mucosa, a two-part 
acid/base formulation would need to undergo very rapid mixing or dissolution.  As a 
lyophilizate, dissolution of MDZopen•2HCl was observed to be nearly instantaneous.  The 
formation of low density, porous cakes during lyophilization greatly increases the surface 
area of the solid material and enhances dissolution.180  Additionally, the lyophilization 
process can result in high energy amorphous and/or polymorphic crystalline forms of a 
material that are more readily solvated compared to the thermodynamically stable crystal 
form.181  Samples of the MDZopen•2HCl lyophilizates characterized by differential scanning 
calorimetry according to the procedure described in Chapter 5 indicated amorphous 
MDZopen•2HCl was present in the lyophilizates, evident by the glass transition at 74.3 °C 
and crystallization exotherm at 154-163 °C (Figure 42).  As the lyophilized samples were 
heated, several metastable modifications were observed that corresponded to high energy 
polymorphs.  Lyophilization will likely improve the dissolution rate of many drugs or drug 
precursors as it does for MDZopen•2HCl, but the extent of improvement will depend on the 
specific compound, excipients, and lyophilization cycle parameters.       
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Figure 42.  DSC thermograms of the MDZ acid/base formulation reactants and 
products.  (A) Insoluble, crystalline MDZ standard.  (B) Amorphous MDZ precipitate 
recovered from reaction of MDZopen•2HCl with NaOH solution.  (C) Crystalline 
MDZopen•2HCl from synthesis of stock.  (D) Rapidly dissolving amorphous material and 
metastable modifications present after lyophilization of MDZopen•2HCl.   
 
 
Homogeneous mixing of the formulation components at the site of deposition is 
important for two-part reactive formulations such the MDZ acid/base formulation.  The 
reactive species should be thoroughly mixed to ensure that complete and efficient 
production of the active drug occurs.  To test the mixing of NaOH in solution with 
MDZopen•2HCl in the lyophilizate, permutations of the formulation were sprayed from drug 
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cartridges onto litmus paper using the CO2 propellant gas system.  Control drug cartridges 
containing water and MDZopen•2HCl lyophilizate sprayed onto blue litmus paper created a 
circular orange spray pattern (Figure 43A).  Blue litmus becomes orange when exposed to 
acidic solutions.  This control demonstrated that rapid dissolution of the MDZopen•2HCl 
lyophilizates resulted in an acidic spray plume.  The pH of the expelled solution was 
measured to be 1.3 when the spray was captured in a vial and subsequently measured with 
a low volume pH meter.  Figure 43B shows the converse control with only NaOH solution 
in the liquid compartment of the drug cartridge and nothing in the solids compartment 
sprayed onto red litmus paper.  (Red litmus becomes blue when exposed to basic solutions.)  
Figure 43C and Figure 43D show the spray patterns from drug cartridges containing both 
NaOH solution and MDZopen•2HCl lyophilizate.  On blue litmus, a light orange hue 
(corresponding to pH ~7.4) was observed in a circular pattern with a smaller radius than 
the radius of the full spray plume, suggesting a higher concentration of MDZopen•2HCl at 
the center of the plume.  However, a faint blue hue (corresponding to pH ~8) was observed 
in the same area from the same formulation sprayed on red litmus.  Multiple replicates 
yielded the same conflicting results.  It seems likely that the entire plume had a pH 7.4-8.0, 
but a color change was only detectable at the center of the blue litmus because that is where 
a larger volume of formulation deposited.  The pH profile of the spray pattern from this 
acid/base formulation demonstrates that large pH shifts can be performed with this device, 
opening up the possibility to administer soluble salts of poorly soluble drugs at a pH 
appropriate for intranasal delivery.                        
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Figure 43.  Images of acid/base formulations sprayed onto litmus paper.  Each image 
shows the pH profile of the spray pattern that resulted from spraying drug cartridges 
containing a two-part formulation with 100 µL liquid and 6.4 mg solid of the stated 
components onto pH indicator paper.  Scale bar on left is in units of cm.  Buffer solutions 
spotted on right to show color scale for pH.  Each condition was tested in triplicate.  (A) 
Water and solid MDZopen•2HCl sprayed onto blue litmus paper.  (B) pH 13.4 NaOH 
solution and no solid sprayed onto red litmus paper.  (C) pH 13.4 NaOH solution and solid 
MDZopen•2HCl sprayed onto blue litmus paper.  (D) pH 13.4 NaOH solution and solid 
MDZopen•2HCl sprayed onto red litmus paper. 
 
  
Instantaneous dissolution and content uniformity between individual spray droplets 
may not be as critical as homogeneous mixing on the surface of the nasal mucosa.  As can 
be seen in Figure 43C and D, orange speckles were observed throughout the spray pattern, 
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indicating punctate acidity.  The formulation in those experiments was expelled from the 
drug cartridges with a 50 ms burst of CO2 propellant.  Given this short time frame, it is 
reasonable to assume that some of the lyophilized material exits the atomizer as a slurry.  
For an acid/base formulation, these scattered droplets of low acidity would quickly dilute 
in the nasal mucus and probably do not contain enough acidic material to overcome the 
natural buffering capacity of the mucus.  Furthermore, mixing of the acid and base 
components does not necessarily have to occur in the cartridge.  Figure 44 demonstrates 
mixing on a deposition surface rather than inside the drug cartridge.  The drug cartridge 
containing a liquid/liquid formulation with an aqueous solution of tartrazine dye (FD&C 
Yellow #5) in one compartment and an aqueous solution of erioglaucine dye (FD&C Blue 
#1) in the other compartment was sprayed onto a paper towel.  The blue dye exited the 
atomizer first, followed by the yellow dye.  The resultant spray pattern was a green color 
because the deposition area for the blue dye was the same as the deposition area of the 
yellow dye.  As long as the components of a two-part reactive formulation are deposited 
on the same area of the nasal mucosa, homogeneous mixing within the drug is not 
imperative.  
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Figure 44.  Mixing of a sprayed liquid/liquid dye formulation.  (A) Drug cartridge 
contained 125 µL yellow dye in one compartment and 50 µL blue dye in the other.  The 
liquids were separated by an elastomer piston that was obscured from view under the 
silicone tubing.  (B) Cartridge pictured in A sprayed onto a paperer towel produced a green 
spray pattern from the mixing of the yellow and blue dyes.  Image captured immediately 
after spraying.  
 
 
6.5.3.2 Prodrug/enzyme formulation 
 
 Intranasal delivery is an attractive alternative for drugs that would otherwise need 
to be administered intravenously.  In the case of biologics and molecular assemblies, the 
intranasal route also offers the potential to bypass the blood brain barrier through direct 
nose-to-brain pathways.182  However, the solution state physicochemical instability of 
many of these therapeutics does not provide adequate shelf life to formulate them as nasal 
sprays.15  Solid state stability is typically much better, thus lyophilization has been used as 
a means to extend the shelf life of unstable pharmacuticals.183  For example, liposomal 
formulations tend to be unstable in solution and lyophilization is often unavoidable.184 
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 Enzymes also tend to be unstable when stored in solution.  We have been 
investigating the feasibility of co-administrating a soluble prodrug with a converting 
enzyme in an aqueous vehicle for rapid intranasal delivery of insoluble drugs.42  One such 
formulation employs the labile enzyme, APB.  APB can be stabilized for long-term storage 
by lyophilizing it in the presence of its prodrug substrate, AVF, and a common 
lyoprotectant, trehalose (Chapter 4).  In fact, the impetus for designing a dual chamber 
nasal spray device was the desire to quickly reconstitute these APB lyophilizates and 
subsequently atomize the solution for convenient intranasal administration of the 
prodrug/enzyme formulation.   
 
 There are several mechanisms by which APB can degrade during the processes of 
filling the drug cartridges and actuating the device to atomize formulation.  Lyophilizing 
material in long, slim containers can be problematic because the geometry is prone to 
uneven heat and mass transfer.185  Differences in APB lyophilizate cake morphology were 
observed at the closed end of a drug cartridge compared to the open end when frozen 
solutions of the APB and trehalose were lyophilized with Piston 2 in place.  While changes 
in cake appearance do not necessarily equate to changes in product performance, if the 
morphology difference was due to partial melt-back there could be excess moisture trapped 
in that region that would affect stability and the reduction in surface area could cause 
slower dissolution.110  Leaving both ends of the drug cartridge open during lyophilization 
produced uniform cakes; however, the freezing and drying steps caused ~30% loss in APB 
activity regardless of the container material or geometry that was used to prepare the 
lyophilizate.  The degradation associated with the lyophilization process is evident when 
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comparing the active APB concentration in pre-lyophilization solutions shown in Figure 
45A to the active concentration after lyophilization shown by the blue bars in Figure 45B.   
 
During actuation, shear stress from forcing the formulation out of the drug cartridge 
and through the atomizer orifice can damage fragile molecules, especially biomolecules 
like APB.186  The amount of shear stress introduced, hence the extent of degradation, is 
correlated to the shear rate.  Figure 45A shows that the concentration of active APB, 
measured by turnover of the prodrug substrate AVF, was unchanged when the solutions 
were sprayed manually using a syringe attached to an atomizer tip.  Depressing the syringe 
plunger by hand generated relatively low shear rates.  Much higher shear rates can be 
obtained using the CO2 propellant gas system to discharge drug formulations from the drug 
cartridges.  The orange bars in Figure 45B show a reduction in APB activity when the 
prodrug/enzyme formulation was sprayed at high pressure (P = 45 psi) compared to simply 
reconstituting the formulation without pressure or spraying (blue bars).  Samples 
containing different concentrations of the lyoprotectant excipient, trehalose, were tested 
(25 and 50 mg/mL in the pre-lyophilization solution).  Two-tailed, unpaired t-test analysis 
indicated that there was no statistical difference in enzyme activity with these 
concentrations of trehalose: t(4) = 0.80 with p = 0.47 for the controls and t(4) = 1.1 with p 
= 0.35 for the sprayed samples.  Testing of prodrug/enzyme formulations for tolerance to 
shear stress using the dual chamber nasal spray device prototype is ongoing. 
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Figure 45.  Stability of enzyme upon spraying prodrug/enzyme formulations. (A) No 
difference in active enzyme concentration was observed between prodrug and enzyme 
admixed from stock solutions without spraying (blue bar) versus mixtures that were drawn 
into a syringe and sprayed though an atomizer by thumb pressure on the syringe plunger 
(orange bar).  The components were not lyophilized.  Reactions were performed in PBS, n 
= 3, ±SD. (B) Reduction in active enzyme was observed between prodrug/enzyme 
lyophilizates reconstituted with PBS and rinsed out (blue bars) versus those that were 
sprayed out of the drug cartridge using the CO2 propellant gas system (orange bars), n = 3, 
±SD. 
 
 
6.5.4 Example of a functional prototype 
 
The laboratory CO2 propellant gas system used for benchtop testing of the proof of 
concept prototype was too bulky to incorporate in a handheld device, so a functional 
prototype was constructed that forces air through the drug cartridge using a compressed 
spring air pump.  Since air is a compressible gas, the pump needs to push a volume of air 
larger than the volume of the drug cartridge in order to generate enough pressure to expel 
the formulation from the cartridge.  Additionally, there is an inverse relationship between 
the pressure that can be generated from the spring force and the area of the piston within 
the pump.  In the prototype pictured in Figure 46, the air pump was fashioned from a 1 mL 
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syringe that had an inner cross-sectional area 2.3 times larger than the inner cross-sectional 
area of the drug cartridge.  With a compression spring rate of 1.05 lbs/in, this prototype 
was able to produce fully developed spray cone angles of ~ 40° when the drug cartridge 
was loaded with 150 µL water in the liquid compartment and 15 mg mannitol lyophilizate 
in the solids compartment.  Frictional forces, formulation properties, and atomizer tip 
geometry had a significant impact on the performance of the device.  The air pump and 
drug cartridge pistons required a thin coat of lubrication to reduce friction and operate 
consistently.  Some test formulations with high viscosity or slowly dissolving lyophilizates 
caused too much back pressure to be effectively atomized with this prototype.  Each nasal 
spray drug formulation will have different fluid properties such as viscosity, density, 
thixotropic behavior, elasticity, and surface tension.  These properties influence spray 
characteristics and ultimately nasal cavity deposition,45 so the device parameters (spring 
force, atomizer orifice, etc.) would need to be optimized to suit the properties of specific 
formulations.  If the device is to be reusable, then a mechanism to retract the spring when 
a new drug cartridge is inserted would also need to be incorporated into the design.   
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Figure 46.  Functional prototype. (A) External surface.  (B) Internal components showing 
liquid compartment of drug cartridge containing water, solid compartment containing 
mannitol, and retracted spring of air pump held in place by a trigger mechanism.  (C) 
Internal components after actuation of device by pressing the trigger button.  Extension of 
the spring forced air though the drug cartridge, causing the pistons to advance forward and 
expel the formulation.     
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6.6 Conclusions 
 
Many drugs cannot be formulated as nasal sprays for use in standard nasal spray 
devices because they are either too unstable or poorly soluble to be stored in solution.  The 
dual chamber nasal spray device we have described enables shelf-stable formulations of 
these types of drugs by segregating the reactive or otherwise unstable components of the 
formulation into separate compartments during storage.  Actuation of the device at the time 
of administration combines the components to create a metastable mixture that is sprayed 
into the nasal cavity.   
We began this report by describing the device mechanism, which is a pneumatically 
driven adaptation of dual chamber syringe technology.  A proof of concept prototype was 
constructed and tested with a placebo formulation, demonstrating that the spray plume 
geometry could be controlled by adjusting the propellant pressure.  However, using the 
device to spray dyed placebo formulations into silicone nasal cavity molds and observing 
the extent of deposition in the target region revealed that optimizing the spray cone angle 
is less important than controlling the angle of administration.  Then, the device was tested 
using two-part reactive formulations that generate supersaturated solutions of 
benzodiazepines.  An acid/base formulation that generates supersaturated midazolam 
demonstrated rapid mixing solid and liquid components could be achieved during actuation 
of the device.  A prodrug/enzyme formulation that generates supersaturated diazepam 
demonstrated the feasibility of using this device to stabilize and deliver labile proteins.  In 
general, examples of drugs that could be used in this device include biomolecules, 
water/air/heat sensitive compounds, combinations that produce metastable states such as 
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supersaturation, lyophilized molecular assemblies such as liposomes and emulsions, 
reactive species, or any other incompatible formulation components that need to be 
separated during storage but combined during administration.   
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Chapter 7: Future directions 
 
  
176 
 The series of experiments described thus far provides a basic framework for investigating 
potential two-part reactive formulations for intranasal delivery of poorly soluble drugs and 
demonstrates a viable path from benchtop to pharmaceutical product.  However, there is much that 
remains to be discovered by expanding the experiments to support generalization of this 
formulation strategy to other drugs and to delve deeper into the minutiae of the phenomena that 
have been observed.  The following subsections provide examples of avenues that are ripe for 
exploration.  
 
 
7.1 Phase separation processes 
 
The prodrug/enzyme and acid/base reactions could be used as tools to further study 
amorphous solubility.  Even though the thermodynamic equilibrium solubilities of DZP 
and MDZ are different, they were observed to have essentially the same intrinsic 
amorphous solubility, as determined by the upper limit for their superstation concentrations 
at a pH in which the reaction products are neutral.  Theoretical calculations of ‘amorphous 
solubility advantage’ rely on accurate measurement of the equilibrium solubility of a stable 
crystalline form and Gibbs free energy difference between the amorphous and crystalline 
forms.187  Perhaps correlations between the upper limits of supersaturation measured from 
for a curated series of compounds and the theoretical calculations of their corresponding 
free energies of mixing can be found which will shed light on the molecular properties that 
dictate solubility limits in non-ideal solutions.  This may lead to an empirical or theoretical 
model for accurate prediction of amorphous solubility without the need to perform a priori 
measurements.             
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The reactions could also be used to investigate precipitation behavior when the 
upper limit of supersaturation is reached.  A metastable zone (i.e. supersaturated 
concentration range) exists between the binodal and spinodal curves of a phase diagram.188  
The binodal curve is defined as the mole fraction of a mixture where the chemical potential 
of the all the components are equal.  The binodal curve corresponds to the boundary 
between conditions where a solution is thermodynamically favored versus conditions 
where phase separation is thermodynamically favored.  The spinodal curve is defined as 
the mole fraction of a mixture where the second derivative of the free energy of mixing 
with respect to mole fraction is zero.189  The spinodal is the boundary beyond which the 
solution is unstable and there is essentially no barrier to phase separation.  Spinodal 
decomposition (i.e. rapid growth and coalescence of phase separated solute clusters) occurs 
spontaneously throughout the solution when solute is generated in excess of the spinodal.190  
These initial solute clusters and their aggregation behavior may explain some of the 
aberrant light scattering observed that was not inversely proportional to wavelength under 
certain reaction conditions (Figure 47).  Furthermore, DZP and MDZ precipitates displayed 
different aggregation behaviors (Figure 48).  Experiments such as measuring the changes 
in the particle count and size distributions by dynamic light scatting as a function of time 
for different rates of solute production, measurements of zeta potential to characterize the 
tendency for the clusters of different drugs to coalesce or flocculate during spinodal 
decomposition, and cryogenic transmission electron microscopy of the initial stages of 
spinodal decomposition could be useful to characterize this process and identify the 
physiochemical properties that control it.    
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Figure 47.  Evolution of light scatting from a high concentration reaction. Reaction 
conditions: 3.90 mM AVF, 0.25 U/mL AOP, pH 7.4 PBS, 32 oC.  (A) DZP solution state 
concentration-time profile (green line) as determined by second derivative spectroscopy 
overlaid with corresponding extinction-time profile (blue dashes).  Green arrow marks 
approximate time of reaction completion (98% conversion of [AVF]0 to DZP at t = 35.3 
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min).  Red point marks t = 50 min, corresponding to the time point of the red colored 
spectrum shown in B and C.  (B) Spectra of reaction measured from t = 0 to 50 min, 1 
scan/min.  Precipitate particle formation, growth, and aggregation.  (C) Spectra of 
reaction measured from t = 50 to 120 min, 1 scan/min.  Precipitate settling.     
 
 
 
 
Figure 48.  Microscope images of precipitate.  (A) Ramified aggregation of DZP 
precipitate particles.  Behavior is typically associated with a fast or diffusion limited 
aggregation regime.191  Image captured 60 min after combining AVF and AOP in pH 7.4 
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PBS.  (B) Compact clustering of MDZ precipitate particles.  Behavior is typically 
associated with a slow or reaction limited aggregation regime.191  Image captured 20 min 
after combining solutions of MDZopen•2HCl and NaOH.   
 
 
7.2 In vivo versus in vitro supersaturation limits  
 
 A much higher limit of DZP supersaturation was inferred from fitting the PBPK 
model to plasma concentration-time in the in vivo rat study (CDZP,lim = 20.8 ± 3.1 mM ±SE, 
Chapter 3) compared to in vitro measurements (CDZP,lim = 1.22 ± 0.03 mM ±SD in PBS, 
Chapter 2).  Some data has been collected suggesting that higher limits of supersaturation 
can be obtained in different media, such as the in the presence of albumin (Appendices A1, 
Figure A1.61).  In addition to lipids, nasal mucus contains proteins such as mucin, albumin, 
immunoglobulins, lysozyme, and lactoferrin.  Thus, protein binding may play a role in the 
higher limit that was observed in vivo.  Testing the two-part reactive drug formulations in 
simulated nasal mucus would help gauge the influence of the matrix on the upper limit of 
supersaturation.  Recipes for simulated nasal mucus can be found in references 192 and 193.  
If the upper limit of supersaturation cannot be increased in simulated mucus as dramatically 
as the in vivo data suggests, then another possibility for the apparently high in vivo value 
for the upper limit of supersaturation could be overestimation due to transport of DZP 
across the nasal mucosa directly from the phase separated DZP.  The PBPK model in 
Chapter 3 assumes that only DZP in the solution phase is absorbed.  Reconciling the 
discrepancy between the in vivo and in vitro determinations of CDZP,lim would help make 
predictive PK models more accurate for DZP as well as other supersaturating drug delivery 
systems.   
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7.3 Propensity to crystalize 
 
 In vitro, MDZ was observed to have a greater tendency to crystallize compared to 
DZP.  A series of physiochemical characterization experiments to measure differences in 
mobility and lattice stacking interactions between these molecules would likely explain 
why MDZ crystalizes more readily, but the more interesting question would be whether or 
not MDZ crystallization would be slowed or even non-existent when supersaturated 
solutions are created in a biological system.  A difference in the propensity of MDZ to 
crystalize in buffer versus a biological medium would be relativity easy to test using the 
simulated nasal mucus recipes mentioned in Section 7.2.   
 
When attempting to measure crystal nucleation frequency and growth rates, the 
method used to generate the supersaturated state may be important.  We have observed a 
greater tendency for crystallization from supersaturated solutions created by a solvent shift 
method compared to a prodrug/enzyme reaction method.  It may be that the protein in the 
prodrug/enzyme reaction has some crystallization inhibiting effect, or it could be that 
creating supersaturation by a solvent shift offers more opportunity for crystal nucleation 
from very high concentration spikes during the mixing process.  If crystallization proceeds 
in nasal mucus, then the crystallization observed with the MDZ formulations (albeit slow 
and sporadic) may not be negligible.  The fraction of the dose sequestered in the crystalline 
phase within the timeframe of mucociliary should be quantified to assess the potential 
impact on the bioavailability of MDZ delivered intranasally via a two-part reactive 
formulation.     
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7.4 Absorption of ORI 
 
All of the prodrugs and precursors used in our studies were derived from open 
diazepine ring structures of the parent benzodiazepines.  There are reasons why creating 
an intermediate species in the pathway from precursor to active drug may be desirable, and 
there are reasons why avoiding the creation of an intermediate may be desirable.  The ORI 
species of DZP and MDZ are able to permeate membranes (the ORI of MDZ to a lesser 
extent than the ORI of DZP), and they are more soluble than the closed ring DZP and MDZ 
drugs.  Therefore, higher concentrations of the ORI can be created in the two-part reactive 
formulations compared to the insoluble parent drugs that quickly reach an upper limit of 
supersaturation and subsequently phase separate.  The high concentration of accumulated 
ORI, hence high driving force for absorption across membranes, may lead to faster delivery 
of drug into the body than could be achieved if the active drug was the only permeating 
species.  The absorption rate advantage of these two-part formulations can be evaluated 
though modeling since estimates of the ORI permeability coefficients can be obtained from 
Transwell drug transport studies: MDZopen Papp = 1.45 ± 0.64 × 10
5 cm/s (Table 4) and ORI 
of DZP Papp = 5.54 ± 2.07 × 10
5 cm/s (unpublished data) across MDCKII-wt cell 
monolayers at pH 7.4 and 32 oC.  External and internal exposure to ORI also depends on 
the ring closing rates in the respective biological media, i.e. cyclization rates should be 
characterized in nasal mucus mixed with the drug formulation as well as in blood to more 
accurately predict the time course of ORI and active drug in the body.  Although the 
exposure to ORI is expected to be short, it would be prudent to assess its toxicity.       
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7.5 Cytotoxicity 
 
The high concentrations of ORI that can accumulate in the nasal cavity and 
potential for ORI to enter the body beg the question of whether or not the ORI species are 
toxic.  There are a variety of software tools commercially available for the prediction of 
Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties.  
These tools offer a starting point to help identify potential mechanisms of toxicity, thereby 
aiding in the design of in vitro experiments to quantify toxic effects or selection of 
tissues/biomarkers to examine for signs of toxicity in in vivo studies.           
In Transwell drug transport studies, we observed a reduction in the confluency 
MDCKII-wt cell monolayers exposed to the DZP and MDZ two-part formulations for long 
periods of time (~2 hr).  Confluency was assessed by comparing transepithelial electrical 
resistance (TEER) measurements before and after treatment, and by measuring dye 
permeability at the conclusion of the experiments.  It should be noted that a 2 hr timeframe 
is not physiologically relevant considering the rate of mucociliary clearance and continual 
reduction in direct exposure to the nasal epithelium from dilution, conversion, and transport 
in vivo.  However, cell monolayer toxicity data does provide some indication of the limits 
of exposure that can lead to compromised membranes.   
Figure 49 shows representative images of live/dead staining of epithelial cell 
monolayers grown in tissue culture plates after exposure to permutations of the MDZ two-
part reactive formulation.  The cells were then exposed to 200 µL of each treatment.  The 
treatment groups for experiments performed at pH 7.4 were: PBS only, 1.00 mM 
MDZopen•2HCl solution that was admixed in PBS immediately before exposure, and 1.00 
mM supersaturated solution of MDZ that was created by admixing MDZopen•2HCl with 
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PBS 1 hr before exposure.  The treatment groups for experiments performed at pH 5.5 
were: CBS only, 1.00 mM MDZopen•2HCl solution that was admixed in CBS at 
immediately before exposure, 1.00 mM Phe-MDZpro in CBS, 1.00 mM Phe-MDZpro with 
200 ug/mL APN in CBS admixed immediately before exposure, and 1.00 mM 
supersaturated solution of MDZ that was created by admixing MDZopen•2HCl and CBS 1 
hr before exposure.  After exposing the cells for 30 min at 32 °C on a 150 rpm orbital 
shaker, the treatment solutions were removed, and cell survival was assessed by live/dead 
staining using acetoxymethyl calcein (Calcein AM) live cell stain and ethidium 
homodimer-1 (EthD-1) dead cell stain.  The results indicated that the cells remained viable 
after 30 min exposure in all treatment groups.  The monolayers did become damaged with 
exposures longer than 1 hr.  However, the residence time for the drug formulation in the 
nasal cavity is expected to be less than 30 min due to MDZ permeation through nasal 
epithelium and mucociliary clearance of any remaining formulation components.  The 
formulation is likely to be well tolerated, though more extensive histology and toxicity 
studies should be performed. 
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Figure 49.  Fluorescence images of MDCKII-wt cells exposed to MDZ formulations.   
Green color indicates live cells; red color indicates dead cells.  Exposure duration was 30 
min, except where indicated.  Experiments at pH 7.4 were performed in PBS and pH 5.5 
in CBS.  Scale bar = 100 µm.  (A) pH 7.4 PBS buffer only.  (B) 1.00 mM MDZopen•2HCl, 
pH 7.4.  (C) 1.00 mM MDZ, pH 7.4, t = 30 min.  (D) 1.00 mM MDZ, pH 7.4, t = 60 min.  
(E) ph 5.5 CBS only.  (F) 1.00 mM MDZopen•2HCl, pH 5.5.  (G) 1.00 mM Phe-MDZpro, 
pH 5.5.  (H) 1.00 mM Phe-MDZpro with 200 ug/mL APN, pH 5.5.  (I) 1.00 mM MDZ, 
pH 5.5.  
 
 
Flow cytometry could be used for more detailed quantification of live, dead, and 
injured cells.  For example, red-flourescent C12-resorufin could be used to mark 
metabolically active (live) cells and green-flourescent SYTOX could be used to mark the 
nucleic acids released from late apoptotic and necrotic cells.  Injured cells then would have 
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combined red and green fluorescence.194  Or, the amount of lactate dehydrogenase released 
into the medium by the cells with damaged membranes can be used as a metric for cell 
injury.  Lactate dehydrogenase is normally quantified using commercially available kits 
and a plate reader.  The morphology and function of the cells after exposure could also be 
examined.  Light microscopy can be used to determine if the cells maintain their shape or 
show abnormalities like crenation.  Finally, any cytotoxicity observed may be temporary.  
Some of these techniques can also be used to determine if and when the cells recover after 
exposure.   
        
7.6 Acid/base formulations 
 
 The acid/base formulation for MDZ that was described in Chapter 5 eliminates the 
need for an enzyme in the formulation.  Enzymes require additional characterization, can 
be more challenging to stabilize, increase the cost of the drug product, may cause an 
immune response, and have potential for off target action.  It is possible to make a DZP 
acid/base formulation, but creation of the DZP open ring salt is more challenging due to 
hydrolysis of the open ring structure at the low pH required to open the diazepine ring.  
However, the side products could be removed by purification of the salt or the salt could 
be obtained under milder conditions by convergent synthesis.  A DZP acid/base 
formulation may be a better choice for a commercial product than a DZP prodrug enzyme 
formulation.      
 
Acid/base reactions are exothermic.  Some amount of heat evolution may be 
desirable.  The ring closing rate of MDZ has been observed to be temperature dependent 
and follows standard Arrhenius reaction rate kinetics.  Therefore, allowing temperature of 
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the formulation to quickly rise from room temperature to physiological temperature, or 
even a couple of degrees above physiological temperature, may result in more rapid 
delivery of MDZ.  Too much heat generation would be undesirable, since it also has the 
potential to damage tissues and cause pain.  The enthalpy change for the MDZopen•2HCl + 
NaOH reaction could be quantified using calorimetry.  Results from calorimetry 
experiments would help determine if the heat generated by this reaction is of any concern 
and allow for a more accurate prediction of the ring closing rate of MDZopen in solutions 
that are concentrated to deliver a full dose intranasally.  
 
7.7 Enzyme engineering 
 
APB was found to be more effective at hydrolyzing Lys from AVF than from Lys-
MDZpro (Figure 27).  This difference in APB activity presents an opportunity to study 
substrate binding mechanisms in the active site of APB.  By identifying the substrate-
enzyme interactions responsible for binding and correctly positioning the substrate in the 
active site, it may be possible to modify the primary structure of APB so that it more readily 
accepts MDZpro as a substrate.  Strategic amino acid substitutions in the active site could 
be guided by simulations of substrate docking into the 3D structure of APB.  Currently, 
there is no experimentally determined 3D structure of APB available in the protein 
databanks because APB is difficult to crystalize.195  Finding the right conditions (pH, 
temperature, cosolvents or other additives) can be accomplished with automated 
instrumentation that enables identification of the optimum crystallization conditions for 
biomolecules by high throughput, low volume, sample processing.   
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In lieu of a crystal structure, molecular modeling approaches can be used.  APB has 
37.2 % sequence identity with human leukotriene A4 hydrolase (LTA4H).196  Both APB 
and LTA4H are members of the M1 peptidase family that encompasses zinc 
metalloenzymes with aminopeptidase activity.  LTA4H has been crystalized, so its 
secondary and tertiary structure can be used as a template to model the 3D structure of 
APB.  This approach has been used by researchers at the University of Paris to model rat 
APB (rAPB).195  The catalytic domains of rAPB and LTA4H are similar with a Zn2+ 
catalytic site between two lobes, one α-helical and the other mixed α/β-helical.  Binding of 
the substrate in the active site of rAPB positions the peptide bond of the substrate in 
proximity to the zinc cofactor (Figure 50).  The carbonyl is polarized upon coordination to 
zinc, catalyzing cleavage of the peptide bond by nucleophilic substitution with water 
present in the active site.      
 
   
Figure 50.  Docking of AVF and MDZpro into active site of rAPB.  (A) Expanded view 
of rAPB stick model with active sight highlighted in green.  (B) Close-up of AVF docked 
in the active site of rAPB.  Surflex docking score: 12.6, distance between Zn2+ and 
carbonyl: 2.74 Å.  (C) Close-up of Lys-MDZpro docked in the active site of rAPB.  
Surflex docking score: 12.7, distance between Zn2+ and carbonyl: 4.27 Å.            
 
 
A B C 
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Preliminary docking studies were performed using Tripos SYBYL Surflex-Dock v. 
2.1 software and the inferred rAPB enzyme structure from reference.195  AVF and Lys-
MDZpro had similar docking scores.  The docking score is related to binding affinity where 
higher scores indicate stronger affinity.  These scores indicated that both prodrugs have 
good affinity for the active site.  However, the carbonyl at the reactive site of Lys-MDZpro 
was further away from the zinc atom, suggesting the positioning of Lys-MDZpro in the 
active site was preventing coordination to zinc.  Residues Gln-169, Phe-297, Asp-406 of 
human APB have been shown to be involved in substrate recognition.76,77  Docked Lys-
MDZpro could be checked for favorable interactions with these residues.  Unlike AVF, Lys-
MDZpro has an additional basic moiety (the imidazole ring).  Interactions of residues in the 
active site with imidazole is the most likely cause of poor substrate positioning and 
inactivity.  One or two strategic amino acid substitutions to reposition the imidazole may 
lead to APB activity towards Lys-MDZpro.   
 
7.8 Scale-up for prodrug/enzyme formulations 
 
 Experiments with the prodrug/enzyme formulations aimed at determining the 
Michaelis-Menten enzyme kinetics parameters, measuring in vitro drug transport across 
cell monolayers, and characterizing the precipitation behavior of drug from supersaturated 
solutions were performed at low concentrations relative to the concentrations that would 
be used to deliver a full dose to humans.  The behavior of the system can change when the 
concentrations are scaled-up to human doses.   
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For example, high concentration solutions of AVF•2HCl (on the order of 
decimolar) are very acidic.  Using a separate buffering agent to control the pH is 
unreasonable for the formulation since the amount of the buffering agent required would 
be excessive.  Fortunately, AVF has a pKa that enables the Lys moiety of the prodrug to be 
utilized as the buffering agent (Appendices A3, Figure A3.74).  High concentration 
solutions of AVF titrated to pH 7.4 have been observed to drift to a more acidic pH upon 
storage.  In turn, the pH drift was observed to affect the conversion rates to DZP when APB 
was added to these AVF solutions.  It is important to allow adequate time for solutions of 
AVF to reach pH equilibrium during the titration unit operation of manufacturing.  
Additionally, it is important to ensure that enzyme co-factors such a Zn and Cl ions are 
sufficiently abundant in the formulation to maintain optimum enzyme activity.  
 
Chapter 4 discusses a formulation stagey that entails combining AVF and APB into 
a single lyophilizate to stabilize APB, stabilize AVF, and ensure a homogeneous ratio of 
AVF:APB upon reconstitution and deposition in the nasal cavity.  In order to achieve rapid 
dissolution of AVF and avoid clogging in the spray device atomizer orifice, the lyophilizate 
must have very high surface area.  Sample C in Figure 51 shows a collapsed cake that was 
produced from lyophilizing an aqueous solution of AVF•2HCl with no other additives.  
Dissolution of this sample was slow due to the low surface area of the material.  Adding a 
bulking agent and/or optimizing the lyo-cycle to produce more elegant cakes can vastly 
improve the rate of dissolution.  Incidentally, AVF titrated to pH 7.4 produces more elegant 
cakes than un-titrated solutions of AVF•2HCl.   
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Figure 51.  Mannitol prevents AVF lyophilizate cake collapse.   Adding the bulking 
agent, mannitol (man), to pre-lyophilization solutions helps to prevent the collapse of 
AVF cakes and improves the rate of dissolution.  
 
 
7.9 Delivery device optimization 
 
Nasal sprays have been shown to provide a more uniform distribution of drug on 
the nasal epithelium and lead to a slower, more consistent rate of mucociliary clearance 
compared to nose drops.197,198  Preliminary testing of the dual chamber nasal spray device 
described in Chapter 6 has demonstrated that rapid mixing and atomization for intranasal 
co-administration of two-part reactive formulations is feasible.  There are many other 
conceivable ways to automate low volume mixing and atomization in a nasal spray device.  
An example of an alternative design that incorporates check valves to separate solid and 
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liquid components prior to actuation is shown in Figure 52.  Ultimately, it will be necessary 
to settle on a design that performs well and is user friendly.   
 
 
Figure 52.  Alternative nasal spray device design.  In this design, there is a one-way 
check valve between the chambers containing the components of the two-part reactive 
formulation.  Pulling the plunger draws solution into the main barrel of the device and 
allows the components of the formulation to mix.  Pushing the plunger back into the body 
of the device forces the mixed formulation through the atomizer tip to produce a spray.  
Note that the action of this device could be wholly or partially automated with a spring 
and trigger mechanism.    
 
 
The total area of formulation deposition in the nasal cavity and distribution of the 
formulation over over ciliated versus non-ciliated nasal mucosa cells can influence the drug 
absorption rate and rate.  Designing a device that deposits the formulation in an area of the 
nasal cavity conducive to optimum absorption depends, in part, on controlling the spray 
plume characteristics such as droplet size, diameter of the cone at a break-up length, and 
193 
cone angle.178  The device design and physicochemical properties of the formulation, such 
as viscosity, dictate these characteristics.45  The effect of device design and formulation 
parameters on spray characteristics could be investigated using standard imaging 
techniques such as particle/droplet image analysis (PDIA) and particle image velocimetry 
(PIV).   
 
The homogeneity of the sprayed mixtures will also need to be well characterized to 
ensure full and rapid conversion to the active drug in the nasal cavity.  A crude method for 
assessing the homogeneity of sprayed acid/base formulations was demonstrated in Figure 
43.  That method is qualitative, relying on changes in pH to visualize mixing of the 
formulation components.  Testing prodrug/enzyme formulations would require a different 
technique.   A quantitative way to assess the homogeneity of prodrug/enzyme formulations 
could involve spraying the formulation on a microtiter plate and monitoring wavelengths 
corresponding to product formation.  The matrix arrangement of microtiter plates allows 
for spatial mapping of the deposition profile and identification of areas that have variable 
benzodiazepine concentration and/or result in precipitation of the benzodiazepine.  An 
alternative to the microtiter plate method for analyzing mixing and deposition involves the 
use of dyes.  Lys-para-nitroaniline (Lys-pNA) is a chromogenic substrate for both AOP 
and APB.  Enzymatic hydrolysis of Lys-pNA releases the fluorescent chromophore para-
nitroaniline (pNA) with a visible absorbance and emission peaks.  The deposition profile 
for the enzyme can be visualized by spraying an enzyme-only formulation onto the surface 
of a native agarose or polyacrylamide gel that is impregnated with Lys-pNA.60  Regions of 
high concentrations of active enzyme will fluoresce from the pNA reaction product.  A 
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second chromophore or fluorophore could be included in the liquid phase of the 
formulation.  This would allow spatial visualization (on a gel) or spatial quantification 
(with a microtiter plate reader) of the distribution of the liquid phase overlaid with the 
distribution of active enzyme.     
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Chapter 8: Conclusion 
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Systemic drug delivery by intranasal administration has been gaining popularity in 
recent years because the route offers a host of advantages that cannot be achieved by other 
routes.  Dense capillary beds and thin epithelium in the nasal cavity allow drugs to quickly 
enter the blood stream, leading to a rapid onset of therapeutic effect.  There is even potential 
for drugs targeting the central nervous system to bypass the blood brain barrier through 
direct nose-to-brain pathways.  The intranasal route can be leveraged to avoid first-pass 
metabolism or degradation of drugs in the gut.  Furthermore, operation of a nasal spray 
device is generally intuitive.  Nasal sprays are non-invasive, convenient, and discrete, 
making the intranasal route of drug administration preferable to many patients.   
 
However, not all drugs are amenable to formulation as a rapid acting nasal spray.  
Drugs with poor aqueous solubility or poor solution stability are often not even considered 
for formulation as a nasal spray.  This may soon change with the introduction of reactive 
nasal spray formulations.  Here we have demonstrated that highly effective metastable 
formulations can be created at the time of administration using a two-part formulation 
strategy.  For these formulations, the reactive components are stored in separate 
compartments within a specially engineered nasal spray device.  The components are 
metered, mixed, and atomized during actuation of the device.   
 
One of the primary examples of this two-part reactive nasal spray formulation 
strategy we presented utilizes a highly soluble prodrug of an insoluble active drug and an 
exogenous enzyme to efficiently convert the prodrug into the active drug.  The prodrug and 
labile enzyme can be stabilized for storage in the device as a homogeneously mixed solid 
lyophilizate.  When a patient or caregiver actuates the device, the solid lyophilizate is 
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automatically reconstituted with buffer and simultaneously atomized into a spray.  In the 
nasal cavity, the deposited droplets containing prodrug and enzyme react to produce a 
metastable supersaturated solution of the active drug.  The active drug is then rapidly 
absorbed into the body.  Other reactive nasal spray formulations utilize acid/base 
chemistry, click chemistry, and even simple non-reactive physical phase changes.  This 
two-part formulation strategy to create metastable solutions of drug at the time of 
administration will enable many life-saving therapies that might not otherwise be possible.   
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Appendices 
 
 
A1: Supporting information for Chapter 2 
 
A1.1 Flow chart for DZP precipitation experiments 
 
 
 
 
A1.2 Derivation of spectroscopic second derivative relationship (eq. 1) 
 
Absorbances for calibration curves in Figure A1.53 A, B, C, and D were measured 
in pH 7.4 PBS at 32 oC.  Limit of quantitation (LOQ) and limit of detection (LOD) were 
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calculated from the standard error in the y intercept and slope of the regression according 
to ICH Q2 guidelines.199  The correlation relating supersaturated DZP concentrations to 
absorbance was confirmed by measuring the absorbance of AVF/enzyme reactions allowed 
to go to completion.   
 
HPLC determinations of [DZP]aq were done on an Agilent 1260 Infinity system: 
quaternary pump G1311B, autosampler G1329B, thermostatted column compartment 
G1316A, diode-array detector G4212B, Agilent OpenLAB CDS software.  The isocratic 
mobile phase was 50 mM phosphate buffer pH 3.0 and acetonitrile (40:60 v/v) with a flow 
rate of 0.4 mL/min through an Agilent ZORBAX Eclipse XDB-C18 column (3.0 x 150 
mm, 3.5 μm particle size).  Samples were prepared in mobile phase using 16 μM (4.33 
μg/mL) tolbuatmide (Tol) as an internal standard.  Analytes from 25 μL injections of each 
sample were detected at 220 nm with retention times of 2.75 and 3.83 min observed for 
Tol and DZP respectively.  A DZP standard calibration curve was constructed and the peak 
area ratios of DZP:Tol were used to calculate DZP concentrations in the samples.  
 
 
 
A B 
C D 
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Figure A1.53.  Calibration curves.  (A) Second derivative calibration curve for AVF, 
LOQ = 269 µM, LOD = 88.7 µM.  (B) Second derivative calibration curve for DZP in 
supersaturated region, LOQ: 83.3 µM, LOD: 27.5 µM.  (C) Second derivative calibration 
curve for DZP below saturation, LOQ = 23.4 µM, LOD = 7.73 µM.  (D) Validation of UV 
method by HPLC.  (E) Zero order spectra of 2.00 mM AVF in different 20 mM buffers 
and at the bounds of tonicity and pH for the experimental conditions.  (F) Zero order spectra 
of 0.100 mM DZP in different 20 mM buffers and at the bounds of tonicity and pH for the 
experimental conditions.   
 
 
 
  
Figure A1.54.  Effect of temperature on molar absorptivity. (A) Second derivative 
spectra of 2.00 mM of AVF in PBS pH 7.4 at 20 – 40 oC.  (B) Second derivative spectra of 
0.125 mM of DZP in PBS pH 7.4 at 20 – 40 oC.  (C) Zero order spectra of 8.00 mM Lys in 
different 20 mM buffers and at the experimental bounds of temperature and pH.  Lys was 
transparent in the region of interest (300 – 400 nm).  (D) Calibration curve slope 
temperature dependence for AVF and DZP. 
E F 
A B 
C D 
AVF DZP
20 0.270 5.91
25 0.271 5.84
30 0.271 5.77
32 0.271 5.74
35 0.272 5.70
40 0.273 5.63
d2ε/dλ2    (M-1cm-1nm-2)Temperature 
(⁰C)
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Figure A1.55.  Sensitivity analysis for calibration curves at different wavelengths.  At 
338 nm: d2ε/dλ2 = 0.271 M-1cm-1nm-2 for AVF, 0.275 M-1cm-1nm-2 for ORI, and 5.74 M-
1cm-1nm-2 for DZP. 
 
A derivation of Equation 1 for the determination of [DZP]aq,t is below.  We start 
from the Beer–Lambert law for the attenuation of light, where Abs is the absorbance of 
light, Ext is the extinction of light, Io is the intensity of incident light, I is the transmitted 
intensity, ℓ is the path length (1 cm), ε is molar absorptivity, and C is concentration with 
C = [AVF] + [ORI] + [DZP]aq. 
Abs = C ×  ε ×  ℓ   and   Ext = Abs + scattering =  log10
Io
I
 
In the absence of precipitate Ext = Abs.  Light scatting from precipitate particles produces 
a very broad peak relative to sharper analyte peaks.  Thus, the contribution of light 
scattering to the second derivative of Ext is small. 
d
dt
d2Ext
dλ2
≈
d
dt
d2Abs
dλ2
=
d
dt
d2
dλ2
(C ×  ε ×  ℓ) 
d
dt
d2Ext
dλ2
= (
d[AVF]
dt
(
d2ε
dλ2
)
AVF
+
d[ORI]
dt
(
d2ε
dλ2
)
ORI
+
d[DZP]aq
dt
(
d2ε
dλ2
)
DZP
) ℓ 
(
d2ε
dλ2
)
AVF
≈ (
d2ε
dλ2
)
ORI
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d2
dλ2
dExt = ((d[AVF] + d[ORI]) (
d2ε
dλ2
)
AVF
+ d[DZP]aq (
d2ε
dλ2
)
DZP
) ℓ 
d[DZP]aq = −d[AVF] − d[ORI] 
d[DZP]aq =
d2
dλ2
dExt
((
d2ε
dλ2
)
DZP
− (
d2ε
dλ2
)
AVF
) ℓ
 
∫ d[DZP]aq
[DZP]t
[DZP]0
= ∫
d2
dλ2
dExt
((
d2ε
dλ2
)
DZP
− (
d2ε
dλ2
)
AVF
) ℓ
Extt
Ext0
 
[DZP]aq,t − [DZP]aq,0 =
d2Extt
dλ2
−
d2Ext0
dλ2
((
d2ε
dλ2
)
DZP
− (
d2ε
dλ2
)
AVF
) ℓ
 
where   [DZP]aq,0 = 0   and   
d2Ext0
dλ2
= [AVF]0 (
d2ε
dλ2
)
AVF
ℓ 
[DZP]aq,t =
d2Extt
dλ2
− [AVF]0 (
d2ε
dλ2
)
AVF
ℓ
((
d2ε
dλ2
)
DZP
− (
d2ε
dλ2
)
AVF
) ℓ
 
[DZP]aq,t =
d2Extt
dλ2
− [AVF]o(0.271 M
−1cm−1nm−2)(1 cm)
(5.74 M−1cm−1nm−2 − 0.271 M−1cm−1nm−2)(1 cm)
 
                                            [DZP]aq,t
=
d2Extt
dλ2
− [AVF]o(0.271 M
−1nm−2)
5.47 M−1nm−2
                       𝑞. 𝑒. 𝑑. 
 
Since (d2ε/dλ2)DZP >> (d2ε/dλ2)AVF, error in the determination of [DZP]aq,t in the 
precipitation regime due to imbalance of the stoichiometric relationship between the 
species in solution is negligible when [AVF]o
 is slightly greater than [DZP]aq,lim.  This error 
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becomes more important when [AVF]o >> [DZP]aq,lim, and is corrected by tracking the 
remaining concentrations of AVF and ORI. 
[DZP]aq,t =
d2Extt
dλ2
− ([AVF]t+[ORI]t) (
d2ε
dλ2
)
AVF
ℓ
(
d2ε
dλ2
)
DZP
ℓ
 
[DZP]aq,t =
d2Extt
dλ2
− ([AVF]t+[ORI]t)(0.271 M
−1nm−2)
5.74 M−1nm−2
 
Where [AVF]t and [ORI]t are found by solving the differential equations  
for the reaction: 
 
d[AVF]
dt
= −
Vmax[AVF]free
KM + [AVF]free
 
d[ORI]
dt
=
Vmax[AVF]free
KM + [AVF]free
− k2[ORI]free 
where     KM =
k−1 + kcat
k1
    and   Vmax = kcat[AOP] 
with     [AVF]free = (
[AVF]
1 + α[AOP]
)     and     [ORI]free = (
[ORI]
1 + α[AOP]
)    
 
 
 
A1.3 Determination of Michaelis-Menten parameters 
 
The enzyme kinetic parameters KM and Vmax for AVF substrate hydrolyzed by 0.25 
U/mL AOP at pH 7.4 and 32 oC were first determined by measuring [DZP]aq,5min by HPLC 
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and fitting the integrated Michaelis-Menten equation shown below to the data using the 
nlinfit function in MATLAB software (The MathWorks, Inc.). 
 
[DZP]aq,t − KM ln (1 −
[DZP]aq,t
[AVF]0
) = Vmaxt 
 
 
Figure A1.56.  Enzyme kinetics for AVF/AOP system.  Concentrations determined by 
HPLC (points) with least squares fit to the integrated Michaelis-Menten equation (line).  
KM = 3.38 ± 0.34 mM, Vmax = 0.518 ± 0.030 mM/min with 0.25 U/mL AOP in pH 7.4 cell 
assay buffer at t = 5 min.42 
 
A1.4 Spectroscopic method development 
 
In this section we demonstrate how zero order UV spectra, second derivative UV 
spectra, and Equations 3-5 were combined to track the conversion of AVF to DZP and 
formation of DZP precipitate. 
 
Zero order spectra   
 
UV spectroscopic determination of [AVF], [ORI], and [DZP]aq during the course 
of the reaction requires knowledge of the molar absorptivity (ε) for each species in the 
reaction mixture.  The absorbance spectra of AVF and DZP were readily obtained from 
standard solutions.  Although Lys and AOP were also present in the reaction mixture, Lys 
did not have a detectable absorbance at 8.00 mM over the wavelength region of interest 
(300-400 nm) and AOP was included in the reference cell.  The ε of ORI was more 
challenging to discern because this species is transient and cannot be physically isolated at 
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physiologically relevant pH values.  However, its presence was evident from the sigmoidal 
shape of the absorbance-time profile.  AOP hydrolysis of Lys from a chromogenic 
substrate, S-Lys-para-nitroanilide, which does not produce an intermediate species, did not 
display this behavior (Supporting Information, Figure A1.62 and Figure A1.63).  
In the absence of precipitation ([AVF]0 < Cind), zero order spectra collected during 
enzymatic conversion of AVF to DZP exhibited isosbestic points at λ = 301 and 338 nm 
with ε = 1810 ± 60 and 255 ± 7 M-1cm-1 (± SD) respectively, as shown in Figure A1.57 for 
[AVF]0 = 1.00 mM.  The values of λ and ε for these isosbestic points did not deviate 
significantly within the range of formulation parameters tested.  As the reaction progressed 
a characteristic absorbance peak for DZP at 315 nm developed between the isosbestic 
points (ε = 204 M-1cm-1 at 315 nm for DZP). 
Isosbestic points typically occur when there is stochiometric conversion between 
two species.  Therefore, the presence of two isosbestic points was a strong indication that 
two of the reaction species in the conversion of AVF to DZP had similar molar absorptivity 
throughout the 300-400 nm region.  The only two reaction species that could exhibit similar 
spectra were AVF and ORI.  AVF and ORI share the same conjugated ring structure and 
minimal ring strain, so the energy required to excite electrons to anti-bonding molecular 
orbitals is expected to be similar.200  Furthermore, the Lys moiety of AVF was transparent 
in this region.  The change in conjugation and ring strain from formation of the 
benzodiazepine moiety in DZP allows for a lower energy transition between the highest 
occupied and anti-boning molecular orbitals.  This structural feature was responsible for 
the absorbance peak observed at 315 nm.   
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Figure A1.57.  UV spectra measured during the enzymatic conversion of AVF.  
Sequence of spectra obtained during enzymatic conversion of 1.00 mM AVF to DZP by 
0.25 U/mL AOP in pH 7.4 PBS at 32 οC, 1 scan/min.  Isosbestic points observed at 301 
and 338 nm with an absorbance peak that is characteristic of DZP emerging at 315 nm.   
 
Indeed, decomposition of the reaction mixture spectrum by subtraction of the 
component spectra revealed a spectrum for ORI resembling that of AVF, with ε = 753 M-
1cm-1 for AVF and 707 M-1cm-1 for ORI at 315 nm.  To perform the decomposition, the 
spectrum of a 2.00 mM reaction was captured at t = 3.75 min (Figure A1.58, purple curve).  
All three small molecule reaction species were expected to be present in significant 
quantities at this time point.  The second derivative of the reaction mixture spectrum was 
calculated, and Equation 2 was used to determine [DZP]aq,3.75min from d
2Abs/dλ2 at 338 nm, 
where Abs is the absorbance (note that d2Abs/dλ2 = d2Ext/dλ2 in this case).  The use of 
Equation 2 is described in more detail in the following section.  Then, the zero order 
spectrum of [DZP]aq,3.75min (i.e. purely [DZP]aq = 0.424 mM) was simulated based on ε 
measurements from DZP standard solutions at lower concentrations.  The simulated 
spectrum of [DZP]aq,3.75min, shown as a blue curve in Figure A1.58, was taken to be the 
absorbance contribution from DZP present in the reaction mixture.  The absorbance 
contribution due to AVF present in the reaction mixture was obtained by using Equation 3 
to predict [AVF]3.75min, and then measuring the spectrum of an AVF standard solution 
prepared to the predicted concentration (i.e. purely [AVF] = 1.09 mM, Figure A1.58, red 
curve).  Finally, the absorbance contributions form DZP and AVF were subtracted from 
the absorbance measured for the reaction mixture at each wavelength to obtain the 
spectrum of ORI shown as a green curve in Figure A1.58. 
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Figure A1.58.  Resolving the ORI spectrum. Extraction of the zero order absorbance 
spectrum for ORI from the reaction mixture.  Purple curve: measured absorbance spectrum 
captured at t = 3.75 min during the conversion of 2.00 mM AVF by 0.50 U/mL AOP in pH 
7.4 PBS at 32 οC.  Red curve: measured absorbance spectrum of 1.09 mM AVF standard 
solution.  Blue curve: simulated spectrum of 0.424 mM DZP.  Green curve: spectrum of 
0.485 mM ORI obtained by subtraction of AVF and DZP spectra from the spectrum of the 
reaction. 
 
 
 
A1.5 Spectral subtraction for determination of ORI spectrum 
 
To mathematically describe the decomposition the absorbance spectrum of a 
mixture of AVF, ORI, and DZP, we start from the Beer–Lambert law where Absλ is the 
absorbance of light at a specific wavelength (λ), ℓ is the path length (1 cm), ελ is molar 
absorptivity at λ, and C is concentration.  The absorbance of any one species is given by: 
Abs𝜆 = C × ε𝜆  ×  ℓ 
Absorbance is additive, meaning each of the species contributes to the total absorbance.  
Thus, the total absorbance is given by: 
Abstotal,λ = AbsAVF,λ + AbsORI,λ + AbsDZP,λ 
Inserting the Beer-Lambert law gives 
Abstotal,λ = εAVF,λ[AVF]ℓ + εORI,λ[ORI]ℓ + εDZP,λ[DZP]aqℓ 
or 
Abstotal,λ = εAVF,λ[AVF]ℓ + AbsORI,λ + εDZP,λ[DZP]aqℓ 
and rearranging gives 
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AbsORI,λ = Abstotal,λ − (εAVF,λ[AVF]ℓ + εDZP,λ[DZP]aqℓ) 
The variables [AVF], [DZP]aq, and ℓ are constant for any given λ at a defined time.  For 
AVF hydrolysis by AOP, the concentration of AVF at a defined time point can be predicted 
from Michaelis–Menten enzyme kinetics, and the concentration of DZP at that same time 
point can be measured using the second derivative of the spectrum produced by the mixture 
(Equation 2).   The other variables εAVF,λ, εDZP,λ, and Abstotal,λ are dependent on λ and 
obtained directly from UV measurements of AVF, DZP, and the reaction mixture.  With 
εAVF,λ, εDZP,λ, and Abstotal,λ known over the λ range of interest, the expression for AbsORI,λ 
shown above will give the spectrum of ORI. 
The spectrum of ORI is not entirely useful in and of itself.  The useful parameter is 
εORI,λ.  With AbsORI,λ calculated by the decomposition technique described above and 
knowledge of the stochiometric relationship between AVF, ORI, and DZP in the mixture, 
we can solve for εORI,λ.   The total concentration of the mixture is given by 
Ctotal = [AVF] + [ORI] + [DZP]aq 
and rearranging gives the concentration of ORI 
[ORI] =  Ctotal − ([AVF] + [DZP]) 
For AVF hydrolysis by AOP, the total concentration, Ctotal, is equal to the initial 
concentration of AVF, i.e. [AVF]0.  Therefore, [ORI] can be known when [AVF] and 
[DZP] are known.  Using the Beer-Lambert law again, AbsORI,λ determined from 
decomposition, known [ORI], and known ℓ gives the desired parameter, εORI,λ 
εORI,λ =
AbsORI,λ
[ORI]ℓ
 
 Second derivative spectra   
 
At high DZP concentrations, resulting from [AVF]0 > Cind, light scattering due to 
formation of precipitates produced a broad band signal as shown in Figure A1.59A.  The 
increased total extinction (Ext = absorbance + scattering) exceeded the linear range of our 
instrument (Ext < 3.7) at 315 nm in most cases.  To permit tracking of aqueous analyte 
concentrations in the presence of precipitates, a second derivative spectroscopic method 
was developed.  As shown in Figure A1.59B, the broad brand effects due to scattering are 
essentially eliminated in the second derivative spectra.  Calibration curves were 
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constructed based on the second derivative absorbance spectra of AVF and DZP standard 
solutions (Supporting Information, Figure A1.53), with λ = 338 nm chosen as the analytical 
wavelength.  At 338 nm, d2ε/dλ2 = 0.271 ± 0.004 M-1cm-1nm-2 for AVF and d2ε/dλ2 = 5.74 
± 0.09 M-1cm-1nm-2 (± SD) for DZP in 32 oC pH 7.4 PBS.  These values were robust to 
changes in the buffer composition (pH, ionic strength, and buffering agent) at 32 °C; some 
weak temperature effects are discussed in the Supporting Information.  The second 
derivative ORI spectrum, inferred by subtraction as for the zero order spectrum, was not 
significantly different than that of AVF at this isosbestic point, i.e. (d2ε/dλ2)AVF ≈ 
(d2ε/dλ2)ORI at 338 nm with (d2ε/dλ2)ORI = 0.275 M-1cm-1nm-2.  Based on the second 
derivative calibration curves and the stoichiometric relationship of the absorbing species, 
the following equation was used to calculate [DZP]aq,t, where Extt is the measured 
extinction of light at time t, ℓ is the path length of the sample (1 cm), and λ = 380 nm     
  
( )
( ) ( )
2 2 2 2
2
t 0 2AVF t
aq,t 022 2 2 2
DZP AVF
d Ext / d d / d [AVF] d Ext
[DZP] (0.183 M nm ) 0.0495[AVF]
dd / d d / d
 −  
= = −
   −  
 
 
 
See Figure A1.53 for a derivation of this equation and method validation by HPLC. 
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Figure A1.59.  Using second derivative spectra to measure [DZP]aq in the presence of 
precipitate.  Rxn: 2.00 mM AVF, 0.25 U/mL AOP, pH 7.4 PBS, 32 οC.  (A) Sequence of 
UV spectra collected during conversion of AVF to DZP, 1 scan/min.  Early spectra parallel 
those of Figure A1.57, with an isosbestic point at 338 nm.  Precipitation of DZP caused 
turbidity and broad band interference, starting at tind = 12 min.  Blue dashed line: spectrum 
of [DZP]aq,sat (0.130 mM, S = 1.00)  (B) Second derivative spectra of data shown in A.  
There was a high signal to noise ratio observed at the isosbestic point, 338 nm.  (C) DZP 
concentration-time profile with time course of precipitation overlaid, n = 3.  Blue points: 
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[DZP]aq determined by the second derivative of Ext at 338 nm.  Grey line: theoretical 
[DZP]aq in the absence of precipitation.  Orange points: zero order Ext at 338 nm.  Double 
headed arrow: onset of DZP precipitation at tind = 11.5 min, Cind = 1.24 mM (S = 9.54). 
   
The blue points in Figure A1.59C are representative of concentration-time profiles 
observed for the enzymatic conversion of AVF to DZP using the second derivative UV 
spectroscopic method with [AVF]0 > Cind.  The concentration of DZP in solution plateaued 
near Cind even though enzymatic hydrolysis of AVF continued to produce DZP.  This 
plateau demarcated [DZP]aq,lim.  By neglecting the [DZP]aq,lim condition in Equation 5, 
Equations 3-5 can be used to predict the theoretical [DZP]aq that would result if no 
precipitation occurred.  Departure of measured [DZP]aq (blue points) from theoretical 
[DZP]aq (grey curve) coincided with light scattering at tind (orange arrow).  DZP produced 
in excess of [DZP]aq,lim phase separated from solution, causing light scattering from the 
resultant precipitate at t > tind and an abrupt rise in the zero order Ext measured at the 
isosbestic point (orange points).  Due to variations in precipitate particle positions between 
samples, error bars became wider once phase separation began. 
 
A1.6 Inhibition of closing reaction by AOP 
 
To explore potential enzyme inhibition, the following differential equations were 
solved numerically using MATLAB.  Comparing theoretical concentration-time profiles 
with experimental data precluded enzyme inhibition by the small molecule reaction 
species. 
d[AVF]
dt
= −
(
1
α′) Vmax
[AVF]
(
α
α′) KM +
[AVF]
 
d[ORI]
dt
=
(
1
α′) Vmax
[AVF]
(
α
α′) KM +
[AVF]
+ k2[ORI] 
d[DZP]aq
dt
= k2[ORI] 
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for α = 1 +
[I]
Ki
and α′ = 1 +
[I]
Ki
′  
where [I] could be [AVF]t, [ORI]t, [DZP]aq,t, or [Lys]t 
 
None of these enzyme inhibition models explained the observed concentrations.  Instead, 
it was found that inhibition of the ring closing reaction was occurring with increasing 
[AOP].  This was thought to be due to non-specific binding of ORI to proteins in the AOP 
mixture.  Bovine serum albumin (BSA) was added to the AVF + AOP reaction to 
investigate potential non-specific binding and its effect on the reaction rate.  The addition 
of BSA did slow the reaction.  However, AOP is a protease mixture with exo- and endo-
peptidase activity.  BSA might act as a competitive substrate thereby reducing the rate of 
DZP production, rending these results inconclusive. 
 
 
Figure A1.60.  No enzyme inhibition from DZP or Lys.  Experimental confirmation that 
neither DZP nor Lys have an inhibitory effect on the Lys endopeptidase activity of AOP.  
Concentration-time profiles of 2.00 mM AVF converted by 0.25 U/mL AOP in pH 7.4 PBS 
at 32 oC containing initial concentrations of DZP or Lys as indicated in the legend.  DZP 
was added as a methanolic solution (10 µL) 390 µL of PBS.             
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Figure A1.61.  Bovine serum albumin controls to determine the effect of protein 
binding.  Concentration-time profiles of 2.00 mM AVF converted by 0.25 U/mL AOP in 
pH 7.4 PBS at 32 oC containing initial concentrations of albumin (BSA) indicated in the 
legend.  The addition of BSA reduced the rate of DZP production, increased Cind, and 
increased [DZP]aq,lim.  Cind = 1.20 mM for 0 mg/mL BSA and 1.36 mM for 1 mg/mL BSA.  
 
 
 
 
 
A1.7 Additional figures and discussion 
 
 
Figure A1.62.  Reaction scheme for the hydrolysis of Lys-pNA. The chromogenic 
substrate, S-Lys-para-nitroanilide (Lys-pNA), can be hydrolyzed by Lys aminopeptidases 
to release the chromophore para-nitroaniline (pNA) that typically monitored at absorbance 
λ = 405 nm. 
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Figure A1.63.  Hydrolysis of Lys-pNA by AOP.  Concentration-time profile of S-Lys-
para-nitroanilide (Lys-pNA) converted to para-nitroaniline (pNA) chromophore by 1.0 
U/mL AOP in pH 7.4 PBS at 32 oC, monitored at λ = 405 nm (ε405nm = 10,600 M−1 cm−1 at 
pH 7.4). 
 
 
 
Figure A1.64.  Reaction with low enzyme concentration.  Concentration-time profile of 
2.00 mM AVF converted by 0.005 U/mL AOP in pH 7.4 PBS at 32 oC.   
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Figure A1.65.  Concentration-time profile of AVF conversion with high [AVF]0.  
Replicates of the 3.90 mM AVF reaction showed similar decreases in [DZP]aq after Cind 
was reached.  Reaction conditions: 0.25 U/mL AOP in pH 7.4 PBS at 32 oC.     
 
Other Formulation Considerations 
There is considerable intersubject and intrasubject variation in nasal cavity pH.  A 
study of 12 healthy volunteers found that the average anterior pH was 6.40 (range: 5.17 – 
8.13) and average posterior pH 6.27 (range: 5.20 – 8.00)55  In order to control the rate of 
enzymatic hydrolysis of AVF in the nasal cavity, an appropriate formulation buffer was 
needed.  According to the FDA Orange Book,127 the most common buffers used in 
commercial nasal spray formulations are citrate (buffering range: pH 3.0 – 6.2), phosphate 
(buffering range: pH 5.8 – 8.0), or a combination of citrate and phosphate (buffering range: 
pH 2.6 – 7.6).  In addition to citrate and phosphate, HEPES (buffering range: pH 6.8 – 8.2) 
and MES (buffering range: pH 5.5 – 6.7) were considered as potential buffering agents.  
HEPES and MES are biologically compatible buffers that do not readily cross cell 
membranes.201   
Nasal mucus is isotonic with 0.9% w/v NaCl.  Buffers made isotonic by the addition 
of NaCl were used in these studies, although hypotonic solutions afforded better 
aminopeptidase activity with the AOP enzyme (Figure A1.66).  Tonicities in the range of 
0.6 – 1.8% w/v NaCl equivalency are generally acceptable for IN drug delivery 
applications.202  The minimum buffer strength needed to overcome the natural buffering 
capacity of nasal mucus has been estimated to be 130 mM.55  IN formulations resulting in 
a therapeutic dose of DZP would be in the hypertonic region when the tonicity 
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contributions from the buffering agent and the salt form of AVF are summed, negating the 
need for a tonicity adjusting agent.  
 
 
 
Figure A1.66.  Comparison of buffers.  Concentration-time profiles of 2.00 mM AVF 
converted by 0.50 U/mL AOP at 32 oC.  (A) Buffered with 20 mM HEPES made isotonic 
with NaCl.  (B) Buffered with 20 mM MES made isotonic with NaCl.  (C) Buffered with 
20 mM phosphate at pH 6.0 with 100 mM NaCl.  (D) Conversion rate of AVF to DZP 
increased in hypotonic solution.  Reaction conditions: 62.5 μM AVF, 0.25 U/mL AOP, pH 
7.4, 32 οC, monitored at abs 315 nm.  Cell assay buffer: 122 mM NaCl, 25 mM NaHCO3, 
10 mM glucose, 10 mM HEPES, 3 mM KCl, 1.2 mM MgSO4, 1.4 mM CaCl2, and 0.4 mM 
K2HPO4.  Hypotonic: 20 mM HEPES.  Isotonic: 20 mM HEPES, 145 mM NaCl.   
  
A B 
C D 
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A2: Supporting information for Chapter 3  
 
Diazepam is commonly studied in rats at doses near 1 mg/kg.103,203-210  To 
investigate dose proportionality, doses equivalent to diazepam at 0.50, 1.00, and 1.50 
kg/mg were chosen.  Since the prodrug has a different molar mass than the active drug, the 
equivalent prodrug doses were 0.885, 1.77, and 2.66 mg/kg.  See Table 1S for dosing and 
sampling details. 
 
 
Table A2.5.  AVF/APB rat PK study design.   Low dose level is equivalent to diazepam 
at 0.5 mg/kg, medium dose level is equivalent to diazepam at 1.0 mg/kg, and high dose 
level is equivalent to diazepam at 1.5 mg/kg.  b = brain tissue, h = nasal tissues for 
histology.  
Group Formulation Route 
Dose  
level 
n 
rats 
Blood draw 
(min) 
Tissue collection 
(min) 
1 Vehicle IN n/a 3 none 90 h 
2 AVF IN med 
3 2, 10, 20, 30, 60 60 b 
3 5, 15, 45, 75, 90 90 b 
3 AVF/APB IN low 
3 2, 10, 20, 30, 60 60 b 
3 5, 15, 45, 75, 90 90 b 
3 none 90 h 
4 AVF/APB IN med 
3 2, 10, 20, 30, 60 60 b 
3 5, 15, 45, 75, 90 90 b 
3 none 90 h 
5 AVF/APB IN high 
3 2, 10, 20, 30, 60 60 b 
3 5, 15, 45, 75, 90 90 b 
3 none 90 h 
6 AVF/APB IN med 
3 2 2 b 
3 5 5 b 
3 8 8 b 
3 10 10 b 
7 DZP IV med 
3 2, 10, 20, 30, 60 60 b 
3 5, 15, 45, 75, 90 90 b 
8 DZP IV med 
3 2 2 b 
3 5 5 b 
3 8 8 b 
3 10 10 b 
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Table A2.6.  PBPK model parameters for DZP disposition in rats. Obtained from 
references 82 and 83.   
Tissue 
Flow Q  
(mL/min) 
Volume V  
(mL) 
Partition 
coefficient KP 
Adipose 2.55 10 21.28 
Brain 0.78 1.2 1.67 
Heart 4.2 1 5.46 
Kidney 16.61 2 5.08 
Liver 3.55 11 7.62 
Lung 80 1.2 4.91 
Muscle 16.25 125 1.88 
Skin 7.1 43.8 3.30 
Splanchnic 20.25 15 3.67 
Stomach 1.9 1.1 5.16 
Testes 1.9 2.5 5.13 
Remainder 4.91 15.8 17.44 
Venous blood 80 13.6  
Arterial blood 80 6.8  
 
 
 
 
Enzyme kinetic parameters for hydrolysis of AVF by APB and the ring closing rate 
of ORI measured in vitro were used to predict the rate of DZP production in vivo.  The 
Michaelis–Menten fit is shown in Figure A2.67.  As illustrated in Figure A2.67B, the APB 
concentrations were scaled with the AVF concentration so that hydrolysis of AVF would 
be complete at t ≈ 4 min, regardless of the dose level.  With calculated log partition 
coefficients (cLogD) of -1.71 at pH 7.4 and -2.85 at pH 6.5,68 AVF does not readily 
partition into membranes.  However, ORI and DZP can under passive transcellular 
transport.  Absorption of these species is illustrated in Figure A2.68. 
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Figure A2.67.  Predicted time course for the conversion of AVF to DZP by APB.  (A) 
Michaelis–Menten equation fit to conversion rates measured using 15 µg/mL APB in pH 
7.4 PBS at 32 °C, n = 3, R2 = 0.988, KM = 370±63 μM and Vmax = 254±13 μM/min (±SE).  
(B) Time course prediction for the amounts each reaction species at each dose level based 
on measured Michaelis–Menten enzyme kinetic parameters, KM and kcat.  Solid lines 
represent the low dose level (0.439 µmol AVF + 0.103 nmol APB), dashed lines medium 
dose level (0.878 µmol AVF + 0.205 nmol APB), and dotted lines high dose level (1.32 
µmol AVF + 0.309 nmol APB) for a 0.250 kg rat.  In vitro conditions simulated, i.e. no 
absorption.     
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Figure A2.68.  Schematic of AVF conversion to DZP.  The rates constants for reversible 
binding of AVF to the active site of APB are k1 and k-1.  The catalytic rate constant for 
conversion of AVF to ORI is kcat.  ORI spontaneously cyclizes to form DZP with 
cyclization rate constant, k2.  The values of these reaction rate constants were determined 
from in vitro measurements and their relationship to Michaelis–Menten enzyme kinetic 
parameters are shown in Equations A2.1-3.   
 
 
KM =
k−1 + kcat
k1
= 370 ± 63 μM (A2.1) 
Vmax = kcatCAPB ⇒ kcat = 1250 ± 60 min
−1 (A2.2) 
k2 = 0.470 ± 0.024 min
−1 (A2.3) 
 
 
 
Figure A2.69.  Representative LC-MS/MS chromatograms: AVF and DZP standards 
in plasma. 
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Figure A2.70.  Representative LC-MS/MS chromatograms: rat #36, IN AVF+APB 
high dose, 10 min, plasma.  In the AVF chromatogram, the red arrow indicates the 
location of the AVF retention time.  There was no AVF detectable in this sample, only 
noise.  
 
Table A2.7.  Ions monitored by MS/MS. 
Compound 
Retention  
(min) 
Precursor ion  
(m/z) 
Product ion  
(m/z) 
AVF 3.4 431 [MH]+ 246 
DZP 9.3 286 [MH]+ (Cl isotope) 193 
Tolbutamide (IS) 7.6 269 [M-H]- 170 
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Table A2.8.  Nasal tissue histology incident report.  NSF = nothing significant found.  
Dose Group 1 3 4 5 
 
Number of Animals 3 3 3 3 
Tissue Lesion Type Severity Number of Incidents Observed 
Turbinate 1 Cellular debris Minimal   2 1   
Cellular debris Mild       1 
Eosinophilic fluid Moderate     1   
Epithelium missing Minimal       3 
Hemorrhage Minimal   1     
Necrosis Minimal   1     
Necrosis Mild     1   
Ulcer Minimal   1     
Artifact Minimal     1   
NSF   3       
Turbinate 2 Cellular debris Minimal       1 
Cellular debris Mild       1 
Degeneration 
epithelium 
Mild       1 
Hemorrhage Minimal 1       
Hemorrhage Mild     1   
NSF   2 3 2 1 
Turbinate 3 Hemorrhage Minimal 1       
Hemorrhage Mild     1   
NSF   2 3 2 3 
Turbinate 4 NSF   3 3 3 3 
Turbinate 5 NSF   3 3 3 3 
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A3: Supporting information for Chapter 4  
 
A4.1 Measurement of enzyme activity 
 
An alternative non-drug chromogenic substrate, LpNA, was used as a surrogate for 
AVF in some experiments because there is no intermediate species formed upon 
hydrolysis.  Hence, the active APB concentration (expressed as specific activity) was 
conveniently determined directly from the slope of linear absorbance increase at 405 nm, 
which is due to formation of the chromophore product, pNA. 
 
 
 
Figure A3.71.  Reaction scheme for the hydrolysis of LpNA. The chromogenic substrate, 
S-Lys-para-nitroanilide (LpNA), can be hydrolyzed by Lys aminopeptidases to release the 
chromophore para-nitroaniline (pNA) that typically monitored at absorbance λ = 405 nm. 
 
 
Table A3.9.  Molar absorptivity temperature dependence.      
Temp 
(°C) 
Molar Absorptivity 
(µM-1cm-1) 
LpNA pNA 
0 3.01E-05 0.00948 
5 3.27E-05 0.00957 
10 3.61E-05 0.00964 
15 4.01E-05 0.00971 
20 4.41E-05 0.00977 
25 4.86E-05 0.00982 
30 5.39E-05 0.00986 
32 5.59E-05 0.00986 
35 5.89E-05 0.00987 
40 6.49E-05 0.00988 
45 7.05E-05 0.00986 
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Figure A3.72.  SDS-PAGE gel of APB. 4–20% gradient SDS-PAGE with purified APB 
in lane 1 at ~ 74 kDa and molecular-weight size marker in lane 3. 
 
 
 
A4.2 Stability of lyophilizates at room temperature   
 
 
Figure A3.73.  Lyophilizate formulations buffered with Tris.  Optimum stability was 
achieved by co-lyophilization of APB+AVF+Tre without Tris buffer.  Concentrations of 
active APB in the lyophilizates were measured in pH 7.4 PBS at 32 °C after storage for the 
specified time at 24 °C.  Pre-lyophilization solutions contained AVF = 1.00 mM, APB = 
50 µg/mL, Tre = 12.5 mg/mL, and/or pH 7.4 Tris buffer = 10 mM.  Error bars are SD with 
n = 3.   
 
 
A4.3 Base titration of AVF 
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The dihydrochloride salt of AVF (17.9 mg, equivalent to 10.1 mg of DZP) was 
dissolved in 100 µL of water and the solution was placed in the electrode well of a Horiba, 
Ltd. (Kyoto, Japan) LAQUAtwin pH-22 low volume pH meter.  The initial concentration 
of AVF was 0.355 M with a measured pH of 2.72.  The solution was titrated with 2.0 µL 
aliquots of pH 13.5 NaOH (0.316 M).  The titrand solution was thoroughly mixed by 
stirring with the pipette tip and allowed to equilibrate to a stable pH after each addition.  
An inflection point indicating an apparent pKa was observed at pH 7.54 after 56 µL of base 
was added.   
 
 
Figure A3.74.  Titration curve for AVF.   Titration of AVF, n = 1.  Inset shows predicted 
pKa values obtained from JChem by ChemAxon Ltd. https:// chemicalize.com/. 
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A4: Supporting information for Chapter 5  
 
A4.1 Characterization of MDZopen•2HCl 
 
A4.1.1 Infrared spectroscopy (ATR-FTIR) 
 
IR spectra of neat MDZ standard and MDZopen•2HCl were measured at room 
temperature using a Bruker, Inc. (Billerica, MA) Vertex 80 spectrometer equipped with an 
attenuated total reflectance (ATR) accessory.  The solid samples were pulverized and 64 
scans from 4000-800 cm−1 at a resolution of 4 cm−1 were averaged.  Samples were 
measured in triplicate, representative spectra a shown in Figure A4.75.  
 
The IR spectrum of the MDZ standard was unremarkable between 1630-4000 cm-
1 (Figure A4.75A).  The fused ring structure of MDZ did not allow for the imidazole 
vibrational frequencies that observed with MDZopen•2HCl.  The unique peaks in the IR 
spectrum of MDZopen•2HCl included a broad, jagged peak between 3100-2300 cm-1 that is 
characteristic the imidazole group; aromatic overtones at 1956 and 1799 cm-1; and a 
carbonyl stretch from the benzophenone group at 1651 cm-1 (Figure A4.75B).    
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Figure A4.75.  ATR-FTIR spectra.  (A) MDZ standard.  (B) MDZopen•2HCl. 
 
 
A4.1.2 Nuclear magnetic resonance (1HNMR) 
 
Solution state 1HNMR spectra of MDZ standard and MDZopen•2HCl were measured 
at room temperature using an Avance III HD spectrometer from Bruker Corporation 
(Billerica, MA).  The spectra were processed with Mestrelab Research S.L. (Escondido, 
CA) MestReNova software version 12.0.4-22023.  Automatic phase correction, full auto 
Bernstein polynomial baseline correction, and residual solvent peak suppression were 
performed before integrating the peaks.  Samples were dissolved in D2O, DMSO-d6, or 
CDCl3 had been allowed to equilibrate for more than 6 hrs.  MDZopen•2HCl was visibly 
insoluble in CDCl3, even when subjected to heating and sonication.                 
 
The spectrum of MDZopen•2HCl in CDCl3 (Figure A4.76A) did not show analyte 
peaks because MDZopen•2HCl was insoluble in CDCl3.  There were no detectable levels of 
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MDZ impurity as was evident by the absence of peaks from soluble analytes.  Figure 
A4.76B shows that MDZ is readily soluble in CDCl3 and produced the expected peaks.  In 
D2O, MDZopen•2HCl converted to MDZ until equilibrium was reached (Figure A4.76C).  
Peak integrations in the spectrum were normalized to 8 total hydrogens in the aromatic 
region.  There was geminal coupling of the stereotopic hydrogens on the fused diazepine 
ring of MDZ with a summed integration of 0.38.  An integration of 1.65 was obtained for 
the same hydrogens that are homotopic in the open ring of MDZopen, suggesting 19% of 
MDZopen had converted to MDZ.  In the same manner, 19% conversion to MDZ was 
calculated by comparing the 0.56 integration of the downfield shifted methyl hydrogens of 
MDZ to an integration of 2.44 for the same methyl hydrogens upfield in MDZopen.  MDZopen 
also partially converted to MDZ in DMSO-d6 (Figure A4.76F).  Again, peak integrations 
in the spectrum were normalized to 8 total hydrogens in the aromatic region.  One of the 
stereotopic hydrogens on the fused diazepine ring of MDZ was overlapping with the tail 
of what appeared to be a broad water peak.  The hydrogen peak that was not overlapping 
had an integration of 0.29, indicating 29% conversion to MDZ.  Two other peaks assigned 
to geminal coupled hydrogens in the open ring of MDZopen were also obscured by the broad 
water peak.  A 29% conversion to MDZ was confirmed by comparing the 0.87 integration 
of the downfield shifted methyl hydrogens of MDZ to an integration of 2.10 for the same 
methyl hydrogens upfield in MDZopen. 
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Figure A4.76.  1H-NMR spectra.  (A) MDZopen•2HCl was insoluble in CDCl3.  (B) MDZ 
in CDCl3.  (C) MDZopen•2HCl in D2O partially converted to MDZ.  (D) MDZ standard in 
DMSO-d6.  (E) Expanded view of the aromatic region of the spectrum shown in D.  (F) 
MDZopen•2HCl in DMSO-d6. Partially converted to MDZ.   
 
 
A4.1.3 Molecular dynamics simulations 
 
Molecular dynamics simulations of the mono-cationic and di-cationic microspecies 
of MDZopen were performed with Chem3D Ultra software version 16.0.1.4 from 
PerkinElmer Informatics, Inc. (Waltham, MA).  A Molecular Mechanics 2 (MM2) force 
field was used to minimize the conformational energy at a rate of 1.000 kcal/atom/ps in 2.0 
fs step intervals to a minimum RMS energy gradient of 0.010 kcal/mol/Å.  Then, the 
intramolecular distance (d) between reactive centers (primary amine and carbonyl carbon 
of benzophenone) was measured in the energy minimized structures as shown in (Figure 
A4.77).     
 
MM2 is a classical force field commonly used in molecular dynamics simulations 
to determine the 3D conformations of a broad range of small organic molecules.  The 
calculated intramolecular distance, d, between reactive centers for cyclization of MDZopen 
was 3.3 Å for the di-cationic microspecies and 6.1 Å for the mono-cationic microspecies 
(Figure A4.77).  Reactive centers that are closer to each other in in the energy minimized 
conformation would have a higher collision frequency.  Thus, the shorter distance that 
results from protonating the imidazole at low pH may contribute to the faster cyclization 
rate.       
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Figure A4.77.  Energy minimized structures of MDZopen microspecies.   The proximity 
of reactive centers involved in the cyclization of MDZopen were closer for the di-cationic 
microspecies (d = 3.3 Å) that predominates at pH 5.5 compared to the mono-cationic 
microspecies (d = 6.1 Å) that predominates at pH 7.4.          
 
 
A4.2 Additional information for UV spectroscopy method 
 
 The analytical wavelength selected for UV spectroscopic monitoring of reaction 
progress was 300 nm, because the molar absorptivity (ε) of MDZ was not dependent on 
pH at this wavelength (ε = 1330 ± 50 M-1cm-1 ±SD, Figure A4.78).  The absorbance spectra 
from 300-400 nm for Phe-MDZpro, Lys-MDZpro, and MDZopen were nearly identical at a 
given pH owing to the relative transparency of the amino acid moiety (Figure A4.79).  The 
ε of Lys-MDZpro and Phe-MDZpro standard solutions was 2510 ± 60 M-1cm-1 ±SD from pH 
4.0-8.0 at 300 nm, with a slight increase in ε as the pH dropped below the pKa of the 
imidazole (Figure A4.80).  MDZopen also had a similar spectrum as MDZpro.  The ε of 
MDZopen at 300 nm was assumed to have the same pH dependence as the prodrugs based 
on their structural similarity.  Formation of the diazepine ring in MDZ caused a change in 
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ε at 300 nm, thus UV spectroscopy was useful for distinguishing MDZopen from MDZ but 
not from MDZpro.           
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Figure A4.78.  Effect of pH on the UV spectrum of MDZ.  Measured in 20 mM PBS at 
32 °C.  (A) Isosbestic point at 300 nm was independent of MDZ concentration.  (B) 
Absolute difference in absorbance of 500 µM MDZ at pH 5.5 and pH 8.0 shows equivalent 
molar absorptivities at 274 and 300 nm.  (C) Evolution of the spectrum of 500 µM MDZ 
from pH 5.5 to pH 8.0 in ~0.2 pH unit increments.  (D) Molar absorptivity pH dependence 
near the isosbestic point. 
     
 
 
 
Figure A4.79.  UV absorbance spectra of MDZ precursors.  All samples were at 32 °C.  
pH was controlled at 7.4 and 5.5 with 20 PBS where indicated.  MDZopen samples were 
prepared by dissolving solid MDZopen•2HCl in pre-warmed buffer or water immediately 
before measurement to mitigate spontaneous conversion to MDZ.  
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Figure A4.80.  Molar absorptivity of MDZ prodrugs.  Molar absorptivity (ε) measured 
at 300 nm and 32 °C with 1.00 mM of each prodrug in 40 mM PBS prepared at the indicated 
pH, n = 3.  Slight change in ε observed near the pKa of the imidazole.  (A) Phe-MDZpro.  
(B) Lys-MDZpro. 
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A4.3 Additional information for HPLC method 
 
 
 
Figure A4.81.  HPLC chromatograms.  (A) 32.0 µM Phe-MDZpro standard.  (B) 32.0 µM 
MDZ standard. 
 
 
 
261 
 
Figure A4.82.  HPLC calibration curves.  n = 3 (A) Phe-MDZpro: LOD = 0.297 µM 
(0.146 µg/mL), LOQ = 0.901 µM (0.443 µg/mL).  (B) MDZ: LOD = 0.0696 µM (0.0227 
µg/mL), LOQ = 0.211 µM (0.0687 µg/mL). 
 
A4.4 APN enzyme kinetics 
 
 
Figure A4.83.  Enzyme kinetics for hydrolysis of Phe-MDZpro by APN.  The Michaelis–
Menten equation was fit to the average MDZ concentrations measured by HPLC after 
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stopping the reactions with two volumes of acetonitrile.  Phe-MDZpro with 15 µg/mL APN 
in pH 5.5 CBS at 32 °C, n = 3, R2 = 0.996, KM = 336 ± 39 μM and Vmax = 16.5 ± 0.6 
μM/min (± SE).  The molecular weight of APN was 104 kDa, so kcat = 114 ± 5 min-1.      
 
 
 
Figure A4.84.  pH dependence of APN enzyme activity.  The activity of 20 µg/mL APN 
was measured at 32 °C in 40 mM PBS using 1.00 mM of the chromogenic substrate S-
phenylalanyl-para-nitroanilide (from a stock solution of the HCl salt in water) by the slope 
of the change in UV absorbance at 405 nm during the first 15 s of the reaction. 
 
 
 
Figure A4.85.  Schematic of MDZ absorption from MDZ precursor reactions.  Both, 
prodrug/enzyme formulation and acid/base formulation, pathways proceed though the 
MDZopen intermediate species to produce supersaturated MDZ in the nasal cavity.  When 
the concentration of MDZ reaches the upper limit of supersaturation, MDZ will phase 
separate as an amorphous precipitate.  The amorphous precipitate acts as a source of MDZ, 
so it remains available for absorption.  Crystallization of MDZ (dotted arrows) could occur, 
but the process requires a nucleation event and lattice growth that is comparatively slower 
than absorption and mucociliary clearance.   
   
A4.5 Titration of AA-MDZpro 
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Phe-MDZpro•2HCl (17.3 mg, equivalent to 10.0 mg of MDZ) was dissolved in 100 
µL of water and the solution was placed in the electrode well of a Horiba, Ltd. (Kyoto, 
Japan) LAQUAtwin pH-22 low volume pH meter.  The initial concentration of Phe-
MDZpro was 0.307 M with a measured pH of 2.40.  The solution was titrated with 2.0 µL 
aliquots of pH 13.5 NaOH (0.316 M).  The titrand solution was thoroughly mixed by 
stirring with the pipette tip and allowed to equilibrate to a stable pH after each addition.  
The titration was stopped when persistent turbidity was observed.  The titration curve is 
shown in Figure A3.74A.         
 
 Lys-MDZpro•3HCl (17.9 mg, equivalent to 10.0 mg of MDZ) was dissolved in 100 
µL of water and the solution was placed in the electrode well of the low volume pH meter.  
The initial concentration of Lys-MDZpro was 0.308 M with a measured pH of 2.14.  The 
solution was titrated with 2.0 µL aliquots of pH 13.5 NaOH (0.316 M).  The titrand solution 
was thoroughly mixed by stirring with the pipette tip and allowed to equilibrate to a stable 
pH after each addition.  The titration was stopped when persistent turbidity was observed.  
The titration curve is shown in Figure A3.74B. 
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Figure A4.86.  Titration curves for AA-MDZpro.   (A)  Titration of Phe-MDZpro•2HCl(aq), 
n = 1.  The start of the buffering region was approximately pH 5.0.  At 160 mM and pH 
5.8, persistent turbidity was overserved in the titrand solution.  An IN formulation utilizing 
Phe-MDZpro would be adjusted to pH 5.5.  (B) Titration of Lys-MDZpro•3HCl(aq), n = 1.  
The start of the buffering region was approximately pH 5.0.  At 136 mM and pH 7.2, 
persistent turbidity was overserved in the titrand solution. 
 
